User login
How vitamin D fights lymphoma
to engulf two particles
Vitamin D can stimulate macrophages to kill lymphoma cells, according to research published in Science Translational Medicine.
The researchers found that activation of the vitamin D signaling pathway activates the antitumor activity of tumor-associated macrophages and improves the efficacy of antibody-dependent cellular cytotoxicity.
The team said these results support the use of vitamin D supplements to boost the effectiveness of existing lymphoma therapies.
Heiko Bruns, PhD, of the University Hospital Erlangen in Germany, and his colleagues knew that vitamin D plays a central role in regulating macrophages, and macrophages often fail to kill tumor cells, partly because of cancer’s ability to evade immune detection.
Previous research has shown that lymphoma patients with low vitamin D levels do not respond to chemotherapy or immunotherapy as well as their peers. And this prompted the recommendation that such patients should take vitamin D supplements before and during treatment.
To uncover the mechanism behind vitamin D’s potential benefits, Dr Bruns and his colleagues analyzed how the vitamin affects macrophages’ ability to fight lymphoma cells.
The researchers found that vitamin D stimulated macrophages to secrete a peptide called cathelicidin, which kills lymphoma cells by damaging their mitochondria.
Macrophages from lymphoma patients were unable to properly metabolize vitamin D. Therefore, the macrophages produced fewer cathelicidin peptides and failed to kill the lymphoma cells.
Treating the macrophages with vitamin D boosted the production of cathelicidin and, in turn, lymphoma cell death.
Similarly, the researchers found that, in healthy individuals with vitamin D deficiency, vitamin D supplements triggered macrophages to release more cathelicidin, making them more effective against cultured lymphoma cells.
Furthermore, treating macrophages from lymphoma patients with both vitamin D and rituximab killed lymphoma cells more effectively than treatment with rituximab alone.
The researchers said these results suggest vitamin D can potentially enhance immunotherapy to more effectively treat lymphoma.
to engulf two particles
Vitamin D can stimulate macrophages to kill lymphoma cells, according to research published in Science Translational Medicine.
The researchers found that activation of the vitamin D signaling pathway activates the antitumor activity of tumor-associated macrophages and improves the efficacy of antibody-dependent cellular cytotoxicity.
The team said these results support the use of vitamin D supplements to boost the effectiveness of existing lymphoma therapies.
Heiko Bruns, PhD, of the University Hospital Erlangen in Germany, and his colleagues knew that vitamin D plays a central role in regulating macrophages, and macrophages often fail to kill tumor cells, partly because of cancer’s ability to evade immune detection.
Previous research has shown that lymphoma patients with low vitamin D levels do not respond to chemotherapy or immunotherapy as well as their peers. And this prompted the recommendation that such patients should take vitamin D supplements before and during treatment.
To uncover the mechanism behind vitamin D’s potential benefits, Dr Bruns and his colleagues analyzed how the vitamin affects macrophages’ ability to fight lymphoma cells.
The researchers found that vitamin D stimulated macrophages to secrete a peptide called cathelicidin, which kills lymphoma cells by damaging their mitochondria.
Macrophages from lymphoma patients were unable to properly metabolize vitamin D. Therefore, the macrophages produced fewer cathelicidin peptides and failed to kill the lymphoma cells.
Treating the macrophages with vitamin D boosted the production of cathelicidin and, in turn, lymphoma cell death.
Similarly, the researchers found that, in healthy individuals with vitamin D deficiency, vitamin D supplements triggered macrophages to release more cathelicidin, making them more effective against cultured lymphoma cells.
Furthermore, treating macrophages from lymphoma patients with both vitamin D and rituximab killed lymphoma cells more effectively than treatment with rituximab alone.
The researchers said these results suggest vitamin D can potentially enhance immunotherapy to more effectively treat lymphoma.
to engulf two particles
Vitamin D can stimulate macrophages to kill lymphoma cells, according to research published in Science Translational Medicine.
The researchers found that activation of the vitamin D signaling pathway activates the antitumor activity of tumor-associated macrophages and improves the efficacy of antibody-dependent cellular cytotoxicity.
The team said these results support the use of vitamin D supplements to boost the effectiveness of existing lymphoma therapies.
Heiko Bruns, PhD, of the University Hospital Erlangen in Germany, and his colleagues knew that vitamin D plays a central role in regulating macrophages, and macrophages often fail to kill tumor cells, partly because of cancer’s ability to evade immune detection.
Previous research has shown that lymphoma patients with low vitamin D levels do not respond to chemotherapy or immunotherapy as well as their peers. And this prompted the recommendation that such patients should take vitamin D supplements before and during treatment.
To uncover the mechanism behind vitamin D’s potential benefits, Dr Bruns and his colleagues analyzed how the vitamin affects macrophages’ ability to fight lymphoma cells.
The researchers found that vitamin D stimulated macrophages to secrete a peptide called cathelicidin, which kills lymphoma cells by damaging their mitochondria.
Macrophages from lymphoma patients were unable to properly metabolize vitamin D. Therefore, the macrophages produced fewer cathelicidin peptides and failed to kill the lymphoma cells.
Treating the macrophages with vitamin D boosted the production of cathelicidin and, in turn, lymphoma cell death.
Similarly, the researchers found that, in healthy individuals with vitamin D deficiency, vitamin D supplements triggered macrophages to release more cathelicidin, making them more effective against cultured lymphoma cells.
Furthermore, treating macrophages from lymphoma patients with both vitamin D and rituximab killed lymphoma cells more effectively than treatment with rituximab alone.
The researchers said these results suggest vitamin D can potentially enhance immunotherapy to more effectively treat lymphoma.
Palliative Care and Last-Minute Heroics
4/8/15
HM15 Presenter: Tammie Quest, MD
Summation: Heroics- a set of medical actions that attempt to prolong life with a low likelihood of success.
Palliative care- an approach of care provided to patients and families suffering from serious and/or life limiting illness; focus on physical, spiritual, psychological and social aspects of distress.
Hospice care- intense palliative care provided when the patient has terminal illness with a prognosis of 6 months or less if the disease runs its usual course.
We underutilize Palliative and Hospice care in the US. Here in the US fewer than 50% of all persons receive hospice care at EOL, of those who receive hospice care more than half receive care for less than 20 days, and 1 in 5 patients die in an ICU. Palliative Care can/should co-exist with life prolonging care following the diagnosis of serious illness.
Common therapies/interventions to be contemplated and discussed with patient at end of life: cpr, mechanical ventilation, central venous/arterial access, renal replacement therapy, surgical procedures, valve therapies, ventricular assist devices, continuous infusions, IV fluids, supplemental oxygen, artificial nutrition, antimicrobials, blood products, cancer directed therapy, antithrombotics, anticoagulation.
Practical Elements of Palliative Care: pain and symptom management, advance care planning, communication/goals of care, truth-telling, social support, spiritual support, psychological support, risk/burden assessment of treatments.
Key Points/HM Takeaways:
1-Palliative Care Bedside Talking Points-
- Cardiac arrest is the moment of death, very few people survive an attempt at reversing death
- If you are one of the few who survive to discharge, you may do well but few will survive to discharge
- Antibiotics DO improve survival, antibiotics DO NOT improve comfort
- No evidence to show that dying from pneumonia, or other infection, is painful
- Allowing natural death includes permitting the body to shut itself down through natural mechanisms, including infection
- Dialysis may extend life, but there will be progressive functional decline
2-Goals of Care define what therapies are indicated. Balance prolongation of life with illness experience.
Julianna Lindsey is a hospitalist and physician leader based in the Dallas-Fort Worth Metroplex. Her focus is patient safety/quality and physician leadership. She is a member of TeamHospitalist.
4/8/15
HM15 Presenter: Tammie Quest, MD
Summation: Heroics- a set of medical actions that attempt to prolong life with a low likelihood of success.
Palliative care- an approach of care provided to patients and families suffering from serious and/or life limiting illness; focus on physical, spiritual, psychological and social aspects of distress.
Hospice care- intense palliative care provided when the patient has terminal illness with a prognosis of 6 months or less if the disease runs its usual course.
We underutilize Palliative and Hospice care in the US. Here in the US fewer than 50% of all persons receive hospice care at EOL, of those who receive hospice care more than half receive care for less than 20 days, and 1 in 5 patients die in an ICU. Palliative Care can/should co-exist with life prolonging care following the diagnosis of serious illness.
Common therapies/interventions to be contemplated and discussed with patient at end of life: cpr, mechanical ventilation, central venous/arterial access, renal replacement therapy, surgical procedures, valve therapies, ventricular assist devices, continuous infusions, IV fluids, supplemental oxygen, artificial nutrition, antimicrobials, blood products, cancer directed therapy, antithrombotics, anticoagulation.
Practical Elements of Palliative Care: pain and symptom management, advance care planning, communication/goals of care, truth-telling, social support, spiritual support, psychological support, risk/burden assessment of treatments.
Key Points/HM Takeaways:
1-Palliative Care Bedside Talking Points-
- Cardiac arrest is the moment of death, very few people survive an attempt at reversing death
- If you are one of the few who survive to discharge, you may do well but few will survive to discharge
- Antibiotics DO improve survival, antibiotics DO NOT improve comfort
- No evidence to show that dying from pneumonia, or other infection, is painful
- Allowing natural death includes permitting the body to shut itself down through natural mechanisms, including infection
- Dialysis may extend life, but there will be progressive functional decline
2-Goals of Care define what therapies are indicated. Balance prolongation of life with illness experience.
Julianna Lindsey is a hospitalist and physician leader based in the Dallas-Fort Worth Metroplex. Her focus is patient safety/quality and physician leadership. She is a member of TeamHospitalist.
4/8/15
HM15 Presenter: Tammie Quest, MD
Summation: Heroics- a set of medical actions that attempt to prolong life with a low likelihood of success.
Palliative care- an approach of care provided to patients and families suffering from serious and/or life limiting illness; focus on physical, spiritual, psychological and social aspects of distress.
Hospice care- intense palliative care provided when the patient has terminal illness with a prognosis of 6 months or less if the disease runs its usual course.
We underutilize Palliative and Hospice care in the US. Here in the US fewer than 50% of all persons receive hospice care at EOL, of those who receive hospice care more than half receive care for less than 20 days, and 1 in 5 patients die in an ICU. Palliative Care can/should co-exist with life prolonging care following the diagnosis of serious illness.
Common therapies/interventions to be contemplated and discussed with patient at end of life: cpr, mechanical ventilation, central venous/arterial access, renal replacement therapy, surgical procedures, valve therapies, ventricular assist devices, continuous infusions, IV fluids, supplemental oxygen, artificial nutrition, antimicrobials, blood products, cancer directed therapy, antithrombotics, anticoagulation.
Practical Elements of Palliative Care: pain and symptom management, advance care planning, communication/goals of care, truth-telling, social support, spiritual support, psychological support, risk/burden assessment of treatments.
Key Points/HM Takeaways:
1-Palliative Care Bedside Talking Points-
- Cardiac arrest is the moment of death, very few people survive an attempt at reversing death
- If you are one of the few who survive to discharge, you may do well but few will survive to discharge
- Antibiotics DO improve survival, antibiotics DO NOT improve comfort
- No evidence to show that dying from pneumonia, or other infection, is painful
- Allowing natural death includes permitting the body to shut itself down through natural mechanisms, including infection
- Dialysis may extend life, but there will be progressive functional decline
2-Goals of Care define what therapies are indicated. Balance prolongation of life with illness experience.
Julianna Lindsey is a hospitalist and physician leader based in the Dallas-Fort Worth Metroplex. Her focus is patient safety/quality and physician leadership. She is a member of TeamHospitalist.
Melanoma incidence drops for U.S. children and teens
The incidence of melanoma among American children and teens decreased by approximately 12% from 2004 to 2010, with the decline most notable for adolescents. The findings were published online in the Journal of Pediatrics.
In a review of data from the period of 2000-2010, Dr. Laura Campbell of Stanford (Calif.) University and her colleagues at Case Western Reserve University in Cleveland found an overall reduction in melanoma diagnoses of 11.58% per year for the period of 2004-2010 (J. Pediatr. 2015 [doi: 10.1016/j.jpeds. 2015.02.050]).
The study was conducted at Case Western Reserve University, and the researchers used the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER-18) registry to examine trends in the incidence of pediatric melanoma.
Of note, the number of new melanoma cases decreased significantly (approximately 11%) among 15- to19-year-olds between 2003 and 2010. In addition, the overall incidence of melanoma decreased significantly (7%) among boys between 2000 and 2010.
The data revealed significant decreases for the number of new cases of melanoma on the trunk (15% per year from 2004 to 2010) and upper extremities (5% from 2000 to 2010).
Dr. Campbell and her colleagues determined that a melanoma diagnosis was equally likely for male and female patients, and was more common in older than in younger patients. White patients had by far the greatest incidence of melanoma, with 97% of the overall diagnoses; 90% of the cases were in non-Hispanic whites. Superficial spreading melanoma was the most common type of melanoma, at 31%, though nodular histology was seen almost as frequently in the 0- to 9-year-olds. This younger group was more likely to have thicker tumors, ulceration, lymph node involvement, and distant metastases.
Drawing on this large registry allowed researchers more confidence that they were identifying true trends in melanoma incidence, Dr. Campbell noted.
The reasons for this decrease, which stands in contrast to earlier data showing increased incidence rates of pediatric melanoma, were not examined in this study. However, Dr. Campbell drew on these earlier studies, as well as some international studies, to identify the potential contribution of public health campaigns advocating sun protection. These campaigns began in the 1990s in the United States, and would have benefited the 15- to 19-year olds in the SEER-18 data, in whom melanoma incidence decreased beginning in 2003. Some Swedish and Australian studies showing decreased melanoma cases were confounded by an immigration-driven decrease in the highest risk light-skinned population, noted Dr. Campbell; however, the quality of the SEER-18 data allowed researchers to account for this variable, she said.
Although the widespread adoption of sun-protective behaviors (wearing hats and protective clothing, using sunscreen appropriately, and avoiding midday sun exposure) may have accounted for some of the reduction in pediatric melanomas, other societal changes may have been at play.
“We hypothesize that there has been a shift in youth participating increasingly in indoor activities, such as television/electronic devices, which may be decreasing their UVR exposure,” Dr. Campbell said.
The incidence of melanoma among American children and teens decreased by approximately 12% from 2004 to 2010, with the decline most notable for adolescents. The findings were published online in the Journal of Pediatrics.
In a review of data from the period of 2000-2010, Dr. Laura Campbell of Stanford (Calif.) University and her colleagues at Case Western Reserve University in Cleveland found an overall reduction in melanoma diagnoses of 11.58% per year for the period of 2004-2010 (J. Pediatr. 2015 [doi: 10.1016/j.jpeds. 2015.02.050]).
The study was conducted at Case Western Reserve University, and the researchers used the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER-18) registry to examine trends in the incidence of pediatric melanoma.
Of note, the number of new melanoma cases decreased significantly (approximately 11%) among 15- to19-year-olds between 2003 and 2010. In addition, the overall incidence of melanoma decreased significantly (7%) among boys between 2000 and 2010.
The data revealed significant decreases for the number of new cases of melanoma on the trunk (15% per year from 2004 to 2010) and upper extremities (5% from 2000 to 2010).
Dr. Campbell and her colleagues determined that a melanoma diagnosis was equally likely for male and female patients, and was more common in older than in younger patients. White patients had by far the greatest incidence of melanoma, with 97% of the overall diagnoses; 90% of the cases were in non-Hispanic whites. Superficial spreading melanoma was the most common type of melanoma, at 31%, though nodular histology was seen almost as frequently in the 0- to 9-year-olds. This younger group was more likely to have thicker tumors, ulceration, lymph node involvement, and distant metastases.
Drawing on this large registry allowed researchers more confidence that they were identifying true trends in melanoma incidence, Dr. Campbell noted.
The reasons for this decrease, which stands in contrast to earlier data showing increased incidence rates of pediatric melanoma, were not examined in this study. However, Dr. Campbell drew on these earlier studies, as well as some international studies, to identify the potential contribution of public health campaigns advocating sun protection. These campaigns began in the 1990s in the United States, and would have benefited the 15- to 19-year olds in the SEER-18 data, in whom melanoma incidence decreased beginning in 2003. Some Swedish and Australian studies showing decreased melanoma cases were confounded by an immigration-driven decrease in the highest risk light-skinned population, noted Dr. Campbell; however, the quality of the SEER-18 data allowed researchers to account for this variable, she said.
Although the widespread adoption of sun-protective behaviors (wearing hats and protective clothing, using sunscreen appropriately, and avoiding midday sun exposure) may have accounted for some of the reduction in pediatric melanomas, other societal changes may have been at play.
“We hypothesize that there has been a shift in youth participating increasingly in indoor activities, such as television/electronic devices, which may be decreasing their UVR exposure,” Dr. Campbell said.
The incidence of melanoma among American children and teens decreased by approximately 12% from 2004 to 2010, with the decline most notable for adolescents. The findings were published online in the Journal of Pediatrics.
In a review of data from the period of 2000-2010, Dr. Laura Campbell of Stanford (Calif.) University and her colleagues at Case Western Reserve University in Cleveland found an overall reduction in melanoma diagnoses of 11.58% per year for the period of 2004-2010 (J. Pediatr. 2015 [doi: 10.1016/j.jpeds. 2015.02.050]).
The study was conducted at Case Western Reserve University, and the researchers used the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER-18) registry to examine trends in the incidence of pediatric melanoma.
Of note, the number of new melanoma cases decreased significantly (approximately 11%) among 15- to19-year-olds between 2003 and 2010. In addition, the overall incidence of melanoma decreased significantly (7%) among boys between 2000 and 2010.
The data revealed significant decreases for the number of new cases of melanoma on the trunk (15% per year from 2004 to 2010) and upper extremities (5% from 2000 to 2010).
Dr. Campbell and her colleagues determined that a melanoma diagnosis was equally likely for male and female patients, and was more common in older than in younger patients. White patients had by far the greatest incidence of melanoma, with 97% of the overall diagnoses; 90% of the cases were in non-Hispanic whites. Superficial spreading melanoma was the most common type of melanoma, at 31%, though nodular histology was seen almost as frequently in the 0- to 9-year-olds. This younger group was more likely to have thicker tumors, ulceration, lymph node involvement, and distant metastases.
Drawing on this large registry allowed researchers more confidence that they were identifying true trends in melanoma incidence, Dr. Campbell noted.
The reasons for this decrease, which stands in contrast to earlier data showing increased incidence rates of pediatric melanoma, were not examined in this study. However, Dr. Campbell drew on these earlier studies, as well as some international studies, to identify the potential contribution of public health campaigns advocating sun protection. These campaigns began in the 1990s in the United States, and would have benefited the 15- to 19-year olds in the SEER-18 data, in whom melanoma incidence decreased beginning in 2003. Some Swedish and Australian studies showing decreased melanoma cases were confounded by an immigration-driven decrease in the highest risk light-skinned population, noted Dr. Campbell; however, the quality of the SEER-18 data allowed researchers to account for this variable, she said.
Although the widespread adoption of sun-protective behaviors (wearing hats and protective clothing, using sunscreen appropriately, and avoiding midday sun exposure) may have accounted for some of the reduction in pediatric melanomas, other societal changes may have been at play.
“We hypothesize that there has been a shift in youth participating increasingly in indoor activities, such as television/electronic devices, which may be decreasing their UVR exposure,” Dr. Campbell said.
FROM THE JOURNAL OF PEDIATRICS
Key clinical point: The overall incidence of melanoma in American children and teens decreased from 2004 to 2010.
Major finding: Researchers identified 1,185 patients younger than 20 years of age with melanoma diagnoses during the period of 2000-2010, and noted a significant decrease of 11.58% per year in melanoma diagnoses from 2004 to 2010.
Data source: The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER-18) registry for 2000-2010.
Disclosures: The authors reported no conflicts of interest.
Individualized Care Plans
High utilizers of hospital services are medically complex, psychosocially vulnerable, and at risk for adverse health outcomes.[1, 2] They make up a fraction of the patient population but use a disproportionate amount of resources, with high rates of emergency department (ED) visits and hospital admissions.[1, 3, 4] Less than 1% of patients account for 21% of national healthcare spending, and hospital costs are the largest category of national healthcare expenditures.[2, 5] Many patients who disproportionately contribute to high healthcare costs also have high hospital admission rates.[6]
Interventions targeting high utilizers have typically focused on the outpatient setting.[7, 8, 9, 10] Interventions using individualized care plans in the ED reduced ED visits from 33% to 70%, but all have required an additional case management program or partnership with an outside nonprofit case management organization.[11, 12, 13] One study by a hospitalist group using individualized care plans reduced ED visits and admissions by 70%, 2 months after care‐plan implementation; however, all of their care plans were focused explicitly on restricting intravenous opiate use for patients with chronic pain.[14]
Given the current focus on cost‐conscious, high‐quality care in the American healthcare system, we designed a quality‐improvement (QI) intervention using individualized care plans to reduce unnecessary healthcare service utilization and hospital costs for the highest utilizers of ED and inpatient care. Our approach focuses on integrating care plans within our electronic medical record (EMR) and implementing them using the existing healthcare workforce. We analyzed pre‐ and postintervention data to determine its effect on service utilization and hospital costs across a regional health system.
METHODS
QI Intervention
We retrospectively analyzed data collected as part of an ongoing QI project at Duke University Hospital, a 924‐bed academic tertiary care center with approximately 36,000 inpatient discharges per year. The Complex Care Plan Committee (CCPC) aims to improve the effectiveness, efficiency, and equity of care for medically, socially, and behaviorally complex adult patients who are the highest utilizers of care in the ED and inpatient medicine service. The CCPC is a volunteer, QI committee comprised of a multidisciplinary team from hospital medicine, emergency medicine, psychiatry, ambulatory care, social work, nursing, risk management, and performance services (system analysts). Individualized care plans are developed on a rolling basis as new patients are identified based on their hospital utilization rates (ED visits and admissions). To be eligible for a care plan, patients have to have at least 3 ED visits or admissions within 6 months and have some degree of medical, social, or behavioral complexity, for example, multiple medical comorbidities with care by several subspecialists, or concomitant psychiatric illness, substance abuse, and homelessness. Strict eligibility criteria are purposefully not imposed to allow flexibility and appropriate tailoring of this intervention to both high‐utilizing and complex patients. Given their complexity, the CCPC felt that without individualized care plans these patients would be at increased risk for rehospitalization and increased morbidity or mortality. The patients included in this analysis are the 24 patients with the most ED visits and hospital admissions at Duke University Hospital, accounting for a total of 183 ED visits and 145 inpatient admissions in the 6 months before the care plans were rolled out.
Each individualized care plan summarizes the patient's medical, psychiatric, and social histories, documents any disruptive behaviors, reviews their hospital utilization patterns, and proposes a set of management strategies focused on providing high‐quality care while limiting unnecessary admissions. They are written by 1 or 2 members of the CCPC who perform a thorough chart review and obtain collateral information from the ED, inpatient, and outpatient providers who have cared for that patient. Care plans are then reviewed and approved by the CCPC as a whole during monthly meetings. Care plans contain detailed information in the following domains: demographics; outpatient care team (primary care provider, specialists, psychiatrist/counselors, social worker, case manager, and home health agency); medical, psychiatric, and behavioral health history; social history; utilization patterns (dates of ED visits and hospitalizations with succinct narratives and outcomes of each admission); and finally ED, inpatient, and outpatient strategies for managing the patient, preventing unnecessary admissions, and connecting them to appropriate services. The CCPC chairperson reviews care plans quarterly to ensure they remain appropriate and relevant.
The care plan is a document uploaded into the EMR (EpicCare; Epic, Verona, WI), where it is available to any provider across the Duke health system. Within Epic, a colored banner visible across the top of the patient's chart notifies the provider of any patient with an individualized care plan. The care plan document is housed in a tab readily visible on the navigation pane. The care plan serves as a roadmap for ED providers and hospitalists, helping them navigate each patient's complex history and guiding them in their disposition decision making. We also developed an automated notification process such that when a high utilizer registers in the ED, a secure page is sent to the admitting hospitalist, who then notifies the ED provider. An automated email is also sent to the CCPC chairperson. These alerts also provide a mechanism for internal oversight and feedback by the CCPC to providers regarding care‐plan adherence.
Outcome Variables and Data Analysis
Our analysis included the 24 patients with individualized care plans developed from August 1, 2012 to August 31, 2013. We analyzed utilization data 6 and 12 months before and 6 and 12 months after the individualized care‐plan intervention was initiated (August 1, 2011 to August 31, 2014). Primary outcomes were the number of ED visits and hospital admissions, as well as ED and inpatient variable direct costs (VDCs). Secondary outcomes included inpatient length of stay (LOS) and 30‐day readmissions. We analyzed outcome data across all 3 hospitals in the Duke University Health System. This includes the only 2 hospitals in Durham, North Carolina (population 245,475) and 1 hospital in Raleigh, North Carolina (population 431,746).
We also describe basic demographic data, payor status, and medical comorbidities for this cohort of patients. Payor status is defined as the most frequently reported payor type prior to care‐plan implementation. Variable direct costs are directly related to patient care and fluctuate with patient volume. They include medications, supplies, laboratory tests, radiology studies, and nursing salaries. They are a proportion of total costs for an ED visit or hospitalization, excluding fixed and indirect costs, such as administrator or physician salaries, utilities, facilities, and equipment.
Primary and secondary outcomes were analyzed using descriptive statistics. Continuous outcomes are summarized with mean (standard deviation) and median (range), whereas categorical outcomes are summarized with N (%). LOS is calculated as the average number of days in the hospital per hospital admission per patient. The time periods of 12 months prior, 6 months prior, 6 months after, and 12 months after care‐plan implementation were examined. Only patients with 6 or more months of postcare‐plan data are included in the 6‐month comparison, and only patients with 12 or more months of postcare‐plan data are included in the 12‐month comparison. One patient in the 6‐month comparison group died very soon after care‐plan implementation, so that patient is included in Table 1 (N=24) but excluded from outcome analyses in Tables 2 and 3 (N=23). Differences between 6 months pre and 6 months postcare plan, and 12 months pre and 12 months postcare plan were examined using the Wilcoxon signed rank test for nonparametric matched data. Mean change is calculated as ([Post‐Pre]/Pre) for each patient, and then averaged across all patients. Mean percentage change is calculated as ([Post‐Pre]/Pre)*100 for each patient, and then averaged across patients. It was done this way to emphasize the effect on the patient level. No adjustments were made for multiple comparisons. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). This study was granted exempt status by the Duke University Institutional Review Board.
Patients With Care Plans, N=24 | Patients With 12 Months PostCare Plan Follow‐up, N=12 | Patients With 6 Months PostCare Plan Follow‐up, N=23* | |
---|---|---|---|
| |||
Age, y, mean (SD) | 38.5 (11.7) | 41.6 (9.2) | 37.3 (10.5) |
Median (range) | 36 (2565) | 41 (2858) | 36 (2558) |
Gender, N (%) | |||
Male | 11 (46%) | 5 (42%) | 11 (48%) |
Female | 13 (54%) | 7 (58%) | 12 (52%) |
Payor, N (%) | |||
Medicare | 11 (46%) | 6 (50%) | 10 (43%) |
Medicaid | 9 (38%) | 4 (33%) | 9 (39%) |
Medicare and Medicaid | 0 (0%) | 0 (0%) | 0 (0%) |
Private insurance | 2 (8%) | 1 (8%) | 2 (9%) |
None | 1 (4%) | 0 (0%) | 1 (4%) |
Other | 1 (4%) | 1 (8%) | 1 (4%) |
Comorbidities, N (%) | |||
Asthma | 9 (38%) | 5 (42%) | 9 (39%) |
Chronic obstructive pulmonary disease | 2 (8%) | 2 (17%) | 2 (9%) |
Chronic pain | 20 (83%) | 12 (100%) | 20 (87%) |
Coronary artery disease | 5 (21%) | 4 (33%) | 5 (22%) |
Diabetes mellitus | 10 (42%) | 6 (50%) | 9 (39%) |
End‐stage renal disease | 4 (17%) | 4 (33%) | 4 (17%) |
Heart failure | 5 (21%) | 2 (17%) | 4 (17%) |
Hypertension | 13 (54%) | 6 (50%) | 12 (52%) |
Mental health/substance abuse | 23 (96%) | 12 (100%) | 22 (96%) |
Sickle cell | 10 (42%) | 5 (42%) | 10 (43%) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Admissions | <0.001 | 0.003 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 145 | 56 | 131 | 58 | 56.0% (41.6%) | 50.5% (43.9%) | ||
Mean (SD) | 6.3 (3.8) | 2.4 (2.4) | 10.9 (6.3) | 4.8 (4.2) | 3.9 (3.76) | 6.1 (6.02) | ||
Median (range) | 5 (114) | 2 (08) | 8 (320) | 3 (011) | ||||
30‐day readmissions | <0.001 | 0.002 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 130 | 44 | 106 | 45 | 66.0% (32.4%) | 51.5% (32.0%) | ||
Mean (SD) | 5.7 (4.1) | 1.9 (2.4) | 8.8 (7.0) | 3.8 (2.7) | 3.7 (3.79) | 5.1 (5.71) | ||
Median (range) | 4 (013) | 1 (08) | 6 (019) | 3 (011) | ||||
Inpatient LOS | 0.506 | 0.910 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766 | 358 | 665 | 317 | 50.8% (51.4%) | 37.8% (78.8%) | ||
Mean (SD) | 5.0 (3.2) | 4.7 (4.3) | 4.7 (1.5) | 4.4 (3.1) | 0.3 (4.3) | 0.3 (2.27) | ||
Median (range) | 4.3 (1.515.8) | 4 (016) | 4.8 (2.26.9) | 3.7 (09) | ||||
ED visits | 0.836 | 0.941 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 183 | 198 | 185 | 307 | +42.9% (148.4%) | +48.4% (145.1%) | ||
Mean (SD) | 8.0 (11.5) | 8.6 (19.8) | 15.4 (14.7) | 25.6 (54.4) | 0.7 (11.92) | 10.2 (43.19) | ||
Median (range) | 5 (050) | 3 (096) | 12 (150) | 7 (1196) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Inpatient costs ($) | 0.001 | 0.052 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 686,612.43 | 358,520.42 | 538,579.90 | 299,501.03 | 47.7% (52.3%) | 35.8% (76.1%) | ||
Mean (SD) | 29,852.71 (21,808.22) | 15,587.84 (21,141.79) | 44,881.66 (30,132.26) | 24,958.42 (27,248.41) | 14,264.9 (19,301.75) | 19,923.2 (31,891.69) | ||
Median (range) | 30,203.43 (1,625.1880,171.87) | 7,041.28 (086,457.05) | 39,936.05 (8,237.5382,861.11) | 13,321.56 (082,309.19) | ||||
ED costs ($) | 0.143 | 0.850 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 80,105.34 | 60,500.38 | 82,473.86 | 98,298.84 | +12.5% (147.5%) | +48.0% (161.8%) | ||
Mean (SD) | 3,482.84 (4,423.57) | 2,630.45 (4,782.56) | 6,872.82 (5,633.70) | 8,191.57 (13,974.75) | 852.4 (2,780.01) | 1,318.7 (10,348.89) | ||
Median (range) | 2,239.19 (019,492.03) | 1,163.45 (022,449.84) | 5,924.31 (277.3019,492.03) | 3,002.70 (553.7250,955.56) | ||||
Combined costs ($) | 0.002 | 0.129 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766,717.77 | 419,020.80 | 621,053.76 | 397,799.87 | 45.3% (48.3%) | 25.5% (76.9%) | ||
Mean (SD) | 33,335.56 (22,427.77) | 18,218.30 (21,398.27) | 51,754.48 (32,248.94) | 33,149.99 (31,769.40) | 15,117.3 (19,932.41) | 18,604.5 (35,513.56) | ||
Median (range) | 32,000.42 (1,625.1880,611.70) | 9,088.88 (087,549.37) | 45,716.08 (10,874.0599,426.72) | 23,971.85 (553.7285,440.12) |
RESULTS
Table 1 shows the demographics and comorbidities for the 24 patients with care plans included in this analysis. The average age of patients is 38.5 years (range, 2565 years) and a nearly even split between males (11) and females (13). Chronic disease burden is high. Furthermore, 83% of patients have chronic pain and 96% have mental health problems or substance abuse.
Table 2 shows inpatient and ED utilization patterns before and after care‐plan implementation. Inpatient admissions decreased by 56% for the 6 months after care‐plan implementation (P<0.001) and by 50.5% for the 12 months after care‐plan implementation (P=0.003). This translates to a decrease in the average number of admissions per patient from 6.3 to 2.4, 6 months postcare plan, and from 10.9 to 4.8, 12 months postcare plan.
Thirty‐day readmissions also significantly decreased after care‐plan implementation. Among the 23 patients with data 6 months pre and postcare plan, there were 130 readmissions before and 44 readmissions after care‐plan implementation, a 66% reduction (P<0.001). Among the 12 patients with data 12 months pre and postcare plan, there were 106 readmissions before and 45 readmissions after care‐plan implementation, a 51.5% reduction (P=0.002). Inpatient LOS did not show a statistically significant change after care‐plan implementation.
ED visits were similar for the 6 months pre compared to 6 months postcare plan. ED visits at 12 months postcare plan increased from an average of 15.4 visits pre to 25.6 visits per patient postcare plan. This was driven by a single homeless patient with dialysis‐dependent end‐stage renal disease, who had 134 ED visits in the 12 months after careplan implementation. Analysis of the data with this outlier removed showed a reduction in ED visits from an average of 12.3 visits per patient to 10.1 visits per patient in the 12 months postcare plan; however, this was not statistically significant (P=0.66, data not shown).
Table 3 shows inpatient and ED VDCs before and after care‐plan implementation. The average VDCs per patient per admission decreased from $29,852.71 to $15,587.84, 6 months after care‐plan implementation, a 47.7% reduction (P=0.001). The average VDCs per patient per admission decreased from $44,881.66 to $24,958.42, 12 months after care‐plan implementation, a 35.8% reduction (P=0.052). ED costs did not show a statistically significant decrease. However, with the outlier removed as above, costs did decrease by 12.3%, 6 months after care‐plan implementation, approaching statistical significance (P=0.073, data not shown). Combined inpatient and ED variable direct costs decreased by an average of $15,117.30, 6 months after care‐plan implementation, a 45.3% reduction (P=0.002), and by an average of $18,604.50, 12 months after care‐plan implementation, a 25.5% reduction, although this did not reach statistical significance (P=0.129).
DISCUSSION
A multidisciplinary team at our academic medical center developed individualized care plans tailored to the specific medical and psychosocial complexities of high utilizers to reduce unnecessary service utilization and hospital costs. Postintervention analysis shows reduced inpatient admissions and 30‐day readmissions among this population by 50%. Furthermore, inpatient variable direct costs decreased by 47% for the 6 months following care‐plan implementation and by 35% for the 12 months following care‐plan implementation. This translates into a $347,696.97 cost savings for the 23 patients 6 months after care‐plan implementation, and a $223,253.89 cost savings for the 12 patients 12 months after care‐plan implementation. This reduction in utilization and cost was seen across all 3 hospitals in the Duke University Health System, including the only 2 hospitals in Durham, North Carolina. Unlike other urban areas, public transportation in our region is scarce, and the options for hospital shopping in central North Carolina are relatively limited. Although this study does not measure utilization in surrounding counties, we do not feel this occurred as we did not see a rise in requests for medical records nor attempts to contact Duke providers for questions on these patients as a result of our intervention. This, along with our regional health system outcome analysis, provides support that our intervention did not cause patients to seek care elsewhere and result in cost‐shifting to other facilities.
We hypothesize that our care plans may be responsible for decreased admissions and 30‐day readmissions through several mechanisms. By raising awareness of these patients' excessive hospital utilization patterns and making this information readily available through our EMR, providers in the ED may be more conscientious about their admission decisions. Problems that at face value seem acute, are often more chronic and can be better managed in the outpatient setting. Several care plans also explicitly recommend limiting unnecessary intravenous opiate use for chronic pain patients. Other patients who have frequent admissions actually have end‐stage disease, and care plans for these patients help facilitate referrals to hospice programs.
Care plans provide a consistent message of patient histories, utilization patterns, and management strategies, and also serve as a communication tool between hospitalists and ED providers. A systematic review of all ED‐based interventions for high utilizers revealed that most studies did show a reduction in ED visits, but all incorporated case management programs to do so.[15] We did not reduce ED visits, possibly because we lacked the resources and care coordination a community‐based case management program provides. However, care plans did serve as a platform with which hospitalists and ED providers can help coordinate care among multiple outpatient providers. This has potentially limited admissions by providing a referral destination or outpatient point of contact for ED providers. For example, as a result of our intervention, referral mechanisms to our comprehensive pain clinic and outpatient psychiatry clinic have both been strengthened and streamlined. The fact that care plans decreased admissions and readmissions, but not ED visits, suggests that our intervention may not have actually changed patient behavior, but instead changed provider practices in relation to disposition decisions in the ED.
Our QI intervention has several strengths. First, it is fully integrated within our existing healthcare workforce, without the need for an extra case management system. Second, it is seamlessly incorporated into our EMR and represents another potential use of an EMR that has not been previously touted. Third, the multidisciplinary nature of the CCPC ensures that all stakeholders involved in the care of high utilizers are represented. Fourth, the outcome analysis across all 3 hospitals in our health system provides a balancing metric against the notion that our intervention simply caused patients to seek care elsewhere in the region. Last, the QI design and lack of strict inclusion and exclusion criteria adds practicality and shows effectiveness, not just efficacy, of the intervention.
Because this was developed as a QI intervention without strict inclusion and exclusion criteria, generalizability is lacking. In the future, one could use the EMR to more systematically identify high‐utilizing, complex patients. One study showed the ability to use the EMR with a standardized framework to identify hot spotting (high utilizers) and contextual anomaly detection (ie, anomalous utilization cases where patient‐incurred levels of utilization are unexpected given their clinical characteristics).[16] The nonrandomized, retrospective pre/post‐intervention analysis without a control group diminishes the external validity of the results and does introduce the potential for bias.
One of the primary study limitations includes the small sample size of only 24 patients. Admittedly, these first 24 patients are the absolute highest utilizers of care at our hospital, possibly making their utilization patterns more amenable to our intervention. The 96% prevalence rate of mental health and substance abuse in our cohort is significantly higher than other published data among high utilizers.[4, 17, 18] We are continuing to develop care plans for additional high‐utilizing, complex patients, and expect to enroll more patients with end‐stage disease, and relatively fewer with substance abuse or psychiatric illness as time goes on. It is possible this new cohort of patients has proportionally less unnecessary utilization, thus limiting our intervention effect. One final limitation of our study is the lack of care quality and patient safety outcomes. In future studies, health outcomes, adverse events, and outpatient care utilization will be important balancing measures to include.
In conclusion, we showed that a QI intervention using individualized care plans reduces hospital admissions, 30‐day readmissions, and hospital costs across a regional health system for a group of complex, high‐utilizing patients. This intervention can, and should, be developed by a multidisciplinary team and fully integrated into the existing healthcare workforce and EMR to ensure appropriateness, effectiveness, and longevity. Going forward, it will be imperative to evaluate this intervention prospectively, at multiple sites, in coordination with outpatient providers, and including quality and safety outcomes to determine if this hospital‐based intervention impacts care coordination, utilization rates, cost, and health outcomes across the broader healthcare system.
Disclosure
Nothing to report.
- Frequent use of the hospital emergency department is indicative of high use of other health care services. Ann Emerg Med. 2001;37:561–567. , , , , .
- Biopsychosocial health care needs at the emergency room: challenge of complexity. PLoS One. 2012;7:e41775. , , , et al.
- Agency for Healthcare Research and Quality. The high concentration of U.S. health care expenditures. Research in Action. Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/ra19/ra19.pdf. Published June 2006. Accessed November 18, 2013.
- Frequent attenders to an emergency department: a study of primary health care use, medical profile, and psychosocial characteristics. Ann Emerg Med. 2003;41:309–318. , , , , , .
- Centers for Medicare 8:665–671.
- Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med. 2000;9:345–351. , , , et al.
- Consultative intervention to improve outcomes of high utilizers in a public mental health system. Perspect Psychiatr Care. 2004;40:53–60, 69. , , .
- The influence of individual, marital, and family therapy on high utilizers of health care. J Marital Fam Ther. 2003;29:353–363. , , .
- The effects of clinical case management on hospital service use among ED frequent users. Am J Emerg Med. 2000;18:603–608. , , , et al.
- For success with frequent ED utilizers, take steps to understand patient needs, connect them with appropriate resources. ED Manag. 2013;25:57–59.
- ED diversion: multidisciplinary approach engages high utilizers, helps them better navigate the health care system. ED Manag. 2011;23:127–130.
- CM program keeps high utilizers out of hospital. Hosp Case Manag. 2012;20:108–109.
- Use of restriction care plans to decrease medically unnecessary admissions and emergency department visits. J Hosp Med. 2012;7:S2. , , .
- Effectiveness of interventions targeting frequent users of emergency departments: a systematic review. Ann Emerg Med. 2011;58:41–52. , , , et al.
- A healthcare utilization analysis framework for hot spotting and contextual anomaly detection. AMIA Annu Symp Proc. 2012;2012:360–369. , , , , .
- High utilizers of psychiatric emergency services. Psychiatr Serv. 2005;56:678–684. , , .
- Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53:899–904. , , , , .
High utilizers of hospital services are medically complex, psychosocially vulnerable, and at risk for adverse health outcomes.[1, 2] They make up a fraction of the patient population but use a disproportionate amount of resources, with high rates of emergency department (ED) visits and hospital admissions.[1, 3, 4] Less than 1% of patients account for 21% of national healthcare spending, and hospital costs are the largest category of national healthcare expenditures.[2, 5] Many patients who disproportionately contribute to high healthcare costs also have high hospital admission rates.[6]
Interventions targeting high utilizers have typically focused on the outpatient setting.[7, 8, 9, 10] Interventions using individualized care plans in the ED reduced ED visits from 33% to 70%, but all have required an additional case management program or partnership with an outside nonprofit case management organization.[11, 12, 13] One study by a hospitalist group using individualized care plans reduced ED visits and admissions by 70%, 2 months after care‐plan implementation; however, all of their care plans were focused explicitly on restricting intravenous opiate use for patients with chronic pain.[14]
Given the current focus on cost‐conscious, high‐quality care in the American healthcare system, we designed a quality‐improvement (QI) intervention using individualized care plans to reduce unnecessary healthcare service utilization and hospital costs for the highest utilizers of ED and inpatient care. Our approach focuses on integrating care plans within our electronic medical record (EMR) and implementing them using the existing healthcare workforce. We analyzed pre‐ and postintervention data to determine its effect on service utilization and hospital costs across a regional health system.
METHODS
QI Intervention
We retrospectively analyzed data collected as part of an ongoing QI project at Duke University Hospital, a 924‐bed academic tertiary care center with approximately 36,000 inpatient discharges per year. The Complex Care Plan Committee (CCPC) aims to improve the effectiveness, efficiency, and equity of care for medically, socially, and behaviorally complex adult patients who are the highest utilizers of care in the ED and inpatient medicine service. The CCPC is a volunteer, QI committee comprised of a multidisciplinary team from hospital medicine, emergency medicine, psychiatry, ambulatory care, social work, nursing, risk management, and performance services (system analysts). Individualized care plans are developed on a rolling basis as new patients are identified based on their hospital utilization rates (ED visits and admissions). To be eligible for a care plan, patients have to have at least 3 ED visits or admissions within 6 months and have some degree of medical, social, or behavioral complexity, for example, multiple medical comorbidities with care by several subspecialists, or concomitant psychiatric illness, substance abuse, and homelessness. Strict eligibility criteria are purposefully not imposed to allow flexibility and appropriate tailoring of this intervention to both high‐utilizing and complex patients. Given their complexity, the CCPC felt that without individualized care plans these patients would be at increased risk for rehospitalization and increased morbidity or mortality. The patients included in this analysis are the 24 patients with the most ED visits and hospital admissions at Duke University Hospital, accounting for a total of 183 ED visits and 145 inpatient admissions in the 6 months before the care plans were rolled out.
Each individualized care plan summarizes the patient's medical, psychiatric, and social histories, documents any disruptive behaviors, reviews their hospital utilization patterns, and proposes a set of management strategies focused on providing high‐quality care while limiting unnecessary admissions. They are written by 1 or 2 members of the CCPC who perform a thorough chart review and obtain collateral information from the ED, inpatient, and outpatient providers who have cared for that patient. Care plans are then reviewed and approved by the CCPC as a whole during monthly meetings. Care plans contain detailed information in the following domains: demographics; outpatient care team (primary care provider, specialists, psychiatrist/counselors, social worker, case manager, and home health agency); medical, psychiatric, and behavioral health history; social history; utilization patterns (dates of ED visits and hospitalizations with succinct narratives and outcomes of each admission); and finally ED, inpatient, and outpatient strategies for managing the patient, preventing unnecessary admissions, and connecting them to appropriate services. The CCPC chairperson reviews care plans quarterly to ensure they remain appropriate and relevant.
The care plan is a document uploaded into the EMR (EpicCare; Epic, Verona, WI), where it is available to any provider across the Duke health system. Within Epic, a colored banner visible across the top of the patient's chart notifies the provider of any patient with an individualized care plan. The care plan document is housed in a tab readily visible on the navigation pane. The care plan serves as a roadmap for ED providers and hospitalists, helping them navigate each patient's complex history and guiding them in their disposition decision making. We also developed an automated notification process such that when a high utilizer registers in the ED, a secure page is sent to the admitting hospitalist, who then notifies the ED provider. An automated email is also sent to the CCPC chairperson. These alerts also provide a mechanism for internal oversight and feedback by the CCPC to providers regarding care‐plan adherence.
Outcome Variables and Data Analysis
Our analysis included the 24 patients with individualized care plans developed from August 1, 2012 to August 31, 2013. We analyzed utilization data 6 and 12 months before and 6 and 12 months after the individualized care‐plan intervention was initiated (August 1, 2011 to August 31, 2014). Primary outcomes were the number of ED visits and hospital admissions, as well as ED and inpatient variable direct costs (VDCs). Secondary outcomes included inpatient length of stay (LOS) and 30‐day readmissions. We analyzed outcome data across all 3 hospitals in the Duke University Health System. This includes the only 2 hospitals in Durham, North Carolina (population 245,475) and 1 hospital in Raleigh, North Carolina (population 431,746).
We also describe basic demographic data, payor status, and medical comorbidities for this cohort of patients. Payor status is defined as the most frequently reported payor type prior to care‐plan implementation. Variable direct costs are directly related to patient care and fluctuate with patient volume. They include medications, supplies, laboratory tests, radiology studies, and nursing salaries. They are a proportion of total costs for an ED visit or hospitalization, excluding fixed and indirect costs, such as administrator or physician salaries, utilities, facilities, and equipment.
Primary and secondary outcomes were analyzed using descriptive statistics. Continuous outcomes are summarized with mean (standard deviation) and median (range), whereas categorical outcomes are summarized with N (%). LOS is calculated as the average number of days in the hospital per hospital admission per patient. The time periods of 12 months prior, 6 months prior, 6 months after, and 12 months after care‐plan implementation were examined. Only patients with 6 or more months of postcare‐plan data are included in the 6‐month comparison, and only patients with 12 or more months of postcare‐plan data are included in the 12‐month comparison. One patient in the 6‐month comparison group died very soon after care‐plan implementation, so that patient is included in Table 1 (N=24) but excluded from outcome analyses in Tables 2 and 3 (N=23). Differences between 6 months pre and 6 months postcare plan, and 12 months pre and 12 months postcare plan were examined using the Wilcoxon signed rank test for nonparametric matched data. Mean change is calculated as ([Post‐Pre]/Pre) for each patient, and then averaged across all patients. Mean percentage change is calculated as ([Post‐Pre]/Pre)*100 for each patient, and then averaged across patients. It was done this way to emphasize the effect on the patient level. No adjustments were made for multiple comparisons. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). This study was granted exempt status by the Duke University Institutional Review Board.
Patients With Care Plans, N=24 | Patients With 12 Months PostCare Plan Follow‐up, N=12 | Patients With 6 Months PostCare Plan Follow‐up, N=23* | |
---|---|---|---|
| |||
Age, y, mean (SD) | 38.5 (11.7) | 41.6 (9.2) | 37.3 (10.5) |
Median (range) | 36 (2565) | 41 (2858) | 36 (2558) |
Gender, N (%) | |||
Male | 11 (46%) | 5 (42%) | 11 (48%) |
Female | 13 (54%) | 7 (58%) | 12 (52%) |
Payor, N (%) | |||
Medicare | 11 (46%) | 6 (50%) | 10 (43%) |
Medicaid | 9 (38%) | 4 (33%) | 9 (39%) |
Medicare and Medicaid | 0 (0%) | 0 (0%) | 0 (0%) |
Private insurance | 2 (8%) | 1 (8%) | 2 (9%) |
None | 1 (4%) | 0 (0%) | 1 (4%) |
Other | 1 (4%) | 1 (8%) | 1 (4%) |
Comorbidities, N (%) | |||
Asthma | 9 (38%) | 5 (42%) | 9 (39%) |
Chronic obstructive pulmonary disease | 2 (8%) | 2 (17%) | 2 (9%) |
Chronic pain | 20 (83%) | 12 (100%) | 20 (87%) |
Coronary artery disease | 5 (21%) | 4 (33%) | 5 (22%) |
Diabetes mellitus | 10 (42%) | 6 (50%) | 9 (39%) |
End‐stage renal disease | 4 (17%) | 4 (33%) | 4 (17%) |
Heart failure | 5 (21%) | 2 (17%) | 4 (17%) |
Hypertension | 13 (54%) | 6 (50%) | 12 (52%) |
Mental health/substance abuse | 23 (96%) | 12 (100%) | 22 (96%) |
Sickle cell | 10 (42%) | 5 (42%) | 10 (43%) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Admissions | <0.001 | 0.003 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 145 | 56 | 131 | 58 | 56.0% (41.6%) | 50.5% (43.9%) | ||
Mean (SD) | 6.3 (3.8) | 2.4 (2.4) | 10.9 (6.3) | 4.8 (4.2) | 3.9 (3.76) | 6.1 (6.02) | ||
Median (range) | 5 (114) | 2 (08) | 8 (320) | 3 (011) | ||||
30‐day readmissions | <0.001 | 0.002 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 130 | 44 | 106 | 45 | 66.0% (32.4%) | 51.5% (32.0%) | ||
Mean (SD) | 5.7 (4.1) | 1.9 (2.4) | 8.8 (7.0) | 3.8 (2.7) | 3.7 (3.79) | 5.1 (5.71) | ||
Median (range) | 4 (013) | 1 (08) | 6 (019) | 3 (011) | ||||
Inpatient LOS | 0.506 | 0.910 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766 | 358 | 665 | 317 | 50.8% (51.4%) | 37.8% (78.8%) | ||
Mean (SD) | 5.0 (3.2) | 4.7 (4.3) | 4.7 (1.5) | 4.4 (3.1) | 0.3 (4.3) | 0.3 (2.27) | ||
Median (range) | 4.3 (1.515.8) | 4 (016) | 4.8 (2.26.9) | 3.7 (09) | ||||
ED visits | 0.836 | 0.941 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 183 | 198 | 185 | 307 | +42.9% (148.4%) | +48.4% (145.1%) | ||
Mean (SD) | 8.0 (11.5) | 8.6 (19.8) | 15.4 (14.7) | 25.6 (54.4) | 0.7 (11.92) | 10.2 (43.19) | ||
Median (range) | 5 (050) | 3 (096) | 12 (150) | 7 (1196) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Inpatient costs ($) | 0.001 | 0.052 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 686,612.43 | 358,520.42 | 538,579.90 | 299,501.03 | 47.7% (52.3%) | 35.8% (76.1%) | ||
Mean (SD) | 29,852.71 (21,808.22) | 15,587.84 (21,141.79) | 44,881.66 (30,132.26) | 24,958.42 (27,248.41) | 14,264.9 (19,301.75) | 19,923.2 (31,891.69) | ||
Median (range) | 30,203.43 (1,625.1880,171.87) | 7,041.28 (086,457.05) | 39,936.05 (8,237.5382,861.11) | 13,321.56 (082,309.19) | ||||
ED costs ($) | 0.143 | 0.850 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 80,105.34 | 60,500.38 | 82,473.86 | 98,298.84 | +12.5% (147.5%) | +48.0% (161.8%) | ||
Mean (SD) | 3,482.84 (4,423.57) | 2,630.45 (4,782.56) | 6,872.82 (5,633.70) | 8,191.57 (13,974.75) | 852.4 (2,780.01) | 1,318.7 (10,348.89) | ||
Median (range) | 2,239.19 (019,492.03) | 1,163.45 (022,449.84) | 5,924.31 (277.3019,492.03) | 3,002.70 (553.7250,955.56) | ||||
Combined costs ($) | 0.002 | 0.129 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766,717.77 | 419,020.80 | 621,053.76 | 397,799.87 | 45.3% (48.3%) | 25.5% (76.9%) | ||
Mean (SD) | 33,335.56 (22,427.77) | 18,218.30 (21,398.27) | 51,754.48 (32,248.94) | 33,149.99 (31,769.40) | 15,117.3 (19,932.41) | 18,604.5 (35,513.56) | ||
Median (range) | 32,000.42 (1,625.1880,611.70) | 9,088.88 (087,549.37) | 45,716.08 (10,874.0599,426.72) | 23,971.85 (553.7285,440.12) |
RESULTS
Table 1 shows the demographics and comorbidities for the 24 patients with care plans included in this analysis. The average age of patients is 38.5 years (range, 2565 years) and a nearly even split between males (11) and females (13). Chronic disease burden is high. Furthermore, 83% of patients have chronic pain and 96% have mental health problems or substance abuse.
Table 2 shows inpatient and ED utilization patterns before and after care‐plan implementation. Inpatient admissions decreased by 56% for the 6 months after care‐plan implementation (P<0.001) and by 50.5% for the 12 months after care‐plan implementation (P=0.003). This translates to a decrease in the average number of admissions per patient from 6.3 to 2.4, 6 months postcare plan, and from 10.9 to 4.8, 12 months postcare plan.
Thirty‐day readmissions also significantly decreased after care‐plan implementation. Among the 23 patients with data 6 months pre and postcare plan, there were 130 readmissions before and 44 readmissions after care‐plan implementation, a 66% reduction (P<0.001). Among the 12 patients with data 12 months pre and postcare plan, there were 106 readmissions before and 45 readmissions after care‐plan implementation, a 51.5% reduction (P=0.002). Inpatient LOS did not show a statistically significant change after care‐plan implementation.
ED visits were similar for the 6 months pre compared to 6 months postcare plan. ED visits at 12 months postcare plan increased from an average of 15.4 visits pre to 25.6 visits per patient postcare plan. This was driven by a single homeless patient with dialysis‐dependent end‐stage renal disease, who had 134 ED visits in the 12 months after careplan implementation. Analysis of the data with this outlier removed showed a reduction in ED visits from an average of 12.3 visits per patient to 10.1 visits per patient in the 12 months postcare plan; however, this was not statistically significant (P=0.66, data not shown).
Table 3 shows inpatient and ED VDCs before and after care‐plan implementation. The average VDCs per patient per admission decreased from $29,852.71 to $15,587.84, 6 months after care‐plan implementation, a 47.7% reduction (P=0.001). The average VDCs per patient per admission decreased from $44,881.66 to $24,958.42, 12 months after care‐plan implementation, a 35.8% reduction (P=0.052). ED costs did not show a statistically significant decrease. However, with the outlier removed as above, costs did decrease by 12.3%, 6 months after care‐plan implementation, approaching statistical significance (P=0.073, data not shown). Combined inpatient and ED variable direct costs decreased by an average of $15,117.30, 6 months after care‐plan implementation, a 45.3% reduction (P=0.002), and by an average of $18,604.50, 12 months after care‐plan implementation, a 25.5% reduction, although this did not reach statistical significance (P=0.129).
DISCUSSION
A multidisciplinary team at our academic medical center developed individualized care plans tailored to the specific medical and psychosocial complexities of high utilizers to reduce unnecessary service utilization and hospital costs. Postintervention analysis shows reduced inpatient admissions and 30‐day readmissions among this population by 50%. Furthermore, inpatient variable direct costs decreased by 47% for the 6 months following care‐plan implementation and by 35% for the 12 months following care‐plan implementation. This translates into a $347,696.97 cost savings for the 23 patients 6 months after care‐plan implementation, and a $223,253.89 cost savings for the 12 patients 12 months after care‐plan implementation. This reduction in utilization and cost was seen across all 3 hospitals in the Duke University Health System, including the only 2 hospitals in Durham, North Carolina. Unlike other urban areas, public transportation in our region is scarce, and the options for hospital shopping in central North Carolina are relatively limited. Although this study does not measure utilization in surrounding counties, we do not feel this occurred as we did not see a rise in requests for medical records nor attempts to contact Duke providers for questions on these patients as a result of our intervention. This, along with our regional health system outcome analysis, provides support that our intervention did not cause patients to seek care elsewhere and result in cost‐shifting to other facilities.
We hypothesize that our care plans may be responsible for decreased admissions and 30‐day readmissions through several mechanisms. By raising awareness of these patients' excessive hospital utilization patterns and making this information readily available through our EMR, providers in the ED may be more conscientious about their admission decisions. Problems that at face value seem acute, are often more chronic and can be better managed in the outpatient setting. Several care plans also explicitly recommend limiting unnecessary intravenous opiate use for chronic pain patients. Other patients who have frequent admissions actually have end‐stage disease, and care plans for these patients help facilitate referrals to hospice programs.
Care plans provide a consistent message of patient histories, utilization patterns, and management strategies, and also serve as a communication tool between hospitalists and ED providers. A systematic review of all ED‐based interventions for high utilizers revealed that most studies did show a reduction in ED visits, but all incorporated case management programs to do so.[15] We did not reduce ED visits, possibly because we lacked the resources and care coordination a community‐based case management program provides. However, care plans did serve as a platform with which hospitalists and ED providers can help coordinate care among multiple outpatient providers. This has potentially limited admissions by providing a referral destination or outpatient point of contact for ED providers. For example, as a result of our intervention, referral mechanisms to our comprehensive pain clinic and outpatient psychiatry clinic have both been strengthened and streamlined. The fact that care plans decreased admissions and readmissions, but not ED visits, suggests that our intervention may not have actually changed patient behavior, but instead changed provider practices in relation to disposition decisions in the ED.
Our QI intervention has several strengths. First, it is fully integrated within our existing healthcare workforce, without the need for an extra case management system. Second, it is seamlessly incorporated into our EMR and represents another potential use of an EMR that has not been previously touted. Third, the multidisciplinary nature of the CCPC ensures that all stakeholders involved in the care of high utilizers are represented. Fourth, the outcome analysis across all 3 hospitals in our health system provides a balancing metric against the notion that our intervention simply caused patients to seek care elsewhere in the region. Last, the QI design and lack of strict inclusion and exclusion criteria adds practicality and shows effectiveness, not just efficacy, of the intervention.
Because this was developed as a QI intervention without strict inclusion and exclusion criteria, generalizability is lacking. In the future, one could use the EMR to more systematically identify high‐utilizing, complex patients. One study showed the ability to use the EMR with a standardized framework to identify hot spotting (high utilizers) and contextual anomaly detection (ie, anomalous utilization cases where patient‐incurred levels of utilization are unexpected given their clinical characteristics).[16] The nonrandomized, retrospective pre/post‐intervention analysis without a control group diminishes the external validity of the results and does introduce the potential for bias.
One of the primary study limitations includes the small sample size of only 24 patients. Admittedly, these first 24 patients are the absolute highest utilizers of care at our hospital, possibly making their utilization patterns more amenable to our intervention. The 96% prevalence rate of mental health and substance abuse in our cohort is significantly higher than other published data among high utilizers.[4, 17, 18] We are continuing to develop care plans for additional high‐utilizing, complex patients, and expect to enroll more patients with end‐stage disease, and relatively fewer with substance abuse or psychiatric illness as time goes on. It is possible this new cohort of patients has proportionally less unnecessary utilization, thus limiting our intervention effect. One final limitation of our study is the lack of care quality and patient safety outcomes. In future studies, health outcomes, adverse events, and outpatient care utilization will be important balancing measures to include.
In conclusion, we showed that a QI intervention using individualized care plans reduces hospital admissions, 30‐day readmissions, and hospital costs across a regional health system for a group of complex, high‐utilizing patients. This intervention can, and should, be developed by a multidisciplinary team and fully integrated into the existing healthcare workforce and EMR to ensure appropriateness, effectiveness, and longevity. Going forward, it will be imperative to evaluate this intervention prospectively, at multiple sites, in coordination with outpatient providers, and including quality and safety outcomes to determine if this hospital‐based intervention impacts care coordination, utilization rates, cost, and health outcomes across the broader healthcare system.
Disclosure
Nothing to report.
High utilizers of hospital services are medically complex, psychosocially vulnerable, and at risk for adverse health outcomes.[1, 2] They make up a fraction of the patient population but use a disproportionate amount of resources, with high rates of emergency department (ED) visits and hospital admissions.[1, 3, 4] Less than 1% of patients account for 21% of national healthcare spending, and hospital costs are the largest category of national healthcare expenditures.[2, 5] Many patients who disproportionately contribute to high healthcare costs also have high hospital admission rates.[6]
Interventions targeting high utilizers have typically focused on the outpatient setting.[7, 8, 9, 10] Interventions using individualized care plans in the ED reduced ED visits from 33% to 70%, but all have required an additional case management program or partnership with an outside nonprofit case management organization.[11, 12, 13] One study by a hospitalist group using individualized care plans reduced ED visits and admissions by 70%, 2 months after care‐plan implementation; however, all of their care plans were focused explicitly on restricting intravenous opiate use for patients with chronic pain.[14]
Given the current focus on cost‐conscious, high‐quality care in the American healthcare system, we designed a quality‐improvement (QI) intervention using individualized care plans to reduce unnecessary healthcare service utilization and hospital costs for the highest utilizers of ED and inpatient care. Our approach focuses on integrating care plans within our electronic medical record (EMR) and implementing them using the existing healthcare workforce. We analyzed pre‐ and postintervention data to determine its effect on service utilization and hospital costs across a regional health system.
METHODS
QI Intervention
We retrospectively analyzed data collected as part of an ongoing QI project at Duke University Hospital, a 924‐bed academic tertiary care center with approximately 36,000 inpatient discharges per year. The Complex Care Plan Committee (CCPC) aims to improve the effectiveness, efficiency, and equity of care for medically, socially, and behaviorally complex adult patients who are the highest utilizers of care in the ED and inpatient medicine service. The CCPC is a volunteer, QI committee comprised of a multidisciplinary team from hospital medicine, emergency medicine, psychiatry, ambulatory care, social work, nursing, risk management, and performance services (system analysts). Individualized care plans are developed on a rolling basis as new patients are identified based on their hospital utilization rates (ED visits and admissions). To be eligible for a care plan, patients have to have at least 3 ED visits or admissions within 6 months and have some degree of medical, social, or behavioral complexity, for example, multiple medical comorbidities with care by several subspecialists, or concomitant psychiatric illness, substance abuse, and homelessness. Strict eligibility criteria are purposefully not imposed to allow flexibility and appropriate tailoring of this intervention to both high‐utilizing and complex patients. Given their complexity, the CCPC felt that without individualized care plans these patients would be at increased risk for rehospitalization and increased morbidity or mortality. The patients included in this analysis are the 24 patients with the most ED visits and hospital admissions at Duke University Hospital, accounting for a total of 183 ED visits and 145 inpatient admissions in the 6 months before the care plans were rolled out.
Each individualized care plan summarizes the patient's medical, psychiatric, and social histories, documents any disruptive behaviors, reviews their hospital utilization patterns, and proposes a set of management strategies focused on providing high‐quality care while limiting unnecessary admissions. They are written by 1 or 2 members of the CCPC who perform a thorough chart review and obtain collateral information from the ED, inpatient, and outpatient providers who have cared for that patient. Care plans are then reviewed and approved by the CCPC as a whole during monthly meetings. Care plans contain detailed information in the following domains: demographics; outpatient care team (primary care provider, specialists, psychiatrist/counselors, social worker, case manager, and home health agency); medical, psychiatric, and behavioral health history; social history; utilization patterns (dates of ED visits and hospitalizations with succinct narratives and outcomes of each admission); and finally ED, inpatient, and outpatient strategies for managing the patient, preventing unnecessary admissions, and connecting them to appropriate services. The CCPC chairperson reviews care plans quarterly to ensure they remain appropriate and relevant.
The care plan is a document uploaded into the EMR (EpicCare; Epic, Verona, WI), where it is available to any provider across the Duke health system. Within Epic, a colored banner visible across the top of the patient's chart notifies the provider of any patient with an individualized care plan. The care plan document is housed in a tab readily visible on the navigation pane. The care plan serves as a roadmap for ED providers and hospitalists, helping them navigate each patient's complex history and guiding them in their disposition decision making. We also developed an automated notification process such that when a high utilizer registers in the ED, a secure page is sent to the admitting hospitalist, who then notifies the ED provider. An automated email is also sent to the CCPC chairperson. These alerts also provide a mechanism for internal oversight and feedback by the CCPC to providers regarding care‐plan adherence.
Outcome Variables and Data Analysis
Our analysis included the 24 patients with individualized care plans developed from August 1, 2012 to August 31, 2013. We analyzed utilization data 6 and 12 months before and 6 and 12 months after the individualized care‐plan intervention was initiated (August 1, 2011 to August 31, 2014). Primary outcomes were the number of ED visits and hospital admissions, as well as ED and inpatient variable direct costs (VDCs). Secondary outcomes included inpatient length of stay (LOS) and 30‐day readmissions. We analyzed outcome data across all 3 hospitals in the Duke University Health System. This includes the only 2 hospitals in Durham, North Carolina (population 245,475) and 1 hospital in Raleigh, North Carolina (population 431,746).
We also describe basic demographic data, payor status, and medical comorbidities for this cohort of patients. Payor status is defined as the most frequently reported payor type prior to care‐plan implementation. Variable direct costs are directly related to patient care and fluctuate with patient volume. They include medications, supplies, laboratory tests, radiology studies, and nursing salaries. They are a proportion of total costs for an ED visit or hospitalization, excluding fixed and indirect costs, such as administrator or physician salaries, utilities, facilities, and equipment.
Primary and secondary outcomes were analyzed using descriptive statistics. Continuous outcomes are summarized with mean (standard deviation) and median (range), whereas categorical outcomes are summarized with N (%). LOS is calculated as the average number of days in the hospital per hospital admission per patient. The time periods of 12 months prior, 6 months prior, 6 months after, and 12 months after care‐plan implementation were examined. Only patients with 6 or more months of postcare‐plan data are included in the 6‐month comparison, and only patients with 12 or more months of postcare‐plan data are included in the 12‐month comparison. One patient in the 6‐month comparison group died very soon after care‐plan implementation, so that patient is included in Table 1 (N=24) but excluded from outcome analyses in Tables 2 and 3 (N=23). Differences between 6 months pre and 6 months postcare plan, and 12 months pre and 12 months postcare plan were examined using the Wilcoxon signed rank test for nonparametric matched data. Mean change is calculated as ([Post‐Pre]/Pre) for each patient, and then averaged across all patients. Mean percentage change is calculated as ([Post‐Pre]/Pre)*100 for each patient, and then averaged across patients. It was done this way to emphasize the effect on the patient level. No adjustments were made for multiple comparisons. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). This study was granted exempt status by the Duke University Institutional Review Board.
Patients With Care Plans, N=24 | Patients With 12 Months PostCare Plan Follow‐up, N=12 | Patients With 6 Months PostCare Plan Follow‐up, N=23* | |
---|---|---|---|
| |||
Age, y, mean (SD) | 38.5 (11.7) | 41.6 (9.2) | 37.3 (10.5) |
Median (range) | 36 (2565) | 41 (2858) | 36 (2558) |
Gender, N (%) | |||
Male | 11 (46%) | 5 (42%) | 11 (48%) |
Female | 13 (54%) | 7 (58%) | 12 (52%) |
Payor, N (%) | |||
Medicare | 11 (46%) | 6 (50%) | 10 (43%) |
Medicaid | 9 (38%) | 4 (33%) | 9 (39%) |
Medicare and Medicaid | 0 (0%) | 0 (0%) | 0 (0%) |
Private insurance | 2 (8%) | 1 (8%) | 2 (9%) |
None | 1 (4%) | 0 (0%) | 1 (4%) |
Other | 1 (4%) | 1 (8%) | 1 (4%) |
Comorbidities, N (%) | |||
Asthma | 9 (38%) | 5 (42%) | 9 (39%) |
Chronic obstructive pulmonary disease | 2 (8%) | 2 (17%) | 2 (9%) |
Chronic pain | 20 (83%) | 12 (100%) | 20 (87%) |
Coronary artery disease | 5 (21%) | 4 (33%) | 5 (22%) |
Diabetes mellitus | 10 (42%) | 6 (50%) | 9 (39%) |
End‐stage renal disease | 4 (17%) | 4 (33%) | 4 (17%) |
Heart failure | 5 (21%) | 2 (17%) | 4 (17%) |
Hypertension | 13 (54%) | 6 (50%) | 12 (52%) |
Mental health/substance abuse | 23 (96%) | 12 (100%) | 22 (96%) |
Sickle cell | 10 (42%) | 5 (42%) | 10 (43%) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Admissions | <0.001 | 0.003 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 145 | 56 | 131 | 58 | 56.0% (41.6%) | 50.5% (43.9%) | ||
Mean (SD) | 6.3 (3.8) | 2.4 (2.4) | 10.9 (6.3) | 4.8 (4.2) | 3.9 (3.76) | 6.1 (6.02) | ||
Median (range) | 5 (114) | 2 (08) | 8 (320) | 3 (011) | ||||
30‐day readmissions | <0.001 | 0.002 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 130 | 44 | 106 | 45 | 66.0% (32.4%) | 51.5% (32.0%) | ||
Mean (SD) | 5.7 (4.1) | 1.9 (2.4) | 8.8 (7.0) | 3.8 (2.7) | 3.7 (3.79) | 5.1 (5.71) | ||
Median (range) | 4 (013) | 1 (08) | 6 (019) | 3 (011) | ||||
Inpatient LOS | 0.506 | 0.910 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766 | 358 | 665 | 317 | 50.8% (51.4%) | 37.8% (78.8%) | ||
Mean (SD) | 5.0 (3.2) | 4.7 (4.3) | 4.7 (1.5) | 4.4 (3.1) | 0.3 (4.3) | 0.3 (2.27) | ||
Median (range) | 4.3 (1.515.8) | 4 (016) | 4.8 (2.26.9) | 3.7 (09) | ||||
ED visits | 0.836 | 0.941 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 183 | 198 | 185 | 307 | +42.9% (148.4%) | +48.4% (145.1%) | ||
Mean (SD) | 8.0 (11.5) | 8.6 (19.8) | 15.4 (14.7) | 25.6 (54.4) | 0.7 (11.92) | 10.2 (43.19) | ||
Median (range) | 5 (050) | 3 (096) | 12 (150) | 7 (1196) |
6 Months Pre Care Plan | 6 Months Post Care Plan | 12 Months Pre Care Plan | 12 Months Post Care Plan | 6‐Month Change | 6‐Month P Value | 12‐Month Change | 12‐Month P Value | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Inpatient costs ($) | 0.001 | 0.052 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 686,612.43 | 358,520.42 | 538,579.90 | 299,501.03 | 47.7% (52.3%) | 35.8% (76.1%) | ||
Mean (SD) | 29,852.71 (21,808.22) | 15,587.84 (21,141.79) | 44,881.66 (30,132.26) | 24,958.42 (27,248.41) | 14,264.9 (19,301.75) | 19,923.2 (31,891.69) | ||
Median (range) | 30,203.43 (1,625.1880,171.87) | 7,041.28 (086,457.05) | 39,936.05 (8,237.5382,861.11) | 13,321.56 (082,309.19) | ||||
ED costs ($) | 0.143 | 0.850 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 80,105.34 | 60,500.38 | 82,473.86 | 98,298.84 | +12.5% (147.5%) | +48.0% (161.8%) | ||
Mean (SD) | 3,482.84 (4,423.57) | 2,630.45 (4,782.56) | 6,872.82 (5,633.70) | 8,191.57 (13,974.75) | 852.4 (2,780.01) | 1,318.7 (10,348.89) | ||
Median (range) | 2,239.19 (019,492.03) | 1,163.45 (022,449.84) | 5,924.31 (277.3019,492.03) | 3,002.70 (553.7250,955.56) | ||||
Combined costs ($) | 0.002 | 0.129 | ||||||
N | 23 | 23 | 12 | 12 | 23 | 23 | 12 | 12 |
Total | 766,717.77 | 419,020.80 | 621,053.76 | 397,799.87 | 45.3% (48.3%) | 25.5% (76.9%) | ||
Mean (SD) | 33,335.56 (22,427.77) | 18,218.30 (21,398.27) | 51,754.48 (32,248.94) | 33,149.99 (31,769.40) | 15,117.3 (19,932.41) | 18,604.5 (35,513.56) | ||
Median (range) | 32,000.42 (1,625.1880,611.70) | 9,088.88 (087,549.37) | 45,716.08 (10,874.0599,426.72) | 23,971.85 (553.7285,440.12) |
RESULTS
Table 1 shows the demographics and comorbidities for the 24 patients with care plans included in this analysis. The average age of patients is 38.5 years (range, 2565 years) and a nearly even split between males (11) and females (13). Chronic disease burden is high. Furthermore, 83% of patients have chronic pain and 96% have mental health problems or substance abuse.
Table 2 shows inpatient and ED utilization patterns before and after care‐plan implementation. Inpatient admissions decreased by 56% for the 6 months after care‐plan implementation (P<0.001) and by 50.5% for the 12 months after care‐plan implementation (P=0.003). This translates to a decrease in the average number of admissions per patient from 6.3 to 2.4, 6 months postcare plan, and from 10.9 to 4.8, 12 months postcare plan.
Thirty‐day readmissions also significantly decreased after care‐plan implementation. Among the 23 patients with data 6 months pre and postcare plan, there were 130 readmissions before and 44 readmissions after care‐plan implementation, a 66% reduction (P<0.001). Among the 12 patients with data 12 months pre and postcare plan, there were 106 readmissions before and 45 readmissions after care‐plan implementation, a 51.5% reduction (P=0.002). Inpatient LOS did not show a statistically significant change after care‐plan implementation.
ED visits were similar for the 6 months pre compared to 6 months postcare plan. ED visits at 12 months postcare plan increased from an average of 15.4 visits pre to 25.6 visits per patient postcare plan. This was driven by a single homeless patient with dialysis‐dependent end‐stage renal disease, who had 134 ED visits in the 12 months after careplan implementation. Analysis of the data with this outlier removed showed a reduction in ED visits from an average of 12.3 visits per patient to 10.1 visits per patient in the 12 months postcare plan; however, this was not statistically significant (P=0.66, data not shown).
Table 3 shows inpatient and ED VDCs before and after care‐plan implementation. The average VDCs per patient per admission decreased from $29,852.71 to $15,587.84, 6 months after care‐plan implementation, a 47.7% reduction (P=0.001). The average VDCs per patient per admission decreased from $44,881.66 to $24,958.42, 12 months after care‐plan implementation, a 35.8% reduction (P=0.052). ED costs did not show a statistically significant decrease. However, with the outlier removed as above, costs did decrease by 12.3%, 6 months after care‐plan implementation, approaching statistical significance (P=0.073, data not shown). Combined inpatient and ED variable direct costs decreased by an average of $15,117.30, 6 months after care‐plan implementation, a 45.3% reduction (P=0.002), and by an average of $18,604.50, 12 months after care‐plan implementation, a 25.5% reduction, although this did not reach statistical significance (P=0.129).
DISCUSSION
A multidisciplinary team at our academic medical center developed individualized care plans tailored to the specific medical and psychosocial complexities of high utilizers to reduce unnecessary service utilization and hospital costs. Postintervention analysis shows reduced inpatient admissions and 30‐day readmissions among this population by 50%. Furthermore, inpatient variable direct costs decreased by 47% for the 6 months following care‐plan implementation and by 35% for the 12 months following care‐plan implementation. This translates into a $347,696.97 cost savings for the 23 patients 6 months after care‐plan implementation, and a $223,253.89 cost savings for the 12 patients 12 months after care‐plan implementation. This reduction in utilization and cost was seen across all 3 hospitals in the Duke University Health System, including the only 2 hospitals in Durham, North Carolina. Unlike other urban areas, public transportation in our region is scarce, and the options for hospital shopping in central North Carolina are relatively limited. Although this study does not measure utilization in surrounding counties, we do not feel this occurred as we did not see a rise in requests for medical records nor attempts to contact Duke providers for questions on these patients as a result of our intervention. This, along with our regional health system outcome analysis, provides support that our intervention did not cause patients to seek care elsewhere and result in cost‐shifting to other facilities.
We hypothesize that our care plans may be responsible for decreased admissions and 30‐day readmissions through several mechanisms. By raising awareness of these patients' excessive hospital utilization patterns and making this information readily available through our EMR, providers in the ED may be more conscientious about their admission decisions. Problems that at face value seem acute, are often more chronic and can be better managed in the outpatient setting. Several care plans also explicitly recommend limiting unnecessary intravenous opiate use for chronic pain patients. Other patients who have frequent admissions actually have end‐stage disease, and care plans for these patients help facilitate referrals to hospice programs.
Care plans provide a consistent message of patient histories, utilization patterns, and management strategies, and also serve as a communication tool between hospitalists and ED providers. A systematic review of all ED‐based interventions for high utilizers revealed that most studies did show a reduction in ED visits, but all incorporated case management programs to do so.[15] We did not reduce ED visits, possibly because we lacked the resources and care coordination a community‐based case management program provides. However, care plans did serve as a platform with which hospitalists and ED providers can help coordinate care among multiple outpatient providers. This has potentially limited admissions by providing a referral destination or outpatient point of contact for ED providers. For example, as a result of our intervention, referral mechanisms to our comprehensive pain clinic and outpatient psychiatry clinic have both been strengthened and streamlined. The fact that care plans decreased admissions and readmissions, but not ED visits, suggests that our intervention may not have actually changed patient behavior, but instead changed provider practices in relation to disposition decisions in the ED.
Our QI intervention has several strengths. First, it is fully integrated within our existing healthcare workforce, without the need for an extra case management system. Second, it is seamlessly incorporated into our EMR and represents another potential use of an EMR that has not been previously touted. Third, the multidisciplinary nature of the CCPC ensures that all stakeholders involved in the care of high utilizers are represented. Fourth, the outcome analysis across all 3 hospitals in our health system provides a balancing metric against the notion that our intervention simply caused patients to seek care elsewhere in the region. Last, the QI design and lack of strict inclusion and exclusion criteria adds practicality and shows effectiveness, not just efficacy, of the intervention.
Because this was developed as a QI intervention without strict inclusion and exclusion criteria, generalizability is lacking. In the future, one could use the EMR to more systematically identify high‐utilizing, complex patients. One study showed the ability to use the EMR with a standardized framework to identify hot spotting (high utilizers) and contextual anomaly detection (ie, anomalous utilization cases where patient‐incurred levels of utilization are unexpected given their clinical characteristics).[16] The nonrandomized, retrospective pre/post‐intervention analysis without a control group diminishes the external validity of the results and does introduce the potential for bias.
One of the primary study limitations includes the small sample size of only 24 patients. Admittedly, these first 24 patients are the absolute highest utilizers of care at our hospital, possibly making their utilization patterns more amenable to our intervention. The 96% prevalence rate of mental health and substance abuse in our cohort is significantly higher than other published data among high utilizers.[4, 17, 18] We are continuing to develop care plans for additional high‐utilizing, complex patients, and expect to enroll more patients with end‐stage disease, and relatively fewer with substance abuse or psychiatric illness as time goes on. It is possible this new cohort of patients has proportionally less unnecessary utilization, thus limiting our intervention effect. One final limitation of our study is the lack of care quality and patient safety outcomes. In future studies, health outcomes, adverse events, and outpatient care utilization will be important balancing measures to include.
In conclusion, we showed that a QI intervention using individualized care plans reduces hospital admissions, 30‐day readmissions, and hospital costs across a regional health system for a group of complex, high‐utilizing patients. This intervention can, and should, be developed by a multidisciplinary team and fully integrated into the existing healthcare workforce and EMR to ensure appropriateness, effectiveness, and longevity. Going forward, it will be imperative to evaluate this intervention prospectively, at multiple sites, in coordination with outpatient providers, and including quality and safety outcomes to determine if this hospital‐based intervention impacts care coordination, utilization rates, cost, and health outcomes across the broader healthcare system.
Disclosure
Nothing to report.
- Frequent use of the hospital emergency department is indicative of high use of other health care services. Ann Emerg Med. 2001;37:561–567. , , , , .
- Biopsychosocial health care needs at the emergency room: challenge of complexity. PLoS One. 2012;7:e41775. , , , et al.
- Agency for Healthcare Research and Quality. The high concentration of U.S. health care expenditures. Research in Action. Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/ra19/ra19.pdf. Published June 2006. Accessed November 18, 2013.
- Frequent attenders to an emergency department: a study of primary health care use, medical profile, and psychosocial characteristics. Ann Emerg Med. 2003;41:309–318. , , , , , .
- Centers for Medicare 8:665–671.
- Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med. 2000;9:345–351. , , , et al.
- Consultative intervention to improve outcomes of high utilizers in a public mental health system. Perspect Psychiatr Care. 2004;40:53–60, 69. , , .
- The influence of individual, marital, and family therapy on high utilizers of health care. J Marital Fam Ther. 2003;29:353–363. , , .
- The effects of clinical case management on hospital service use among ED frequent users. Am J Emerg Med. 2000;18:603–608. , , , et al.
- For success with frequent ED utilizers, take steps to understand patient needs, connect them with appropriate resources. ED Manag. 2013;25:57–59.
- ED diversion: multidisciplinary approach engages high utilizers, helps them better navigate the health care system. ED Manag. 2011;23:127–130.
- CM program keeps high utilizers out of hospital. Hosp Case Manag. 2012;20:108–109.
- Use of restriction care plans to decrease medically unnecessary admissions and emergency department visits. J Hosp Med. 2012;7:S2. , , .
- Effectiveness of interventions targeting frequent users of emergency departments: a systematic review. Ann Emerg Med. 2011;58:41–52. , , , et al.
- A healthcare utilization analysis framework for hot spotting and contextual anomaly detection. AMIA Annu Symp Proc. 2012;2012:360–369. , , , , .
- High utilizers of psychiatric emergency services. Psychiatr Serv. 2005;56:678–684. , , .
- Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53:899–904. , , , , .
- Frequent use of the hospital emergency department is indicative of high use of other health care services. Ann Emerg Med. 2001;37:561–567. , , , , .
- Biopsychosocial health care needs at the emergency room: challenge of complexity. PLoS One. 2012;7:e41775. , , , et al.
- Agency for Healthcare Research and Quality. The high concentration of U.S. health care expenditures. Research in Action. Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/ra19/ra19.pdf. Published June 2006. Accessed November 18, 2013.
- Frequent attenders to an emergency department: a study of primary health care use, medical profile, and psychosocial characteristics. Ann Emerg Med. 2003;41:309–318. , , , , , .
- Centers for Medicare 8:665–671.
- Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med. 2000;9:345–351. , , , et al.
- Consultative intervention to improve outcomes of high utilizers in a public mental health system. Perspect Psychiatr Care. 2004;40:53–60, 69. , , .
- The influence of individual, marital, and family therapy on high utilizers of health care. J Marital Fam Ther. 2003;29:353–363. , , .
- The effects of clinical case management on hospital service use among ED frequent users. Am J Emerg Med. 2000;18:603–608. , , , et al.
- For success with frequent ED utilizers, take steps to understand patient needs, connect them with appropriate resources. ED Manag. 2013;25:57–59.
- ED diversion: multidisciplinary approach engages high utilizers, helps them better navigate the health care system. ED Manag. 2011;23:127–130.
- CM program keeps high utilizers out of hospital. Hosp Case Manag. 2012;20:108–109.
- Use of restriction care plans to decrease medically unnecessary admissions and emergency department visits. J Hosp Med. 2012;7:S2. , , .
- Effectiveness of interventions targeting frequent users of emergency departments: a systematic review. Ann Emerg Med. 2011;58:41–52. , , , et al.
- A healthcare utilization analysis framework for hot spotting and contextual anomaly detection. AMIA Annu Symp Proc. 2012;2012:360–369. , , , , .
- High utilizers of psychiatric emergency services. Psychiatr Serv. 2005;56:678–684. , , .
- Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry. 1996;53:899–904. , , , , .
© 2015 Society of Hospital Medicine
Patient‐Reported Outcome Measures
Despite widespread efforts to predict 30‐day rehospitalizations among discharged general medical patients,[1, 2, 3] not many strategies have incorporated patient‐reported outcome (PRO) measures in predictive models.[4] This despite the many longitudinal studies of the ambulatory population that demonstrate the higher likelihood of hospitalizations among those who score poorly on General Self‐Rated Health (GSRH),[5, 6, 7] baseline or declining Health‐Related Quality of Life,[8, 9, 10, 11, 12] psychological symptoms,[13, 14] and physical symptoms assessments.[15] One of the few existing studies that included PRO measures in 30‐day readmission models showed the predictive value of the 12‐item short form (SF12) Physical Component Score.[16] Others showed that persistent symptoms were associated with readmissions in patients with heart disease.[17, 18]
The paucity of efforts to connect PRO measures to utilization may be due to the limited availability of these measures in routine clinical records and the incomplete knowledge about how various PRO measures may fluctuate during episodes of acute illnesses and their treatments during hospitalizations. Health perception measures reflect both enduring features like self‐concept as well as dynamic features like a person's immediate health status.[19] As such, GSRH reflects the presence of chronic illnesses but is also responsive to acute events.[20, 21] Similarly, Health‐Related Quality of Life measures are dynamic as they decline around episodes of acute illness but are stable over a longer time window in their tendency to recover.[22] We do not know how fluctuations in measures of symptom burden, perceived health, and quality of life around the hospital‐to‐home transition may differentially inform readmission risk. Using a longitudinal cohort study, we addressed 2 questions: (1) How do PRO measures change when measured serially during the hospital‐to‐home transition? (2) How does the relative timing of each PRO measure variably inform the risk of subsequent utilization events including hospital readmissions?
METHODS
We conducted a longitudinal cohort study using data originally collected for a trial (
The following instruments were administered at each interview. The physical symptom severity portion of the Memorial Symptom Assessment Scale (MSAS) solicited the severity rank (none/a little bit/somewhat/quite a bit/very much) of 17 physical symptoms in the last week; the score was calculated by averaging the severity rank of the 12 most common symptom in the sample.[25, 26] The Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form is an instrument assessing GSRH (1 item), Social Activities (1 item), Global Physical Health (4 items), and Global Mental Health (4 items including a single‐item quality‐of‐life measure). Fatigue and pain for Global Physical Health, and emotional health for Global Mental Health were assessed over the past 7 days. Each of the 2 Global Health scores was standardized to a national mean of 50 and standard deviation of 10.[27]
The rate of survey completion at each follow‐up was calculated. Characteristics of participants were tabulated. Characteristics of patients censored prior to study completion were compared with patients with complete data. Box plots for MSAS physical symptom severity, and Global Physical and Mental Health scores were constructed to illustrate the comparisons of the mean scores between each consecutive survey period using t tests assuming unequal variance. A similar box plot of GSRH illustrated the comparison of the median score between consecutive surveys using the rank sum test. Hospital‐based utilization events were defined as either an emergency department visit or hospitalization at 1 of the 2 hospitals of the Cook County Health & Hospitals System (CCHHS). After accounting for patient data censored due to death (date reported by family) or withdrawal from study, Kaplan‐Meier curves showing time to first hospital‐based utilization event during each interval between surveys were drawn separately for above‐ and below‐median MSAS, Global Physical and Mental Health scores, and for poor or fair versus good, very good, or excellent GSRH assessment. The null hypothesis that the survivor functions were equal between the better and worse median quantiles or GSRH categories was tested using the log‐rank test at 14 and 30 days from survey completion. Hazard ratios for time to first utilization event within 14 days of each survey were calculated for the MSAS score, Global Physical and Mental Health as continuous variables, and GSRH response categories relative to poor using bivariate and multivariate Cox proportional hazard equations. Multivariate models incorporated the following 5 covariates: at least 1 utilization event during the study period prior to the survey, Charlson score, age, gender, and race/ethnicity category. Likelihood ratio statistics were calculated to test the hypothesis that the model including the PRO measure and covariates predicted the outcome equally well compared to the nested model with only covariates. We used the traditional threshold of .05 when reporting significance. All analyses were performed in Stata 13 (StataCorp, College Station, TX). The methods for patient consent, data collection, analyses, and reporting were reviewed and approved by the CCHHS institutional review board.
RESULTS
A total of 196 patients completed the initial survey. The completion rates were 98%, 90%, and 88% for the 30‐, 90‐, and 180‐day follow‐up surveys, respectively. As shown in Table 1, participants average age was 52 years, and about half were women. The majority was non‐Hispanic black, and 21% preferred to complete the survey in Spanish. Diabetes, congestive heart failure, cancer, and chronic pulmonary disease were each prevalent in at least one‐fifth of our patient cohort. Demographic characteristics were similar between the 160 patients who completed all 3 follow‐up surveys and the 36 who missed at least 1 follow‐up survey. Among the latter group, 1 withdrew at 30 days, 1 withdrew and 4 had died at 90 days, and 1 withdrew and 9 had died at 180 days.
| |
Age, y, mean (SD) | 52 (10) |
Female, n (%) | 100 (51) |
Race/ethnicity category, n (%) | |
Non‐Hispanic black | 117 (60) |
Hispanic | 52 (27) |
Non‐Hispanic white | 20 (10) |
Other | 6 (3) |
Language, n (%) | |
English | 155 (79) |
Spanish | 41 (21) |
Charlson Comorbidity Index, median (range) | 1 (09) |
Charlson comorbidities, n (%) | |
Diabetes | 71 (36) |
Congestive heart failure | 52 (27) |
Cancer (with and without metastases) | 43 (22) |
Chronic pulmonary disease | 40 (20) |
Myocardial infarction | 17 (9) |
Renal disease | 11 (6) |
Figure 1 shows a timeline of the follow‐up surveys and utilization events in the form of overlapping histograms. The majority of 30‐day follow‐up questionnaires were completed earlier than targeted, at a median of 17 (interquartile range [IQR] 16, 20) days after discharge. Similarly, questionnaires targeted for 90 and 180 days were completed at medians of 78 (IQR 7684) and 167 (IQR 166169) days from discharge. Fifty‐four (28%) patients experienced a first utilization event in the first 30 days following discharge. During the 60‐, 90‐, and 30‐day intervals after the first, second, and third follow‐up surveys, respectively, 63 (33%), 54 (31%), and 16 (9%) patients experienced a first utilization event.

A significant improvement in MSAS physical symptom severity was detected between the hospitalization and the 30‐day follow‐up (Figure 2A). Although the mean Global Physical Health score was below the national mean of 50 at every survey period, a similar improvement in the measure was noted between the hospitalization and the 30‐day follow‐up (Figure 2B). The mean Global Mental Health score was also below the national mean but remained stable throughout the study (Figure 2C). The median GSRH was stable at 2 (IQR 23) at every survey wave (Figure 2D). Of note, compared to patients who completed all 3 follow‐up surveys, patients who missed at least 1 follow‐up reported higher MSAS score (1.5 vs 1.8, P=0.03), lower Global Physical Health (36.1 vs 33.5, P=0.09), and lower Global Mental Health (44.7 vs 41.0, P=0.03) during their hospitalization. In addition, patients with complete data experienced an average of 1.2 utilization events during the study, whereas those with missing data experienced an average of 2.1 utilization events (P=0.03).

The MSAS physical symptom severity and Global Physical Health scores from the index hospitalizations did not identify patients with a first utilization event within 30 days. However, patients with poor Global Mental Health and GSRH in the hospital were more likely to experience a utilization event within 14 days of discharge (Figure 3). During the postdischarge period, patients scoring poorly on each of the PRO measures trended toward a greater risk of an early utilization event, but the association between utilization and MSAS was most consistently significant (Figure 3A). In general, the associations with MSAS, Global Physical Health, and GSRH were stronger with the risk of utilization events within 14 days than within 30 days (Figure 3A,B,D). The Global Mental Health score was not associated with a subsequent utilization when measured during the 180‐day postdischarge period.

As shown in Table 2, Cox proportional hazard models incorporating covariates preserved most of the significant associations seen in the unadjusted analyses. Global Mental Health and good relative to poor GSRH obtained during the hospitalization remained significant. MSAS obtained at each postdischarge follow‐up trended positively with utilization and was statistically significant at 90 and 180 days. Global Physical Health obtained at each postdischarge follow‐up similarly trended negatively with utilization and was significant at 180 days. Each multivariate model incorporating a PRO measure with a significant coefficient contributed to better fit of the predictive model compared to the nested model without the PRO measure.
Unadjusted Hazard Ratio | P | Adjusted Hazard Ratio* | P | Likelihood Ratio | P | |
---|---|---|---|---|---|---|
| ||||||
Hospital discharge | ||||||
MSAS | 1.47 | 0.11 | 1.38 | 0.19 | 1.65 | 0.20 |
Global Physical Health | 0.96 | 0.10 | 0.96 | 0.13 | 2.29 | 0.13 |
Global Mental Health | 0.96 | 0.05 | 0.96 | 0.05 | 4.05 | 0.04 |
GSRH | ||||||
Fair | 1.09 | 0.85 | 1.26 | 0.61 | 12.27 | 0.02 |
Good | 0.24 | 0.04 | 0.23 | 0.03 | ||
Very good | 1.09 | 0.90 | 1.40 | 0.63 | ||
Excellent | NC | NS | NC | NS | ||
30 days | ||||||
MSAS | 1.54 | 0.07 | 1.40 | 0.20 | 1.57 | 0.21 |
Global Physical Health | 0.96 | 0.08 | 0.97 | 0.24 | 1.42 | 0.23 |
Global Mental Health | 0.98 | 0.42 | 0.99 | 0.62 | 0.25 | 0.62 |
GSRH | ||||||
Fair | 0.92 | 0.86 | 1.19 | 0.72 | 8.85 | 0.07 |
Good | 0.85 | 0.31 | 0.94 | 0.91 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.69 | 0.36 | 6.28 | 0.11 | ||
90 days | ||||||
MSAS | 2.23 | 0.03 | 2.20 | 0.05 | 3.79 | 0.05 |
Global Physical Health | 0.94 | 0.07 | 0.95 | 0.11 | 2.75 | 0.10 |
Global Mental Health | 0.96 | 0.20 | 0.95 | 0.15 | 2.11 | 0.15 |
GSRH | ||||||
Fair | 0.75 | 0.63 | 0.67 | 0.53 | 6.67 | 0.15 |
Good | 0.32 | 0.19 | 0.28 | 0.15 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.12 | 0.50 | 2.20 | 0.49 | ||
180 days | ||||||
MSAS | 2.39 | 0.03 | 3.51 | 0.01 | 7.04 | 0.01 |
Global Physical Health | 0.93 | 0.06 | 0.93 | 0.03 | 4.61 | 0.03 |
Global Mental Health | 0.97 | 0.38 | 0.96 | 0.33 | 0.95 | 0.33 |
GSRH | ||||||
Fair | 0.98 | 0.98 | 0.64 | 0.55 | 7.13 | 0.13 |
Good | 0.33 | 0.23 | 0.20 | 0.09 | ||
Very good | NC | NS | NC | NS | ||
Excellent | NC | NS | NC | NS |
DISCUSSION
In this longitudinal cohort study, patients, on average, reported relatively severe symptoms, low PROMIS Global Physical and Mental Health scores, and poor GSRH during the inpatient stay in an urban safety‐net hospital. Symptom severity and Global Physical Health improved, on average, by 30 days before stabilizing, but their poor levels in the hospital did not predict 30‐day hospital‐based utilization events. On the other hand, Global Mental Health and GSRH were stable through hospitalizations, and patients scoring poorly on these measures were at greater risk of utilization events within 14 days of discharge. PRO measures obtained during the 180‐day postdischarge period trended toward distinguishing populations with greater baseline risk of proximate utilization events. However, MSAS physical symptom severity and Global Physical Health were more consistently predictive of these events at statistically significant levels compared to Global Mental Health and GSRH in our relatively small sample of patients. Each of these measures selectively improved the fit‐of‐risk prediction models for hospital‐based utilization.
Some of the heterogeneity in readmission risk is explained by differences in PRO measures. Although the MSAS score and Global Physical Health assessment were reliable predictors of utilization when measured in ambulatory settings, they were less discriminating during acute hospitalizations when everyone, on average, reported severe symptoms and poor function. Our results were consistent with other studies that demonstrated the fairly rapid recovery in symptoms that follow hospitalizations,[28, 29] and these measures may become informative of utilization risk as early as 2 weeks postdischarge. GSRH and Global Mental Health (a measure of health‐related quality of life) only predicted utilizations immediately at hospital discharge. As multidimensional measures that reflect physical, social, and emotional capacity, these measures may indicate vulnerabilities in patients least able to handle the stresses of the early postdischarge period.
There is growing momentum around collecting PRO measures in routine clinical care as quality indicators that capture patient‐centered concerns.[30] Our study explored a novel application of these measures whose routine collection will likely proliferate, not solely for the purpose of helping healthcare systems identify patients at risk of unplanned resource utilization. Although multidimensional PRO measures seldom reflect conditions directly modifiable by simple interventions, we believe that the association between physical symptom burden and utilization in our data reveals a possible target for practice improvement. Hospitalists have contributed enormously to shorter lengths of stay that risk sicker and quicker discharges.[31] To mitigate its potential side effects on symptom management, a discharge plan that acknowledges physical symptoms that sometimes persist or recur beyond the hospitalization may be appropriate. This may be accomplished by ensuring that acute symptoms are resolving, giving clear instructions for symptom management at home, as now the standard of care for conditions like asthma,[32] and explicitly communicating the presence of residual symptoms to providers entrusted with continuity care. As an effective feedback measure that can drive continuous quality improvement, we believe that a technology‐based surveillance strategy that spans both the inpatient and outpatient domains is necessary.[23]
There are some notable similarities and differences between the results of our study and a recent hospital‐based study of PRO measures that used data from the Multi‐Center Hospitalist Project.[16] The Physical Component Score of the SF12 is similar to the PROMIS Global Physical Health score in that both incorporate measures of physical function, perceived health, pain, and energy level. Curiously, the SF12 Physical Component Score, but not the PROMIS Global Physical Health score, was associated with 30‐day rehospitalizations. An important difference between the measures is where the SF12 asks about limitations during the past 4 weeks the PROMIS instrument inquires about physical function in general and levels of fatigue and pain in the past 7 days. Considering most hospitalizations last <7 days, the PROMIS instrument may better reflect the declines associated with the acute illness related to the hospitalization than the SF12 score. Additionally, the discrepancy between the association between hospital‐based GSRH and utilization in our study and the absence, thereof, in Hasan et al. is noteworthy. The difference here may be explained by their use of a 0‐ to 100‐point response scale in contrast to our study's verbally labeled 5‐point scale in the PROMIS instrument. The range of rating scales for survey questions is traditionally governed by the tension between the difficulty with mapping respondents judgment on an excessively large scale on one hand, and the failure of insufficient response options to discriminate between respondents with different underlying judgment on the other.[33] We suspect the former to be a drawback of the unlabeled 100‐point response scale, and conjecture that an association might be found in the Multi‐Center Hospitalist Study data if the responses were grouped into summative categories.
We recognize several limitations in our study. The first is the generalizability of our patient population to others, not insignificantly because of the high proportion of the uninsured (around 70% during the study period) and racial/ethnic minorities among them. Although utilization patterns are clearly affected by socioeconomic status,[34] there may also be differences in the way validated PRO measures are calibrated between patients of public and private healthcare systems.[35] Another limitation is our inability to count utilization events at institutions outside of the CCHHS during our study. However, because the study was conducted prior to Cook County's Medicaid expansion demonstration program as part of the Affordable Care Act,[36] many patients established in our system faced barriers to receiving nonemergency care outside of the CCHHS supporting our assumption that few of our patients were discharged from other hospitals. Causality cannot be established in observational studies. Consequently, high prior‐symptom burden may be associated with utilizations through unmeasured variables. Measures of symptom burden are vulnerable to overendorsement and amplification.[37, 38] Inferences based on statistical significance are affected by sample size, and our conclusions may change if conducted with a larger number of participants. Our response rates were excellent through the survey waves, but we did not achieve perfect follow‐up. Worse levels of PRO responses and higher levels of utilization among censored patients biased our results toward the null. Finally, although we did not find any predominant comorbidities associated with hospital‐based utilizations in our sample, our analyses may be vulnerable to inadequate control for illness severity, which may also have biased our results.
PRO measures are likely to be useful in clinical medicine.[39] But to fully apply the powers of PROs in informing clinically and operationally relevant outcomes, we must actively develop a system for obtaining these measures in routine clinical care. The availability of patient downtime makes hospitalizations conducive to gathering patient‐generated data, and may further enhance patient‐provider communication if survey output was readily available in electronic medical records. Exploring innovative strategies for collecting PROs in the hospital and beyond remains our future work.
Disclosures
Funded by the Agency for Healthcare Research and Quality: R24 HS19481‐01 to support technology implementation. The authors report no conflicts of interest, relevant financial interests, activities, relationships, and affiliations that influenced this work. The first and senior authors had full access to all data and take responsibility for their integrity and the accuracy of the data analysis.
- Potentially avoidable 30‐day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med. 2013;173:632–638. , , , .
- Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ. 2010;182:551–557. , , , et al.
- Redefining readmission risk factors for general medicine patients. J Hosp Med. 2011;6:54–60. , , , .
- Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306:1688–1698. , , , et al.
- Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–1246. , , , .
- Repeated hospitalizations and self‐rated health among the elderly: a multivariate failure time analysis. Am J Epidemiol. 2001;153 3 232–241. , , .
- Screening elders for risk of hospital admission. J Am Geriatr Soc. 1993;41:811–817. , , , , , .
- Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol. 1996;78:890–895. , , , et al.
- Using quality of life to predict hospitalization and mortality in patients with obstructive lung disease. Chest. 2002;122:429–436. , , , , .
- Intraindividual change in SF‐36 in ambulatory clinic primary care patients predicted mortality and hospitalizations. J Clin Epidemiol. 2004;57:277–283. , , , .
- Use of health‐related, quality‐of‐life metrics to predict mortality and hospitalizations in community‐dwelling seniors. J Am Geriatr Soc. 2006;54:667–673. , , , et al.
- Medical outcomes study short form‐36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41:1286–1292. , , , .
- Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–1856. , , , et al.
- Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002;62:199–207. , , , et al.
- Health status predicts long‐term outcomes in outpatients with coronary disease. Circulation. 2002;106:43–49. , , , , .
- Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med. 2010;25:211–219. , , , et al.
- Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. Eur J Heart Fail. 2014;16:854–860. , , , , , .
- Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. Am J Cardiol. 2015;115:75–81. , , , et al.
- Two views of self‐rated general health status. Soc Sci Med. 2003;56:203–217. , , .
- Self‐rated health and physical disability in elderly survivors of a major medical event. J Gerontol B Psychol Sci Soc Sci. 1996;51:S96–S104. , , .
- Predicting changes in perceived health status. Am J Public Health. 1984;74:611–614. , , .
- Quality of life before and after intensive care. Anaesthesia. 2005;60:322–329. , , , , .
- Trick WE. Health perceptions and symptom burden in primary care: measuring health using audio computer‐assisted self‐interviews [published online ahead of print December 7, 2014]. Qual Life Res. doi: 10.1007/s11136‐014‐0884‐4. , , , , ,
- Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992;45:613–619. , , .
- The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326–1336. , , , et al.
- The Memorial Symptom Assessment Scale short form (MSAS‐SF). Cancer. 2000;89:1162–1171. , , , , .
- Development of physical and mental health summary schores from the Patient‐Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18:873–880. , , , , .
- Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE‐AHF). J Card Fail. 2008;14:777–784. , , , et al.
- Longitudinal assessment of symptom severity among hospitalized elders diagnosed with cancer, heart failure, and chronic obstructive pulmonary disease. J Hosp Med. 2012;7:567–572. , , , .
- The patient experience and health outcomes. N Engl J Med. 2013;368:201–203. , , , .
- "Quicker and sicker" under Medicare's prospective payment system for hospitals: new evidence on an old issue from a national longitudinal survey. Bull Econ Res. 2011;63:1–27. , , , .
- Agency for Healthcare Research and Quality. Asthma care quality improvement measures. Available at: http://www.ahrq.gov/professionals/quality‐patient‐safety/quality‐resources/tools/asthmaqual/asthmacare/appendix‐d.html. Accessed January 30, 2015.
- The Psychology of Survey Response. New York, NY: Cambridge University Press; 2000. , , .
- Health care for children and youth in the United States: annual report on patterns of coverage, utilization, quality, and expenditures by income. Ambul Pediatr. 2005;5:6–44. , , , et al.
- Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011;29:2859–2865. , , , et al.
- http://kff.org/medicaid/issue-brief/profiles-of-medicaid-outreach-and-enrollment-strategies-the-cook-county-early-expansion-initiative. Published April 7, 2014. Accessed December 2, 2014. . Profiles of Medicaid outreach and enrollment strategies: the Cook County early expansion initiative. The Henry J. Kaiser Family Foundation. Available at:
- A primary care perspective on prevailing assumptions about persistent medically unexplained physical symptoms. Int J Psychiatry Med. 2002;32:125–140. , , .
- Symptom burden and comorbidities impact the consistency of responses on patient‐reported functional outcomes. Arch Phys Med Rehabil. 2014;95:79–86. , , , .
- Implementing patient‐reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305–1314. , , , et al.
Despite widespread efforts to predict 30‐day rehospitalizations among discharged general medical patients,[1, 2, 3] not many strategies have incorporated patient‐reported outcome (PRO) measures in predictive models.[4] This despite the many longitudinal studies of the ambulatory population that demonstrate the higher likelihood of hospitalizations among those who score poorly on General Self‐Rated Health (GSRH),[5, 6, 7] baseline or declining Health‐Related Quality of Life,[8, 9, 10, 11, 12] psychological symptoms,[13, 14] and physical symptoms assessments.[15] One of the few existing studies that included PRO measures in 30‐day readmission models showed the predictive value of the 12‐item short form (SF12) Physical Component Score.[16] Others showed that persistent symptoms were associated with readmissions in patients with heart disease.[17, 18]
The paucity of efforts to connect PRO measures to utilization may be due to the limited availability of these measures in routine clinical records and the incomplete knowledge about how various PRO measures may fluctuate during episodes of acute illnesses and their treatments during hospitalizations. Health perception measures reflect both enduring features like self‐concept as well as dynamic features like a person's immediate health status.[19] As such, GSRH reflects the presence of chronic illnesses but is also responsive to acute events.[20, 21] Similarly, Health‐Related Quality of Life measures are dynamic as they decline around episodes of acute illness but are stable over a longer time window in their tendency to recover.[22] We do not know how fluctuations in measures of symptom burden, perceived health, and quality of life around the hospital‐to‐home transition may differentially inform readmission risk. Using a longitudinal cohort study, we addressed 2 questions: (1) How do PRO measures change when measured serially during the hospital‐to‐home transition? (2) How does the relative timing of each PRO measure variably inform the risk of subsequent utilization events including hospital readmissions?
METHODS
We conducted a longitudinal cohort study using data originally collected for a trial (
The following instruments were administered at each interview. The physical symptom severity portion of the Memorial Symptom Assessment Scale (MSAS) solicited the severity rank (none/a little bit/somewhat/quite a bit/very much) of 17 physical symptoms in the last week; the score was calculated by averaging the severity rank of the 12 most common symptom in the sample.[25, 26] The Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form is an instrument assessing GSRH (1 item), Social Activities (1 item), Global Physical Health (4 items), and Global Mental Health (4 items including a single‐item quality‐of‐life measure). Fatigue and pain for Global Physical Health, and emotional health for Global Mental Health were assessed over the past 7 days. Each of the 2 Global Health scores was standardized to a national mean of 50 and standard deviation of 10.[27]
The rate of survey completion at each follow‐up was calculated. Characteristics of participants were tabulated. Characteristics of patients censored prior to study completion were compared with patients with complete data. Box plots for MSAS physical symptom severity, and Global Physical and Mental Health scores were constructed to illustrate the comparisons of the mean scores between each consecutive survey period using t tests assuming unequal variance. A similar box plot of GSRH illustrated the comparison of the median score between consecutive surveys using the rank sum test. Hospital‐based utilization events were defined as either an emergency department visit or hospitalization at 1 of the 2 hospitals of the Cook County Health & Hospitals System (CCHHS). After accounting for patient data censored due to death (date reported by family) or withdrawal from study, Kaplan‐Meier curves showing time to first hospital‐based utilization event during each interval between surveys were drawn separately for above‐ and below‐median MSAS, Global Physical and Mental Health scores, and for poor or fair versus good, very good, or excellent GSRH assessment. The null hypothesis that the survivor functions were equal between the better and worse median quantiles or GSRH categories was tested using the log‐rank test at 14 and 30 days from survey completion. Hazard ratios for time to first utilization event within 14 days of each survey were calculated for the MSAS score, Global Physical and Mental Health as continuous variables, and GSRH response categories relative to poor using bivariate and multivariate Cox proportional hazard equations. Multivariate models incorporated the following 5 covariates: at least 1 utilization event during the study period prior to the survey, Charlson score, age, gender, and race/ethnicity category. Likelihood ratio statistics were calculated to test the hypothesis that the model including the PRO measure and covariates predicted the outcome equally well compared to the nested model with only covariates. We used the traditional threshold of .05 when reporting significance. All analyses were performed in Stata 13 (StataCorp, College Station, TX). The methods for patient consent, data collection, analyses, and reporting were reviewed and approved by the CCHHS institutional review board.
RESULTS
A total of 196 patients completed the initial survey. The completion rates were 98%, 90%, and 88% for the 30‐, 90‐, and 180‐day follow‐up surveys, respectively. As shown in Table 1, participants average age was 52 years, and about half were women. The majority was non‐Hispanic black, and 21% preferred to complete the survey in Spanish. Diabetes, congestive heart failure, cancer, and chronic pulmonary disease were each prevalent in at least one‐fifth of our patient cohort. Demographic characteristics were similar between the 160 patients who completed all 3 follow‐up surveys and the 36 who missed at least 1 follow‐up survey. Among the latter group, 1 withdrew at 30 days, 1 withdrew and 4 had died at 90 days, and 1 withdrew and 9 had died at 180 days.
| |
Age, y, mean (SD) | 52 (10) |
Female, n (%) | 100 (51) |
Race/ethnicity category, n (%) | |
Non‐Hispanic black | 117 (60) |
Hispanic | 52 (27) |
Non‐Hispanic white | 20 (10) |
Other | 6 (3) |
Language, n (%) | |
English | 155 (79) |
Spanish | 41 (21) |
Charlson Comorbidity Index, median (range) | 1 (09) |
Charlson comorbidities, n (%) | |
Diabetes | 71 (36) |
Congestive heart failure | 52 (27) |
Cancer (with and without metastases) | 43 (22) |
Chronic pulmonary disease | 40 (20) |
Myocardial infarction | 17 (9) |
Renal disease | 11 (6) |
Figure 1 shows a timeline of the follow‐up surveys and utilization events in the form of overlapping histograms. The majority of 30‐day follow‐up questionnaires were completed earlier than targeted, at a median of 17 (interquartile range [IQR] 16, 20) days after discharge. Similarly, questionnaires targeted for 90 and 180 days were completed at medians of 78 (IQR 7684) and 167 (IQR 166169) days from discharge. Fifty‐four (28%) patients experienced a first utilization event in the first 30 days following discharge. During the 60‐, 90‐, and 30‐day intervals after the first, second, and third follow‐up surveys, respectively, 63 (33%), 54 (31%), and 16 (9%) patients experienced a first utilization event.

A significant improvement in MSAS physical symptom severity was detected between the hospitalization and the 30‐day follow‐up (Figure 2A). Although the mean Global Physical Health score was below the national mean of 50 at every survey period, a similar improvement in the measure was noted between the hospitalization and the 30‐day follow‐up (Figure 2B). The mean Global Mental Health score was also below the national mean but remained stable throughout the study (Figure 2C). The median GSRH was stable at 2 (IQR 23) at every survey wave (Figure 2D). Of note, compared to patients who completed all 3 follow‐up surveys, patients who missed at least 1 follow‐up reported higher MSAS score (1.5 vs 1.8, P=0.03), lower Global Physical Health (36.1 vs 33.5, P=0.09), and lower Global Mental Health (44.7 vs 41.0, P=0.03) during their hospitalization. In addition, patients with complete data experienced an average of 1.2 utilization events during the study, whereas those with missing data experienced an average of 2.1 utilization events (P=0.03).

The MSAS physical symptom severity and Global Physical Health scores from the index hospitalizations did not identify patients with a first utilization event within 30 days. However, patients with poor Global Mental Health and GSRH in the hospital were more likely to experience a utilization event within 14 days of discharge (Figure 3). During the postdischarge period, patients scoring poorly on each of the PRO measures trended toward a greater risk of an early utilization event, but the association between utilization and MSAS was most consistently significant (Figure 3A). In general, the associations with MSAS, Global Physical Health, and GSRH were stronger with the risk of utilization events within 14 days than within 30 days (Figure 3A,B,D). The Global Mental Health score was not associated with a subsequent utilization when measured during the 180‐day postdischarge period.

As shown in Table 2, Cox proportional hazard models incorporating covariates preserved most of the significant associations seen in the unadjusted analyses. Global Mental Health and good relative to poor GSRH obtained during the hospitalization remained significant. MSAS obtained at each postdischarge follow‐up trended positively with utilization and was statistically significant at 90 and 180 days. Global Physical Health obtained at each postdischarge follow‐up similarly trended negatively with utilization and was significant at 180 days. Each multivariate model incorporating a PRO measure with a significant coefficient contributed to better fit of the predictive model compared to the nested model without the PRO measure.
Unadjusted Hazard Ratio | P | Adjusted Hazard Ratio* | P | Likelihood Ratio | P | |
---|---|---|---|---|---|---|
| ||||||
Hospital discharge | ||||||
MSAS | 1.47 | 0.11 | 1.38 | 0.19 | 1.65 | 0.20 |
Global Physical Health | 0.96 | 0.10 | 0.96 | 0.13 | 2.29 | 0.13 |
Global Mental Health | 0.96 | 0.05 | 0.96 | 0.05 | 4.05 | 0.04 |
GSRH | ||||||
Fair | 1.09 | 0.85 | 1.26 | 0.61 | 12.27 | 0.02 |
Good | 0.24 | 0.04 | 0.23 | 0.03 | ||
Very good | 1.09 | 0.90 | 1.40 | 0.63 | ||
Excellent | NC | NS | NC | NS | ||
30 days | ||||||
MSAS | 1.54 | 0.07 | 1.40 | 0.20 | 1.57 | 0.21 |
Global Physical Health | 0.96 | 0.08 | 0.97 | 0.24 | 1.42 | 0.23 |
Global Mental Health | 0.98 | 0.42 | 0.99 | 0.62 | 0.25 | 0.62 |
GSRH | ||||||
Fair | 0.92 | 0.86 | 1.19 | 0.72 | 8.85 | 0.07 |
Good | 0.85 | 0.31 | 0.94 | 0.91 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.69 | 0.36 | 6.28 | 0.11 | ||
90 days | ||||||
MSAS | 2.23 | 0.03 | 2.20 | 0.05 | 3.79 | 0.05 |
Global Physical Health | 0.94 | 0.07 | 0.95 | 0.11 | 2.75 | 0.10 |
Global Mental Health | 0.96 | 0.20 | 0.95 | 0.15 | 2.11 | 0.15 |
GSRH | ||||||
Fair | 0.75 | 0.63 | 0.67 | 0.53 | 6.67 | 0.15 |
Good | 0.32 | 0.19 | 0.28 | 0.15 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.12 | 0.50 | 2.20 | 0.49 | ||
180 days | ||||||
MSAS | 2.39 | 0.03 | 3.51 | 0.01 | 7.04 | 0.01 |
Global Physical Health | 0.93 | 0.06 | 0.93 | 0.03 | 4.61 | 0.03 |
Global Mental Health | 0.97 | 0.38 | 0.96 | 0.33 | 0.95 | 0.33 |
GSRH | ||||||
Fair | 0.98 | 0.98 | 0.64 | 0.55 | 7.13 | 0.13 |
Good | 0.33 | 0.23 | 0.20 | 0.09 | ||
Very good | NC | NS | NC | NS | ||
Excellent | NC | NS | NC | NS |
DISCUSSION
In this longitudinal cohort study, patients, on average, reported relatively severe symptoms, low PROMIS Global Physical and Mental Health scores, and poor GSRH during the inpatient stay in an urban safety‐net hospital. Symptom severity and Global Physical Health improved, on average, by 30 days before stabilizing, but their poor levels in the hospital did not predict 30‐day hospital‐based utilization events. On the other hand, Global Mental Health and GSRH were stable through hospitalizations, and patients scoring poorly on these measures were at greater risk of utilization events within 14 days of discharge. PRO measures obtained during the 180‐day postdischarge period trended toward distinguishing populations with greater baseline risk of proximate utilization events. However, MSAS physical symptom severity and Global Physical Health were more consistently predictive of these events at statistically significant levels compared to Global Mental Health and GSRH in our relatively small sample of patients. Each of these measures selectively improved the fit‐of‐risk prediction models for hospital‐based utilization.
Some of the heterogeneity in readmission risk is explained by differences in PRO measures. Although the MSAS score and Global Physical Health assessment were reliable predictors of utilization when measured in ambulatory settings, they were less discriminating during acute hospitalizations when everyone, on average, reported severe symptoms and poor function. Our results were consistent with other studies that demonstrated the fairly rapid recovery in symptoms that follow hospitalizations,[28, 29] and these measures may become informative of utilization risk as early as 2 weeks postdischarge. GSRH and Global Mental Health (a measure of health‐related quality of life) only predicted utilizations immediately at hospital discharge. As multidimensional measures that reflect physical, social, and emotional capacity, these measures may indicate vulnerabilities in patients least able to handle the stresses of the early postdischarge period.
There is growing momentum around collecting PRO measures in routine clinical care as quality indicators that capture patient‐centered concerns.[30] Our study explored a novel application of these measures whose routine collection will likely proliferate, not solely for the purpose of helping healthcare systems identify patients at risk of unplanned resource utilization. Although multidimensional PRO measures seldom reflect conditions directly modifiable by simple interventions, we believe that the association between physical symptom burden and utilization in our data reveals a possible target for practice improvement. Hospitalists have contributed enormously to shorter lengths of stay that risk sicker and quicker discharges.[31] To mitigate its potential side effects on symptom management, a discharge plan that acknowledges physical symptoms that sometimes persist or recur beyond the hospitalization may be appropriate. This may be accomplished by ensuring that acute symptoms are resolving, giving clear instructions for symptom management at home, as now the standard of care for conditions like asthma,[32] and explicitly communicating the presence of residual symptoms to providers entrusted with continuity care. As an effective feedback measure that can drive continuous quality improvement, we believe that a technology‐based surveillance strategy that spans both the inpatient and outpatient domains is necessary.[23]
There are some notable similarities and differences between the results of our study and a recent hospital‐based study of PRO measures that used data from the Multi‐Center Hospitalist Project.[16] The Physical Component Score of the SF12 is similar to the PROMIS Global Physical Health score in that both incorporate measures of physical function, perceived health, pain, and energy level. Curiously, the SF12 Physical Component Score, but not the PROMIS Global Physical Health score, was associated with 30‐day rehospitalizations. An important difference between the measures is where the SF12 asks about limitations during the past 4 weeks the PROMIS instrument inquires about physical function in general and levels of fatigue and pain in the past 7 days. Considering most hospitalizations last <7 days, the PROMIS instrument may better reflect the declines associated with the acute illness related to the hospitalization than the SF12 score. Additionally, the discrepancy between the association between hospital‐based GSRH and utilization in our study and the absence, thereof, in Hasan et al. is noteworthy. The difference here may be explained by their use of a 0‐ to 100‐point response scale in contrast to our study's verbally labeled 5‐point scale in the PROMIS instrument. The range of rating scales for survey questions is traditionally governed by the tension between the difficulty with mapping respondents judgment on an excessively large scale on one hand, and the failure of insufficient response options to discriminate between respondents with different underlying judgment on the other.[33] We suspect the former to be a drawback of the unlabeled 100‐point response scale, and conjecture that an association might be found in the Multi‐Center Hospitalist Study data if the responses were grouped into summative categories.
We recognize several limitations in our study. The first is the generalizability of our patient population to others, not insignificantly because of the high proportion of the uninsured (around 70% during the study period) and racial/ethnic minorities among them. Although utilization patterns are clearly affected by socioeconomic status,[34] there may also be differences in the way validated PRO measures are calibrated between patients of public and private healthcare systems.[35] Another limitation is our inability to count utilization events at institutions outside of the CCHHS during our study. However, because the study was conducted prior to Cook County's Medicaid expansion demonstration program as part of the Affordable Care Act,[36] many patients established in our system faced barriers to receiving nonemergency care outside of the CCHHS supporting our assumption that few of our patients were discharged from other hospitals. Causality cannot be established in observational studies. Consequently, high prior‐symptom burden may be associated with utilizations through unmeasured variables. Measures of symptom burden are vulnerable to overendorsement and amplification.[37, 38] Inferences based on statistical significance are affected by sample size, and our conclusions may change if conducted with a larger number of participants. Our response rates were excellent through the survey waves, but we did not achieve perfect follow‐up. Worse levels of PRO responses and higher levels of utilization among censored patients biased our results toward the null. Finally, although we did not find any predominant comorbidities associated with hospital‐based utilizations in our sample, our analyses may be vulnerable to inadequate control for illness severity, which may also have biased our results.
PRO measures are likely to be useful in clinical medicine.[39] But to fully apply the powers of PROs in informing clinically and operationally relevant outcomes, we must actively develop a system for obtaining these measures in routine clinical care. The availability of patient downtime makes hospitalizations conducive to gathering patient‐generated data, and may further enhance patient‐provider communication if survey output was readily available in electronic medical records. Exploring innovative strategies for collecting PROs in the hospital and beyond remains our future work.
Disclosures
Funded by the Agency for Healthcare Research and Quality: R24 HS19481‐01 to support technology implementation. The authors report no conflicts of interest, relevant financial interests, activities, relationships, and affiliations that influenced this work. The first and senior authors had full access to all data and take responsibility for their integrity and the accuracy of the data analysis.
Despite widespread efforts to predict 30‐day rehospitalizations among discharged general medical patients,[1, 2, 3] not many strategies have incorporated patient‐reported outcome (PRO) measures in predictive models.[4] This despite the many longitudinal studies of the ambulatory population that demonstrate the higher likelihood of hospitalizations among those who score poorly on General Self‐Rated Health (GSRH),[5, 6, 7] baseline or declining Health‐Related Quality of Life,[8, 9, 10, 11, 12] psychological symptoms,[13, 14] and physical symptoms assessments.[15] One of the few existing studies that included PRO measures in 30‐day readmission models showed the predictive value of the 12‐item short form (SF12) Physical Component Score.[16] Others showed that persistent symptoms were associated with readmissions in patients with heart disease.[17, 18]
The paucity of efforts to connect PRO measures to utilization may be due to the limited availability of these measures in routine clinical records and the incomplete knowledge about how various PRO measures may fluctuate during episodes of acute illnesses and their treatments during hospitalizations. Health perception measures reflect both enduring features like self‐concept as well as dynamic features like a person's immediate health status.[19] As such, GSRH reflects the presence of chronic illnesses but is also responsive to acute events.[20, 21] Similarly, Health‐Related Quality of Life measures are dynamic as they decline around episodes of acute illness but are stable over a longer time window in their tendency to recover.[22] We do not know how fluctuations in measures of symptom burden, perceived health, and quality of life around the hospital‐to‐home transition may differentially inform readmission risk. Using a longitudinal cohort study, we addressed 2 questions: (1) How do PRO measures change when measured serially during the hospital‐to‐home transition? (2) How does the relative timing of each PRO measure variably inform the risk of subsequent utilization events including hospital readmissions?
METHODS
We conducted a longitudinal cohort study using data originally collected for a trial (
The following instruments were administered at each interview. The physical symptom severity portion of the Memorial Symptom Assessment Scale (MSAS) solicited the severity rank (none/a little bit/somewhat/quite a bit/very much) of 17 physical symptoms in the last week; the score was calculated by averaging the severity rank of the 12 most common symptom in the sample.[25, 26] The Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form is an instrument assessing GSRH (1 item), Social Activities (1 item), Global Physical Health (4 items), and Global Mental Health (4 items including a single‐item quality‐of‐life measure). Fatigue and pain for Global Physical Health, and emotional health for Global Mental Health were assessed over the past 7 days. Each of the 2 Global Health scores was standardized to a national mean of 50 and standard deviation of 10.[27]
The rate of survey completion at each follow‐up was calculated. Characteristics of participants were tabulated. Characteristics of patients censored prior to study completion were compared with patients with complete data. Box plots for MSAS physical symptom severity, and Global Physical and Mental Health scores were constructed to illustrate the comparisons of the mean scores between each consecutive survey period using t tests assuming unequal variance. A similar box plot of GSRH illustrated the comparison of the median score between consecutive surveys using the rank sum test. Hospital‐based utilization events were defined as either an emergency department visit or hospitalization at 1 of the 2 hospitals of the Cook County Health & Hospitals System (CCHHS). After accounting for patient data censored due to death (date reported by family) or withdrawal from study, Kaplan‐Meier curves showing time to first hospital‐based utilization event during each interval between surveys were drawn separately for above‐ and below‐median MSAS, Global Physical and Mental Health scores, and for poor or fair versus good, very good, or excellent GSRH assessment. The null hypothesis that the survivor functions were equal between the better and worse median quantiles or GSRH categories was tested using the log‐rank test at 14 and 30 days from survey completion. Hazard ratios for time to first utilization event within 14 days of each survey were calculated for the MSAS score, Global Physical and Mental Health as continuous variables, and GSRH response categories relative to poor using bivariate and multivariate Cox proportional hazard equations. Multivariate models incorporated the following 5 covariates: at least 1 utilization event during the study period prior to the survey, Charlson score, age, gender, and race/ethnicity category. Likelihood ratio statistics were calculated to test the hypothesis that the model including the PRO measure and covariates predicted the outcome equally well compared to the nested model with only covariates. We used the traditional threshold of .05 when reporting significance. All analyses were performed in Stata 13 (StataCorp, College Station, TX). The methods for patient consent, data collection, analyses, and reporting were reviewed and approved by the CCHHS institutional review board.
RESULTS
A total of 196 patients completed the initial survey. The completion rates were 98%, 90%, and 88% for the 30‐, 90‐, and 180‐day follow‐up surveys, respectively. As shown in Table 1, participants average age was 52 years, and about half were women. The majority was non‐Hispanic black, and 21% preferred to complete the survey in Spanish. Diabetes, congestive heart failure, cancer, and chronic pulmonary disease were each prevalent in at least one‐fifth of our patient cohort. Demographic characteristics were similar between the 160 patients who completed all 3 follow‐up surveys and the 36 who missed at least 1 follow‐up survey. Among the latter group, 1 withdrew at 30 days, 1 withdrew and 4 had died at 90 days, and 1 withdrew and 9 had died at 180 days.
| |
Age, y, mean (SD) | 52 (10) |
Female, n (%) | 100 (51) |
Race/ethnicity category, n (%) | |
Non‐Hispanic black | 117 (60) |
Hispanic | 52 (27) |
Non‐Hispanic white | 20 (10) |
Other | 6 (3) |
Language, n (%) | |
English | 155 (79) |
Spanish | 41 (21) |
Charlson Comorbidity Index, median (range) | 1 (09) |
Charlson comorbidities, n (%) | |
Diabetes | 71 (36) |
Congestive heart failure | 52 (27) |
Cancer (with and without metastases) | 43 (22) |
Chronic pulmonary disease | 40 (20) |
Myocardial infarction | 17 (9) |
Renal disease | 11 (6) |
Figure 1 shows a timeline of the follow‐up surveys and utilization events in the form of overlapping histograms. The majority of 30‐day follow‐up questionnaires were completed earlier than targeted, at a median of 17 (interquartile range [IQR] 16, 20) days after discharge. Similarly, questionnaires targeted for 90 and 180 days were completed at medians of 78 (IQR 7684) and 167 (IQR 166169) days from discharge. Fifty‐four (28%) patients experienced a first utilization event in the first 30 days following discharge. During the 60‐, 90‐, and 30‐day intervals after the first, second, and third follow‐up surveys, respectively, 63 (33%), 54 (31%), and 16 (9%) patients experienced a first utilization event.

A significant improvement in MSAS physical symptom severity was detected between the hospitalization and the 30‐day follow‐up (Figure 2A). Although the mean Global Physical Health score was below the national mean of 50 at every survey period, a similar improvement in the measure was noted between the hospitalization and the 30‐day follow‐up (Figure 2B). The mean Global Mental Health score was also below the national mean but remained stable throughout the study (Figure 2C). The median GSRH was stable at 2 (IQR 23) at every survey wave (Figure 2D). Of note, compared to patients who completed all 3 follow‐up surveys, patients who missed at least 1 follow‐up reported higher MSAS score (1.5 vs 1.8, P=0.03), lower Global Physical Health (36.1 vs 33.5, P=0.09), and lower Global Mental Health (44.7 vs 41.0, P=0.03) during their hospitalization. In addition, patients with complete data experienced an average of 1.2 utilization events during the study, whereas those with missing data experienced an average of 2.1 utilization events (P=0.03).

The MSAS physical symptom severity and Global Physical Health scores from the index hospitalizations did not identify patients with a first utilization event within 30 days. However, patients with poor Global Mental Health and GSRH in the hospital were more likely to experience a utilization event within 14 days of discharge (Figure 3). During the postdischarge period, patients scoring poorly on each of the PRO measures trended toward a greater risk of an early utilization event, but the association between utilization and MSAS was most consistently significant (Figure 3A). In general, the associations with MSAS, Global Physical Health, and GSRH were stronger with the risk of utilization events within 14 days than within 30 days (Figure 3A,B,D). The Global Mental Health score was not associated with a subsequent utilization when measured during the 180‐day postdischarge period.

As shown in Table 2, Cox proportional hazard models incorporating covariates preserved most of the significant associations seen in the unadjusted analyses. Global Mental Health and good relative to poor GSRH obtained during the hospitalization remained significant. MSAS obtained at each postdischarge follow‐up trended positively with utilization and was statistically significant at 90 and 180 days. Global Physical Health obtained at each postdischarge follow‐up similarly trended negatively with utilization and was significant at 180 days. Each multivariate model incorporating a PRO measure with a significant coefficient contributed to better fit of the predictive model compared to the nested model without the PRO measure.
Unadjusted Hazard Ratio | P | Adjusted Hazard Ratio* | P | Likelihood Ratio | P | |
---|---|---|---|---|---|---|
| ||||||
Hospital discharge | ||||||
MSAS | 1.47 | 0.11 | 1.38 | 0.19 | 1.65 | 0.20 |
Global Physical Health | 0.96 | 0.10 | 0.96 | 0.13 | 2.29 | 0.13 |
Global Mental Health | 0.96 | 0.05 | 0.96 | 0.05 | 4.05 | 0.04 |
GSRH | ||||||
Fair | 1.09 | 0.85 | 1.26 | 0.61 | 12.27 | 0.02 |
Good | 0.24 | 0.04 | 0.23 | 0.03 | ||
Very good | 1.09 | 0.90 | 1.40 | 0.63 | ||
Excellent | NC | NS | NC | NS | ||
30 days | ||||||
MSAS | 1.54 | 0.07 | 1.40 | 0.20 | 1.57 | 0.21 |
Global Physical Health | 0.96 | 0.08 | 0.97 | 0.24 | 1.42 | 0.23 |
Global Mental Health | 0.98 | 0.42 | 0.99 | 0.62 | 0.25 | 0.62 |
GSRH | ||||||
Fair | 0.92 | 0.86 | 1.19 | 0.72 | 8.85 | 0.07 |
Good | 0.85 | 0.31 | 0.94 | 0.91 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.69 | 0.36 | 6.28 | 0.11 | ||
90 days | ||||||
MSAS | 2.23 | 0.03 | 2.20 | 0.05 | 3.79 | 0.05 |
Global Physical Health | 0.94 | 0.07 | 0.95 | 0.11 | 2.75 | 0.10 |
Global Mental Health | 0.96 | 0.20 | 0.95 | 0.15 | 2.11 | 0.15 |
GSRH | ||||||
Fair | 0.75 | 0.63 | 0.67 | 0.53 | 6.67 | 0.15 |
Good | 0.32 | 0.19 | 0.28 | 0.15 | ||
Very good | NC | NS | NC | NS | ||
Excellent | 2.12 | 0.50 | 2.20 | 0.49 | ||
180 days | ||||||
MSAS | 2.39 | 0.03 | 3.51 | 0.01 | 7.04 | 0.01 |
Global Physical Health | 0.93 | 0.06 | 0.93 | 0.03 | 4.61 | 0.03 |
Global Mental Health | 0.97 | 0.38 | 0.96 | 0.33 | 0.95 | 0.33 |
GSRH | ||||||
Fair | 0.98 | 0.98 | 0.64 | 0.55 | 7.13 | 0.13 |
Good | 0.33 | 0.23 | 0.20 | 0.09 | ||
Very good | NC | NS | NC | NS | ||
Excellent | NC | NS | NC | NS |
DISCUSSION
In this longitudinal cohort study, patients, on average, reported relatively severe symptoms, low PROMIS Global Physical and Mental Health scores, and poor GSRH during the inpatient stay in an urban safety‐net hospital. Symptom severity and Global Physical Health improved, on average, by 30 days before stabilizing, but their poor levels in the hospital did not predict 30‐day hospital‐based utilization events. On the other hand, Global Mental Health and GSRH were stable through hospitalizations, and patients scoring poorly on these measures were at greater risk of utilization events within 14 days of discharge. PRO measures obtained during the 180‐day postdischarge period trended toward distinguishing populations with greater baseline risk of proximate utilization events. However, MSAS physical symptom severity and Global Physical Health were more consistently predictive of these events at statistically significant levels compared to Global Mental Health and GSRH in our relatively small sample of patients. Each of these measures selectively improved the fit‐of‐risk prediction models for hospital‐based utilization.
Some of the heterogeneity in readmission risk is explained by differences in PRO measures. Although the MSAS score and Global Physical Health assessment were reliable predictors of utilization when measured in ambulatory settings, they were less discriminating during acute hospitalizations when everyone, on average, reported severe symptoms and poor function. Our results were consistent with other studies that demonstrated the fairly rapid recovery in symptoms that follow hospitalizations,[28, 29] and these measures may become informative of utilization risk as early as 2 weeks postdischarge. GSRH and Global Mental Health (a measure of health‐related quality of life) only predicted utilizations immediately at hospital discharge. As multidimensional measures that reflect physical, social, and emotional capacity, these measures may indicate vulnerabilities in patients least able to handle the stresses of the early postdischarge period.
There is growing momentum around collecting PRO measures in routine clinical care as quality indicators that capture patient‐centered concerns.[30] Our study explored a novel application of these measures whose routine collection will likely proliferate, not solely for the purpose of helping healthcare systems identify patients at risk of unplanned resource utilization. Although multidimensional PRO measures seldom reflect conditions directly modifiable by simple interventions, we believe that the association between physical symptom burden and utilization in our data reveals a possible target for practice improvement. Hospitalists have contributed enormously to shorter lengths of stay that risk sicker and quicker discharges.[31] To mitigate its potential side effects on symptom management, a discharge plan that acknowledges physical symptoms that sometimes persist or recur beyond the hospitalization may be appropriate. This may be accomplished by ensuring that acute symptoms are resolving, giving clear instructions for symptom management at home, as now the standard of care for conditions like asthma,[32] and explicitly communicating the presence of residual symptoms to providers entrusted with continuity care. As an effective feedback measure that can drive continuous quality improvement, we believe that a technology‐based surveillance strategy that spans both the inpatient and outpatient domains is necessary.[23]
There are some notable similarities and differences between the results of our study and a recent hospital‐based study of PRO measures that used data from the Multi‐Center Hospitalist Project.[16] The Physical Component Score of the SF12 is similar to the PROMIS Global Physical Health score in that both incorporate measures of physical function, perceived health, pain, and energy level. Curiously, the SF12 Physical Component Score, but not the PROMIS Global Physical Health score, was associated with 30‐day rehospitalizations. An important difference between the measures is where the SF12 asks about limitations during the past 4 weeks the PROMIS instrument inquires about physical function in general and levels of fatigue and pain in the past 7 days. Considering most hospitalizations last <7 days, the PROMIS instrument may better reflect the declines associated with the acute illness related to the hospitalization than the SF12 score. Additionally, the discrepancy between the association between hospital‐based GSRH and utilization in our study and the absence, thereof, in Hasan et al. is noteworthy. The difference here may be explained by their use of a 0‐ to 100‐point response scale in contrast to our study's verbally labeled 5‐point scale in the PROMIS instrument. The range of rating scales for survey questions is traditionally governed by the tension between the difficulty with mapping respondents judgment on an excessively large scale on one hand, and the failure of insufficient response options to discriminate between respondents with different underlying judgment on the other.[33] We suspect the former to be a drawback of the unlabeled 100‐point response scale, and conjecture that an association might be found in the Multi‐Center Hospitalist Study data if the responses were grouped into summative categories.
We recognize several limitations in our study. The first is the generalizability of our patient population to others, not insignificantly because of the high proportion of the uninsured (around 70% during the study period) and racial/ethnic minorities among them. Although utilization patterns are clearly affected by socioeconomic status,[34] there may also be differences in the way validated PRO measures are calibrated between patients of public and private healthcare systems.[35] Another limitation is our inability to count utilization events at institutions outside of the CCHHS during our study. However, because the study was conducted prior to Cook County's Medicaid expansion demonstration program as part of the Affordable Care Act,[36] many patients established in our system faced barriers to receiving nonemergency care outside of the CCHHS supporting our assumption that few of our patients were discharged from other hospitals. Causality cannot be established in observational studies. Consequently, high prior‐symptom burden may be associated with utilizations through unmeasured variables. Measures of symptom burden are vulnerable to overendorsement and amplification.[37, 38] Inferences based on statistical significance are affected by sample size, and our conclusions may change if conducted with a larger number of participants. Our response rates were excellent through the survey waves, but we did not achieve perfect follow‐up. Worse levels of PRO responses and higher levels of utilization among censored patients biased our results toward the null. Finally, although we did not find any predominant comorbidities associated with hospital‐based utilizations in our sample, our analyses may be vulnerable to inadequate control for illness severity, which may also have biased our results.
PRO measures are likely to be useful in clinical medicine.[39] But to fully apply the powers of PROs in informing clinically and operationally relevant outcomes, we must actively develop a system for obtaining these measures in routine clinical care. The availability of patient downtime makes hospitalizations conducive to gathering patient‐generated data, and may further enhance patient‐provider communication if survey output was readily available in electronic medical records. Exploring innovative strategies for collecting PROs in the hospital and beyond remains our future work.
Disclosures
Funded by the Agency for Healthcare Research and Quality: R24 HS19481‐01 to support technology implementation. The authors report no conflicts of interest, relevant financial interests, activities, relationships, and affiliations that influenced this work. The first and senior authors had full access to all data and take responsibility for their integrity and the accuracy of the data analysis.
- Potentially avoidable 30‐day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med. 2013;173:632–638. , , , .
- Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ. 2010;182:551–557. , , , et al.
- Redefining readmission risk factors for general medicine patients. J Hosp Med. 2011;6:54–60. , , , .
- Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306:1688–1698. , , , et al.
- Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–1246. , , , .
- Repeated hospitalizations and self‐rated health among the elderly: a multivariate failure time analysis. Am J Epidemiol. 2001;153 3 232–241. , , .
- Screening elders for risk of hospital admission. J Am Geriatr Soc. 1993;41:811–817. , , , , , .
- Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol. 1996;78:890–895. , , , et al.
- Using quality of life to predict hospitalization and mortality in patients with obstructive lung disease. Chest. 2002;122:429–436. , , , , .
- Intraindividual change in SF‐36 in ambulatory clinic primary care patients predicted mortality and hospitalizations. J Clin Epidemiol. 2004;57:277–283. , , , .
- Use of health‐related, quality‐of‐life metrics to predict mortality and hospitalizations in community‐dwelling seniors. J Am Geriatr Soc. 2006;54:667–673. , , , et al.
- Medical outcomes study short form‐36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41:1286–1292. , , , .
- Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–1856. , , , et al.
- Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002;62:199–207. , , , et al.
- Health status predicts long‐term outcomes in outpatients with coronary disease. Circulation. 2002;106:43–49. , , , , .
- Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med. 2010;25:211–219. , , , et al.
- Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. Eur J Heart Fail. 2014;16:854–860. , , , , , .
- Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. Am J Cardiol. 2015;115:75–81. , , , et al.
- Two views of self‐rated general health status. Soc Sci Med. 2003;56:203–217. , , .
- Self‐rated health and physical disability in elderly survivors of a major medical event. J Gerontol B Psychol Sci Soc Sci. 1996;51:S96–S104. , , .
- Predicting changes in perceived health status. Am J Public Health. 1984;74:611–614. , , .
- Quality of life before and after intensive care. Anaesthesia. 2005;60:322–329. , , , , .
- Trick WE. Health perceptions and symptom burden in primary care: measuring health using audio computer‐assisted self‐interviews [published online ahead of print December 7, 2014]. Qual Life Res. doi: 10.1007/s11136‐014‐0884‐4. , , , , ,
- Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992;45:613–619. , , .
- The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326–1336. , , , et al.
- The Memorial Symptom Assessment Scale short form (MSAS‐SF). Cancer. 2000;89:1162–1171. , , , , .
- Development of physical and mental health summary schores from the Patient‐Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18:873–880. , , , , .
- Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE‐AHF). J Card Fail. 2008;14:777–784. , , , et al.
- Longitudinal assessment of symptom severity among hospitalized elders diagnosed with cancer, heart failure, and chronic obstructive pulmonary disease. J Hosp Med. 2012;7:567–572. , , , .
- The patient experience and health outcomes. N Engl J Med. 2013;368:201–203. , , , .
- "Quicker and sicker" under Medicare's prospective payment system for hospitals: new evidence on an old issue from a national longitudinal survey. Bull Econ Res. 2011;63:1–27. , , , .
- Agency for Healthcare Research and Quality. Asthma care quality improvement measures. Available at: http://www.ahrq.gov/professionals/quality‐patient‐safety/quality‐resources/tools/asthmaqual/asthmacare/appendix‐d.html. Accessed January 30, 2015.
- The Psychology of Survey Response. New York, NY: Cambridge University Press; 2000. , , .
- Health care for children and youth in the United States: annual report on patterns of coverage, utilization, quality, and expenditures by income. Ambul Pediatr. 2005;5:6–44. , , , et al.
- Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011;29:2859–2865. , , , et al.
- http://kff.org/medicaid/issue-brief/profiles-of-medicaid-outreach-and-enrollment-strategies-the-cook-county-early-expansion-initiative. Published April 7, 2014. Accessed December 2, 2014. . Profiles of Medicaid outreach and enrollment strategies: the Cook County early expansion initiative. The Henry J. Kaiser Family Foundation. Available at:
- A primary care perspective on prevailing assumptions about persistent medically unexplained physical symptoms. Int J Psychiatry Med. 2002;32:125–140. , , .
- Symptom burden and comorbidities impact the consistency of responses on patient‐reported functional outcomes. Arch Phys Med Rehabil. 2014;95:79–86. , , , .
- Implementing patient‐reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305–1314. , , , et al.
- Potentially avoidable 30‐day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med. 2013;173:632–638. , , , .
- Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community. CMAJ. 2010;182:551–557. , , , et al.
- Redefining readmission risk factors for general medicine patients. J Hosp Med. 2011;6:54–60. , , , .
- Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306:1688–1698. , , , et al.
- Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–1246. , , , .
- Repeated hospitalizations and self‐rated health among the elderly: a multivariate failure time analysis. Am J Epidemiol. 2001;153 3 232–241. , , .
- Screening elders for risk of hospital admission. J Am Geriatr Soc. 1993;41:811–817. , , , , , .
- Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol. 1996;78:890–895. , , , et al.
- Using quality of life to predict hospitalization and mortality in patients with obstructive lung disease. Chest. 2002;122:429–436. , , , , .
- Intraindividual change in SF‐36 in ambulatory clinic primary care patients predicted mortality and hospitalizations. J Clin Epidemiol. 2004;57:277–283. , , , .
- Use of health‐related, quality‐of‐life metrics to predict mortality and hospitalizations in community‐dwelling seniors. J Am Geriatr Soc. 2006;54:667–673. , , , et al.
- Medical outcomes study short form‐36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41:1286–1292. , , , .
- Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–1856. , , , et al.
- Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int. 2002;62:199–207. , , , et al.
- Health status predicts long‐term outcomes in outpatients with coronary disease. Circulation. 2002;106:43–49. , , , , .
- Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med. 2010;25:211–219. , , , et al.
- Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events. Eur J Heart Fail. 2014;16:854–860. , , , , , .
- Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. Am J Cardiol. 2015;115:75–81. , , , et al.
- Two views of self‐rated general health status. Soc Sci Med. 2003;56:203–217. , , .
- Self‐rated health and physical disability in elderly survivors of a major medical event. J Gerontol B Psychol Sci Soc Sci. 1996;51:S96–S104. , , .
- Predicting changes in perceived health status. Am J Public Health. 1984;74:611–614. , , .
- Quality of life before and after intensive care. Anaesthesia. 2005;60:322–329. , , , , .
- Trick WE. Health perceptions and symptom burden in primary care: measuring health using audio computer‐assisted self‐interviews [published online ahead of print December 7, 2014]. Qual Life Res. doi: 10.1007/s11136‐014‐0884‐4. , , , , ,
- Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992;45:613–619. , , .
- The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326–1336. , , , et al.
- The Memorial Symptom Assessment Scale short form (MSAS‐SF). Cancer. 2000;89:1162–1171. , , , , .
- Development of physical and mental health summary schores from the Patient‐Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18:873–880. , , , , .
- Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE‐AHF). J Card Fail. 2008;14:777–784. , , , et al.
- Longitudinal assessment of symptom severity among hospitalized elders diagnosed with cancer, heart failure, and chronic obstructive pulmonary disease. J Hosp Med. 2012;7:567–572. , , , .
- The patient experience and health outcomes. N Engl J Med. 2013;368:201–203. , , , .
- "Quicker and sicker" under Medicare's prospective payment system for hospitals: new evidence on an old issue from a national longitudinal survey. Bull Econ Res. 2011;63:1–27. , , , .
- Agency for Healthcare Research and Quality. Asthma care quality improvement measures. Available at: http://www.ahrq.gov/professionals/quality‐patient‐safety/quality‐resources/tools/asthmaqual/asthmacare/appendix‐d.html. Accessed January 30, 2015.
- The Psychology of Survey Response. New York, NY: Cambridge University Press; 2000. , , .
- Health care for children and youth in the United States: annual report on patterns of coverage, utilization, quality, and expenditures by income. Ambul Pediatr. 2005;5:6–44. , , , et al.
- Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center. J Clin Oncol. 2011;29:2859–2865. , , , et al.
- http://kff.org/medicaid/issue-brief/profiles-of-medicaid-outreach-and-enrollment-strategies-the-cook-county-early-expansion-initiative. Published April 7, 2014. Accessed December 2, 2014. . Profiles of Medicaid outreach and enrollment strategies: the Cook County early expansion initiative. The Henry J. Kaiser Family Foundation. Available at:
- A primary care perspective on prevailing assumptions about persistent medically unexplained physical symptoms. Int J Psychiatry Med. 2002;32:125–140. , , .
- Symptom burden and comorbidities impact the consistency of responses on patient‐reported functional outcomes. Arch Phys Med Rehabil. 2014;95:79–86. , , , .
- Implementing patient‐reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305–1314. , , , et al.
© 2015 Society of Hospital Medicine
Implementing Physician Value-Based Purchasing in Your Practice: HM15 Session Analysis
HM15 Session: Putting Your Nickel Down: The What, Why, and How of Implementing Physician Value-Based Purchasing in Your Practice
Presenters: Stephen Besch, Simone Karp RPh, Patrick Torcson MD MMM SFHM, Gregory Seymann MD SFHM
Medicare is transforming itself from a “passive payer” to an “active purchaser” of high quality, efficient healthcare. As such- active participation by physicians, physician groups, and hospitals is required for payment eligibility.
At the physician/group level, hospitalists should be reporting PQRS measures. Incentive payments for PQRS ended in 2014, Medicare is now making “negative payment adjustments.” Penalties are equal to a percentage of all Medicare Part B FFS (Fee-for-Service) charges and there is a 2-year delay between reporting or performance failure and penalization.
Physician Value-Based Purchasing (P-VBP) affects all Eligible Providers (EPs) in 2015. P4P (Pay for Performance) assesses both quality and cost. Aim is for budget neutrality via “quality tiering” which rewards “high quality/low cost” practices with penalties from “low quality/high cost” practices. As of now (2015) ACPs and therapists can be penalized under P-VBP.
Key Points/HM Takeaways:
- Hospitalists should be reporting PQRS measures- penalty phase has begun
- Key PQRS Changes for 2015:
- 6 measures applicable to inpatient billing removed
- no useful inpatient measures added
- penalty avoidance requires 9 measures at 50% or higher rates, covering at least 3 of the 6 NQS (National Quality Strategy) domains- including 1 cross-cutting measure
- all 2015 PQRS data will be posted to Physician Compare website in 2016
- 3 Examples of hospitalist applicable “cross-cutting measures” are
- 47-advance care plan
- 130-documentation of current medications
- 317-preventative care: bp screening
- PQRS data must be reported with respect to MAV clusters (Measure Applicability Validation)- reporting only measure that have no MAV cluster is a safe strategy so long as one of the measures is “cross-cutting”
- Maximum P-VBP penalties automatically apply if group does not report enough PQRS data
- visit CMS website for more information
HM15 Session: Putting Your Nickel Down: The What, Why, and How of Implementing Physician Value-Based Purchasing in Your Practice
Presenters: Stephen Besch, Simone Karp RPh, Patrick Torcson MD MMM SFHM, Gregory Seymann MD SFHM
Medicare is transforming itself from a “passive payer” to an “active purchaser” of high quality, efficient healthcare. As such- active participation by physicians, physician groups, and hospitals is required for payment eligibility.
At the physician/group level, hospitalists should be reporting PQRS measures. Incentive payments for PQRS ended in 2014, Medicare is now making “negative payment adjustments.” Penalties are equal to a percentage of all Medicare Part B FFS (Fee-for-Service) charges and there is a 2-year delay between reporting or performance failure and penalization.
Physician Value-Based Purchasing (P-VBP) affects all Eligible Providers (EPs) in 2015. P4P (Pay for Performance) assesses both quality and cost. Aim is for budget neutrality via “quality tiering” which rewards “high quality/low cost” practices with penalties from “low quality/high cost” practices. As of now (2015) ACPs and therapists can be penalized under P-VBP.
Key Points/HM Takeaways:
- Hospitalists should be reporting PQRS measures- penalty phase has begun
- Key PQRS Changes for 2015:
- 6 measures applicable to inpatient billing removed
- no useful inpatient measures added
- penalty avoidance requires 9 measures at 50% or higher rates, covering at least 3 of the 6 NQS (National Quality Strategy) domains- including 1 cross-cutting measure
- all 2015 PQRS data will be posted to Physician Compare website in 2016
- 3 Examples of hospitalist applicable “cross-cutting measures” are
- 47-advance care plan
- 130-documentation of current medications
- 317-preventative care: bp screening
- PQRS data must be reported with respect to MAV clusters (Measure Applicability Validation)- reporting only measure that have no MAV cluster is a safe strategy so long as one of the measures is “cross-cutting”
- Maximum P-VBP penalties automatically apply if group does not report enough PQRS data
- visit CMS website for more information
HM15 Session: Putting Your Nickel Down: The What, Why, and How of Implementing Physician Value-Based Purchasing in Your Practice
Presenters: Stephen Besch, Simone Karp RPh, Patrick Torcson MD MMM SFHM, Gregory Seymann MD SFHM
Medicare is transforming itself from a “passive payer” to an “active purchaser” of high quality, efficient healthcare. As such- active participation by physicians, physician groups, and hospitals is required for payment eligibility.
At the physician/group level, hospitalists should be reporting PQRS measures. Incentive payments for PQRS ended in 2014, Medicare is now making “negative payment adjustments.” Penalties are equal to a percentage of all Medicare Part B FFS (Fee-for-Service) charges and there is a 2-year delay between reporting or performance failure and penalization.
Physician Value-Based Purchasing (P-VBP) affects all Eligible Providers (EPs) in 2015. P4P (Pay for Performance) assesses both quality and cost. Aim is for budget neutrality via “quality tiering” which rewards “high quality/low cost” practices with penalties from “low quality/high cost” practices. As of now (2015) ACPs and therapists can be penalized under P-VBP.
Key Points/HM Takeaways:
- Hospitalists should be reporting PQRS measures- penalty phase has begun
- Key PQRS Changes for 2015:
- 6 measures applicable to inpatient billing removed
- no useful inpatient measures added
- penalty avoidance requires 9 measures at 50% or higher rates, covering at least 3 of the 6 NQS (National Quality Strategy) domains- including 1 cross-cutting measure
- all 2015 PQRS data will be posted to Physician Compare website in 2016
- 3 Examples of hospitalist applicable “cross-cutting measures” are
- 47-advance care plan
- 130-documentation of current medications
- 317-preventative care: bp screening
- PQRS data must be reported with respect to MAV clusters (Measure Applicability Validation)- reporting only measure that have no MAV cluster is a safe strategy so long as one of the measures is “cross-cutting”
- Maximum P-VBP penalties automatically apply if group does not report enough PQRS data
- visit CMS website for more information
Hot Topics in Practice Management; HM15 Session Analysis
HM15 Presenters: Roy Sittig MD SFHM, Jeffrey Frank MD MBA, Jodi Braun
Summation: Speakers covered timely topics regarding the Accountable Care Act, namely Medicaid Expansion and Bundled Payment arrangements; and reviewed the seminal paper on “Key Principals and Characteristics of an Effective Hospitalist Medicine Group” and lessons learned in implementing those 10 Key Principles.
Medicaid Expansion: EDs serving the 29 Medicaid expansion states are reporting higher volumes, likely due to 11.4million new lives now insured under the ACA. While the ACA does provide for higher Medicaid payment rates thus far, only 34% of providers accept Medicaid, a 21% drop since the ACA went into effect.
Bundled Payment Arrangements:
- Bundled Payment Care Initiative (BPCI) lexicon:
- Model 2-Episode Anchor (anchor admission) AND 90days post d/c; Medicare pays 98% of usual cost
- Model 3-90days post d/c AFTER anchor admission; Medicare pays 97% of usual cost
- Convener-entity that brings providers together and enters into CMS agreement to bear risk for bundles
- Awardee (entity having agreement with Medicare to assume risk and receive payment via BPCI) and Convener own the Bundle
- Episode initiator (EI) triggers “bundle period”
- Bundles based on DRG
10-Key Principles of an Effective Hospitalist Medicine Group:
- Effective Leadership
- Engaged Hospitalists
- Adequate Resources
- Planning and Management Infrastructure
- Alignment with Hospital/Health System
- Care Coordination Across Settings
- Leadership in Key Clinical Issues in the Hospital/Health System
- Thoughtful Approach to Scope of Activity
- Patient/Family-Centered, Team-Based Care; Effective Communication
- Recruiting/Retaining Qualified Clinicians
Key Points/HM Takeaways:
Medicaid Expansion- many of the 11.4M newly insured lives under the ACA have moved into Medicaid. Only about 1/3 of providers now accept Medicaid- 1 in 5 covered persons now have Medicaid, nearly 20% increase since 2013.
Bundled Payments- Majority of savings opportunity lies in Post-Acute Care. Awardee and Convener make profit is total cost is less than 98% of Target Price. In gainsharing agreements individuals can be reimbursed up to 150% usual Medicare rate. Pay occurs in usual Medicare fashion but is reconciled 60-90 days after end of bundle. For more information: http://innovation.cms.gov/initiatives/bundled-payments/
Effective HM Groups- Three important areas for focus when beginning to address group performance are: engaged hospitalists, planning and management infrastructure, care coordination across settings. These three topics have broad reaching implications into the hospitalist practice and patient care. [Cawley P, et al. Journal of Hospital Medicine 2014; 9(2):123-128]
HM15 Presenters: Roy Sittig MD SFHM, Jeffrey Frank MD MBA, Jodi Braun
Summation: Speakers covered timely topics regarding the Accountable Care Act, namely Medicaid Expansion and Bundled Payment arrangements; and reviewed the seminal paper on “Key Principals and Characteristics of an Effective Hospitalist Medicine Group” and lessons learned in implementing those 10 Key Principles.
Medicaid Expansion: EDs serving the 29 Medicaid expansion states are reporting higher volumes, likely due to 11.4million new lives now insured under the ACA. While the ACA does provide for higher Medicaid payment rates thus far, only 34% of providers accept Medicaid, a 21% drop since the ACA went into effect.
Bundled Payment Arrangements:
- Bundled Payment Care Initiative (BPCI) lexicon:
- Model 2-Episode Anchor (anchor admission) AND 90days post d/c; Medicare pays 98% of usual cost
- Model 3-90days post d/c AFTER anchor admission; Medicare pays 97% of usual cost
- Convener-entity that brings providers together and enters into CMS agreement to bear risk for bundles
- Awardee (entity having agreement with Medicare to assume risk and receive payment via BPCI) and Convener own the Bundle
- Episode initiator (EI) triggers “bundle period”
- Bundles based on DRG
10-Key Principles of an Effective Hospitalist Medicine Group:
- Effective Leadership
- Engaged Hospitalists
- Adequate Resources
- Planning and Management Infrastructure
- Alignment with Hospital/Health System
- Care Coordination Across Settings
- Leadership in Key Clinical Issues in the Hospital/Health System
- Thoughtful Approach to Scope of Activity
- Patient/Family-Centered, Team-Based Care; Effective Communication
- Recruiting/Retaining Qualified Clinicians
Key Points/HM Takeaways:
Medicaid Expansion- many of the 11.4M newly insured lives under the ACA have moved into Medicaid. Only about 1/3 of providers now accept Medicaid- 1 in 5 covered persons now have Medicaid, nearly 20% increase since 2013.
Bundled Payments- Majority of savings opportunity lies in Post-Acute Care. Awardee and Convener make profit is total cost is less than 98% of Target Price. In gainsharing agreements individuals can be reimbursed up to 150% usual Medicare rate. Pay occurs in usual Medicare fashion but is reconciled 60-90 days after end of bundle. For more information: http://innovation.cms.gov/initiatives/bundled-payments/
Effective HM Groups- Three important areas for focus when beginning to address group performance are: engaged hospitalists, planning and management infrastructure, care coordination across settings. These three topics have broad reaching implications into the hospitalist practice and patient care. [Cawley P, et al. Journal of Hospital Medicine 2014; 9(2):123-128]
HM15 Presenters: Roy Sittig MD SFHM, Jeffrey Frank MD MBA, Jodi Braun
Summation: Speakers covered timely topics regarding the Accountable Care Act, namely Medicaid Expansion and Bundled Payment arrangements; and reviewed the seminal paper on “Key Principals and Characteristics of an Effective Hospitalist Medicine Group” and lessons learned in implementing those 10 Key Principles.
Medicaid Expansion: EDs serving the 29 Medicaid expansion states are reporting higher volumes, likely due to 11.4million new lives now insured under the ACA. While the ACA does provide for higher Medicaid payment rates thus far, only 34% of providers accept Medicaid, a 21% drop since the ACA went into effect.
Bundled Payment Arrangements:
- Bundled Payment Care Initiative (BPCI) lexicon:
- Model 2-Episode Anchor (anchor admission) AND 90days post d/c; Medicare pays 98% of usual cost
- Model 3-90days post d/c AFTER anchor admission; Medicare pays 97% of usual cost
- Convener-entity that brings providers together and enters into CMS agreement to bear risk for bundles
- Awardee (entity having agreement with Medicare to assume risk and receive payment via BPCI) and Convener own the Bundle
- Episode initiator (EI) triggers “bundle period”
- Bundles based on DRG
10-Key Principles of an Effective Hospitalist Medicine Group:
- Effective Leadership
- Engaged Hospitalists
- Adequate Resources
- Planning and Management Infrastructure
- Alignment with Hospital/Health System
- Care Coordination Across Settings
- Leadership in Key Clinical Issues in the Hospital/Health System
- Thoughtful Approach to Scope of Activity
- Patient/Family-Centered, Team-Based Care; Effective Communication
- Recruiting/Retaining Qualified Clinicians
Key Points/HM Takeaways:
Medicaid Expansion- many of the 11.4M newly insured lives under the ACA have moved into Medicaid. Only about 1/3 of providers now accept Medicaid- 1 in 5 covered persons now have Medicaid, nearly 20% increase since 2013.
Bundled Payments- Majority of savings opportunity lies in Post-Acute Care. Awardee and Convener make profit is total cost is less than 98% of Target Price. In gainsharing agreements individuals can be reimbursed up to 150% usual Medicare rate. Pay occurs in usual Medicare fashion but is reconciled 60-90 days after end of bundle. For more information: http://innovation.cms.gov/initiatives/bundled-payments/
Effective HM Groups- Three important areas for focus when beginning to address group performance are: engaged hospitalists, planning and management infrastructure, care coordination across settings. These three topics have broad reaching implications into the hospitalist practice and patient care. [Cawley P, et al. Journal of Hospital Medicine 2014; 9(2):123-128]
Cloning and Chart Similarity
Health care providers select Current Procedural Terminology codes based on the service provided and then document to support the level of service reported.1 According to the Office of Inspector General (OIG) for the US Department of Health and Human Services, “Medicare contractors have noted an increased frequency of medical records with identical documentation across services,” which may under certain circumstances be considered inappropriate.2 Regarding this practice, the OIG work plan for the 2014 fiscal year stated: "We will determine the extent to which selected payments for evaluation and management (E/M) services were inappropriate. We will also review multiple E/M services associated with the same providers and beneficiaries to determine the extent to which electronic or paper medical records had documentation vulnerabilities."2The OIG’s annual work plan reflects areas of concern that will be investigated in the coming years. These investigations may result in audits of specific Medicare and Medicaid providers, including physicians.
Concerns about physicians providing identical documentation across services has evinced an ongoing focus on the so-called cloning of medical records. Cloning is not well defined but generally refers to inappropriate use of the same exact documentation, perhaps via cutting and pasting, in different patient encounters. This type of cloning could occur in office visits with the same patient or different patients. The advent of electronic health records has made such duplication easier, and the concern is that duplicated notes in a medical record for a particular encounter may not accurately reflect the services that were provided in another encounter; in some cases, services may be overdocumented, with this creating a risk that that they may also be overcoded.
How can dermatologists minimize the risk for being flagged for cloning records? If you use templates for procedures, you may consider reviewing the completed template before filing the record to ensure that the details are consistent with the procedure that was performed. If you use abbreviations or other unique documentation that may not be easily understandable to an outside authority, you may want to keep a manual somewhere in your office that defines or describes such abbreviations and notations. Also, be aware that scribing is different than cloning, and scribing is not under scrutiny by OIG. A scribe writes word for word as a physician dictates and cannot act independently to alter or embellish the notes; once scribing is complete, both the scribe and the physician should sign the notes.
The American Academy of Dermatology has been concerned that an imprecise definition of so-called cloning can unfairly marginalize appropriate coding practices. In particular, when similar procedures or E/M services are performed by the same physician, the documentation may be very similar, even identical, while still being accurate and appropriately descriptive of the services provided. To help explain when similar notes are an acceptable practice in dermatology and when notes should be different, the American Academy of Dermatology has developed a guidance document that has been approved by its board of directors.3
Current Procedural Terminology coding guidelines clearly indicate that documentation cannot drive the level of coding and that excessive documentation cannot be used to justify a higher-level code, such as a higher-level E/M code. Instead, the level of service delivered should be appropriate for the patient’s condition and should be documented accordingly.4
It is important for dermatologists to document patient encounters as accurately and completely as is necessary for good patient care. Documentation will often vary substantially from patient to patient and encounter to encounter, but sometimes routine procedures or E/M visits may be coded similarly. For instance, a shave biopsy on the cheek to rule out nonmelanoma skin cancer may be performed by a particular practitioner with a standard instrument and after standard preparation and infiltration of local anesthetic; postoperative care may also be the same. To minimize regulatory scrutiny when similar descriptions are used, review the documentation for accuracy and to confirm that important specific information has not been inadvertently omitted or that wrong information has not been appended.
Unfortunately, there are dermatologists who have been audited for cloning during the last year. As with any audit, it is important to be vigilant regarding deadlines and to file appeals in a timely manner. Keep all the notifications you receive safely and explain to your staff that any communications should be promptly forwarded to you. If you are audited for suspected cloning, you may wish to contact the coding staff of professional dermatology societies for general guidance.
1. Centers for Medicare & Medicaid Services. Medicare claim processing manual: chapter 12 – physicians/nonphysician practitioners. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c12.pdf. Revised October 17, 2014. Accessed March 4, 2015.
2. Work plan for fiscal year 2014. Office of Inspector General, US Department of Health and Human Services Web site. https://oig.hhs.gov/reports-and-publications/archives/workplan/2014/Work-Plan-2014.pdf. Accessed March 4, 2015.
3. American Academy of Dermatology and AAD Association. Guidance statement: documentation of patient encounters and procedures. https://www.aad.org/forms/policies/Uploads/PS/Guidance%20Statement%20on%20Charting%20Practices.pdf. Approved October 23, 2014. Accessed March 6, 2015.
4. Evaluation and management services guide. Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/eval_mgmt_serv_guide-icn006764.pdf. Published November 2014. Accessed March 5, 2015.
Health care providers select Current Procedural Terminology codes based on the service provided and then document to support the level of service reported.1 According to the Office of Inspector General (OIG) for the US Department of Health and Human Services, “Medicare contractors have noted an increased frequency of medical records with identical documentation across services,” which may under certain circumstances be considered inappropriate.2 Regarding this practice, the OIG work plan for the 2014 fiscal year stated: "We will determine the extent to which selected payments for evaluation and management (E/M) services were inappropriate. We will also review multiple E/M services associated with the same providers and beneficiaries to determine the extent to which electronic or paper medical records had documentation vulnerabilities."2The OIG’s annual work plan reflects areas of concern that will be investigated in the coming years. These investigations may result in audits of specific Medicare and Medicaid providers, including physicians.
Concerns about physicians providing identical documentation across services has evinced an ongoing focus on the so-called cloning of medical records. Cloning is not well defined but generally refers to inappropriate use of the same exact documentation, perhaps via cutting and pasting, in different patient encounters. This type of cloning could occur in office visits with the same patient or different patients. The advent of electronic health records has made such duplication easier, and the concern is that duplicated notes in a medical record for a particular encounter may not accurately reflect the services that were provided in another encounter; in some cases, services may be overdocumented, with this creating a risk that that they may also be overcoded.
How can dermatologists minimize the risk for being flagged for cloning records? If you use templates for procedures, you may consider reviewing the completed template before filing the record to ensure that the details are consistent with the procedure that was performed. If you use abbreviations or other unique documentation that may not be easily understandable to an outside authority, you may want to keep a manual somewhere in your office that defines or describes such abbreviations and notations. Also, be aware that scribing is different than cloning, and scribing is not under scrutiny by OIG. A scribe writes word for word as a physician dictates and cannot act independently to alter or embellish the notes; once scribing is complete, both the scribe and the physician should sign the notes.
The American Academy of Dermatology has been concerned that an imprecise definition of so-called cloning can unfairly marginalize appropriate coding practices. In particular, when similar procedures or E/M services are performed by the same physician, the documentation may be very similar, even identical, while still being accurate and appropriately descriptive of the services provided. To help explain when similar notes are an acceptable practice in dermatology and when notes should be different, the American Academy of Dermatology has developed a guidance document that has been approved by its board of directors.3
Current Procedural Terminology coding guidelines clearly indicate that documentation cannot drive the level of coding and that excessive documentation cannot be used to justify a higher-level code, such as a higher-level E/M code. Instead, the level of service delivered should be appropriate for the patient’s condition and should be documented accordingly.4
It is important for dermatologists to document patient encounters as accurately and completely as is necessary for good patient care. Documentation will often vary substantially from patient to patient and encounter to encounter, but sometimes routine procedures or E/M visits may be coded similarly. For instance, a shave biopsy on the cheek to rule out nonmelanoma skin cancer may be performed by a particular practitioner with a standard instrument and after standard preparation and infiltration of local anesthetic; postoperative care may also be the same. To minimize regulatory scrutiny when similar descriptions are used, review the documentation for accuracy and to confirm that important specific information has not been inadvertently omitted or that wrong information has not been appended.
Unfortunately, there are dermatologists who have been audited for cloning during the last year. As with any audit, it is important to be vigilant regarding deadlines and to file appeals in a timely manner. Keep all the notifications you receive safely and explain to your staff that any communications should be promptly forwarded to you. If you are audited for suspected cloning, you may wish to contact the coding staff of professional dermatology societies for general guidance.
Health care providers select Current Procedural Terminology codes based on the service provided and then document to support the level of service reported.1 According to the Office of Inspector General (OIG) for the US Department of Health and Human Services, “Medicare contractors have noted an increased frequency of medical records with identical documentation across services,” which may under certain circumstances be considered inappropriate.2 Regarding this practice, the OIG work plan for the 2014 fiscal year stated: "We will determine the extent to which selected payments for evaluation and management (E/M) services were inappropriate. We will also review multiple E/M services associated with the same providers and beneficiaries to determine the extent to which electronic or paper medical records had documentation vulnerabilities."2The OIG’s annual work plan reflects areas of concern that will be investigated in the coming years. These investigations may result in audits of specific Medicare and Medicaid providers, including physicians.
Concerns about physicians providing identical documentation across services has evinced an ongoing focus on the so-called cloning of medical records. Cloning is not well defined but generally refers to inappropriate use of the same exact documentation, perhaps via cutting and pasting, in different patient encounters. This type of cloning could occur in office visits with the same patient or different patients. The advent of electronic health records has made such duplication easier, and the concern is that duplicated notes in a medical record for a particular encounter may not accurately reflect the services that were provided in another encounter; in some cases, services may be overdocumented, with this creating a risk that that they may also be overcoded.
How can dermatologists minimize the risk for being flagged for cloning records? If you use templates for procedures, you may consider reviewing the completed template before filing the record to ensure that the details are consistent with the procedure that was performed. If you use abbreviations or other unique documentation that may not be easily understandable to an outside authority, you may want to keep a manual somewhere in your office that defines or describes such abbreviations and notations. Also, be aware that scribing is different than cloning, and scribing is not under scrutiny by OIG. A scribe writes word for word as a physician dictates and cannot act independently to alter or embellish the notes; once scribing is complete, both the scribe and the physician should sign the notes.
The American Academy of Dermatology has been concerned that an imprecise definition of so-called cloning can unfairly marginalize appropriate coding practices. In particular, when similar procedures or E/M services are performed by the same physician, the documentation may be very similar, even identical, while still being accurate and appropriately descriptive of the services provided. To help explain when similar notes are an acceptable practice in dermatology and when notes should be different, the American Academy of Dermatology has developed a guidance document that has been approved by its board of directors.3
Current Procedural Terminology coding guidelines clearly indicate that documentation cannot drive the level of coding and that excessive documentation cannot be used to justify a higher-level code, such as a higher-level E/M code. Instead, the level of service delivered should be appropriate for the patient’s condition and should be documented accordingly.4
It is important for dermatologists to document patient encounters as accurately and completely as is necessary for good patient care. Documentation will often vary substantially from patient to patient and encounter to encounter, but sometimes routine procedures or E/M visits may be coded similarly. For instance, a shave biopsy on the cheek to rule out nonmelanoma skin cancer may be performed by a particular practitioner with a standard instrument and after standard preparation and infiltration of local anesthetic; postoperative care may also be the same. To minimize regulatory scrutiny when similar descriptions are used, review the documentation for accuracy and to confirm that important specific information has not been inadvertently omitted or that wrong information has not been appended.
Unfortunately, there are dermatologists who have been audited for cloning during the last year. As with any audit, it is important to be vigilant regarding deadlines and to file appeals in a timely manner. Keep all the notifications you receive safely and explain to your staff that any communications should be promptly forwarded to you. If you are audited for suspected cloning, you may wish to contact the coding staff of professional dermatology societies for general guidance.
1. Centers for Medicare & Medicaid Services. Medicare claim processing manual: chapter 12 – physicians/nonphysician practitioners. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c12.pdf. Revised October 17, 2014. Accessed March 4, 2015.
2. Work plan for fiscal year 2014. Office of Inspector General, US Department of Health and Human Services Web site. https://oig.hhs.gov/reports-and-publications/archives/workplan/2014/Work-Plan-2014.pdf. Accessed March 4, 2015.
3. American Academy of Dermatology and AAD Association. Guidance statement: documentation of patient encounters and procedures. https://www.aad.org/forms/policies/Uploads/PS/Guidance%20Statement%20on%20Charting%20Practices.pdf. Approved October 23, 2014. Accessed March 6, 2015.
4. Evaluation and management services guide. Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/eval_mgmt_serv_guide-icn006764.pdf. Published November 2014. Accessed March 5, 2015.
1. Centers for Medicare & Medicaid Services. Medicare claim processing manual: chapter 12 – physicians/nonphysician practitioners. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c12.pdf. Revised October 17, 2014. Accessed March 4, 2015.
2. Work plan for fiscal year 2014. Office of Inspector General, US Department of Health and Human Services Web site. https://oig.hhs.gov/reports-and-publications/archives/workplan/2014/Work-Plan-2014.pdf. Accessed March 4, 2015.
3. American Academy of Dermatology and AAD Association. Guidance statement: documentation of patient encounters and procedures. https://www.aad.org/forms/policies/Uploads/PS/Guidance%20Statement%20on%20Charting%20Practices.pdf. Approved October 23, 2014. Accessed March 6, 2015.
4. Evaluation and management services guide. Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/eval_mgmt_serv_guide-icn006764.pdf. Published November 2014. Accessed March 5, 2015.
Practice Points
- Medical record documentation for evaluation and management services includes information relevant to the patient encounter. Providing identical documentation for different patients may under certain circumstances be considered cloning and hence inappropriate.
- Following best practices can minimize the risk for being flagged for cloning.
Ibrutinib highly active against refractory Waldenstrom’s macroglobulinemia
Ibrutinib proved to be “highly active” against refractory Waldenstrom’s macroglobulinemia in the first clinical trial to assess the agent’s safety and efficacy in this patient population, producing an overall response rate of 90.5% and a major response rate of 73.0% in a series of 63 consecutive patients, according to a report published online April 9 in the New England Journal of Medicine.
Waldenstrom’s macroglobulinemia is a malignant B-cell lymphoma in which whole-genome sequencing has revealed several activating mutations. Ibrutinib – an oral inhibitor of Bruton’s tyrosine kinase (BTK), which is activated in tumor cells by some of these mutations – was found to trigger apoptosis of Waldenstrom’s macroglobulinemia cells in vitro and to show clinical activity in a phase I study. Investigators now report their findings from a prospective, industry-sponsored study of adults enrolled at the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, and Stanford University Medical Center during a 1-year period and followed up for another 18 months.
All the participants had progressive disease at baseline despite receiving previous treatments including monoclonal antibodies, glucocorticoids, proteasome inhibitors, alkylators, immunomodulators, anthracyclines, and experimental therapies. Ibrutinib was taken orally every day for 26 4-week cycles until disease progressed or unacceptable toxic effects developed; treatment responders were permitted to continue the therapy after that time, if they wished, said Dr. Steven P. Treon of the Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, and his associates.
The primary objective of the study was to determine the overall rate of any treatment response (it was 90.5%) and the rate of major treatment response, defined as a 50% or greater decline in serum IgM levels (it was 73.0%). In addition, at 24 months, the progression-free survival was 69.1% and the overall survival was 95.2%. In comparison, previous studies of other monotherapies have shown overall response rates of only 40%-80% and median progression-free survival of only 8-20 months, the investigators said (N. Engl. J. Med. 2015 April 9 [doi:10.1056/NEJMoa1501548]).
Treatment response was rapid, with a median onset at 4 weeks, and both serum IgM and hemoglobin levels improved even in patients who showed modest or no changes in bone marrow disease burden. “This suggests that a mechanism other than tumor debulking could contribute to the clinical benefit with ibrutinib,” they added.
On CT imaging, 68% of patients showed decreased or resolved adenopathy and 57% showed decreased splenomegaly. Malignant pleural effusions resolved in two of three patients who had them, and peripheral neuropathy stabilized or improved in all nine who were affected. The latter result is “particularly encouraging given the challenging nature of treating IgM-related peripheral neuropathy in Waldenstrom’s macroglobulinemia,” Dr. Treon and his associates noted.
The toxic effects of treatment were moderate in these heavily pretreated patients and included neutropenia (22% of patients), thrombocytopenia (14%), bleeding events (3%), and reversible atrial fibrillation (5%) in patients with a history of arrhythmia. There were few infections, and no unexpected toxicities occurred, the investigators reported.
This study was supported by Pharmacyclics and Janssen Pharmaceuticals; with additional funding by Peter S. Bing, M.D.; the International Waldenstrom’s Macroglobulinemia Foundation; the Leukemia and Lymphoma Society; the Linda and Edward Nelson Fund for Waldenstrom’s Macroglobulinemia Research; the D’Amato Family Fund for Genomic Discovery; the Coyote Fund; and the Bauman Family Foundation. Dr. Treon reported ties to Pharmacyclics and Janssen; his associates reported ties to several industry sources.
Ibrutinib proved to be “highly active” against refractory Waldenstrom’s macroglobulinemia in the first clinical trial to assess the agent’s safety and efficacy in this patient population, producing an overall response rate of 90.5% and a major response rate of 73.0% in a series of 63 consecutive patients, according to a report published online April 9 in the New England Journal of Medicine.
Waldenstrom’s macroglobulinemia is a malignant B-cell lymphoma in which whole-genome sequencing has revealed several activating mutations. Ibrutinib – an oral inhibitor of Bruton’s tyrosine kinase (BTK), which is activated in tumor cells by some of these mutations – was found to trigger apoptosis of Waldenstrom’s macroglobulinemia cells in vitro and to show clinical activity in a phase I study. Investigators now report their findings from a prospective, industry-sponsored study of adults enrolled at the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, and Stanford University Medical Center during a 1-year period and followed up for another 18 months.
All the participants had progressive disease at baseline despite receiving previous treatments including monoclonal antibodies, glucocorticoids, proteasome inhibitors, alkylators, immunomodulators, anthracyclines, and experimental therapies. Ibrutinib was taken orally every day for 26 4-week cycles until disease progressed or unacceptable toxic effects developed; treatment responders were permitted to continue the therapy after that time, if they wished, said Dr. Steven P. Treon of the Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, and his associates.
The primary objective of the study was to determine the overall rate of any treatment response (it was 90.5%) and the rate of major treatment response, defined as a 50% or greater decline in serum IgM levels (it was 73.0%). In addition, at 24 months, the progression-free survival was 69.1% and the overall survival was 95.2%. In comparison, previous studies of other monotherapies have shown overall response rates of only 40%-80% and median progression-free survival of only 8-20 months, the investigators said (N. Engl. J. Med. 2015 April 9 [doi:10.1056/NEJMoa1501548]).
Treatment response was rapid, with a median onset at 4 weeks, and both serum IgM and hemoglobin levels improved even in patients who showed modest or no changes in bone marrow disease burden. “This suggests that a mechanism other than tumor debulking could contribute to the clinical benefit with ibrutinib,” they added.
On CT imaging, 68% of patients showed decreased or resolved adenopathy and 57% showed decreased splenomegaly. Malignant pleural effusions resolved in two of three patients who had them, and peripheral neuropathy stabilized or improved in all nine who were affected. The latter result is “particularly encouraging given the challenging nature of treating IgM-related peripheral neuropathy in Waldenstrom’s macroglobulinemia,” Dr. Treon and his associates noted.
The toxic effects of treatment were moderate in these heavily pretreated patients and included neutropenia (22% of patients), thrombocytopenia (14%), bleeding events (3%), and reversible atrial fibrillation (5%) in patients with a history of arrhythmia. There were few infections, and no unexpected toxicities occurred, the investigators reported.
This study was supported by Pharmacyclics and Janssen Pharmaceuticals; with additional funding by Peter S. Bing, M.D.; the International Waldenstrom’s Macroglobulinemia Foundation; the Leukemia and Lymphoma Society; the Linda and Edward Nelson Fund for Waldenstrom’s Macroglobulinemia Research; the D’Amato Family Fund for Genomic Discovery; the Coyote Fund; and the Bauman Family Foundation. Dr. Treon reported ties to Pharmacyclics and Janssen; his associates reported ties to several industry sources.
Ibrutinib proved to be “highly active” against refractory Waldenstrom’s macroglobulinemia in the first clinical trial to assess the agent’s safety and efficacy in this patient population, producing an overall response rate of 90.5% and a major response rate of 73.0% in a series of 63 consecutive patients, according to a report published online April 9 in the New England Journal of Medicine.
Waldenstrom’s macroglobulinemia is a malignant B-cell lymphoma in which whole-genome sequencing has revealed several activating mutations. Ibrutinib – an oral inhibitor of Bruton’s tyrosine kinase (BTK), which is activated in tumor cells by some of these mutations – was found to trigger apoptosis of Waldenstrom’s macroglobulinemia cells in vitro and to show clinical activity in a phase I study. Investigators now report their findings from a prospective, industry-sponsored study of adults enrolled at the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, and Stanford University Medical Center during a 1-year period and followed up for another 18 months.
All the participants had progressive disease at baseline despite receiving previous treatments including monoclonal antibodies, glucocorticoids, proteasome inhibitors, alkylators, immunomodulators, anthracyclines, and experimental therapies. Ibrutinib was taken orally every day for 26 4-week cycles until disease progressed or unacceptable toxic effects developed; treatment responders were permitted to continue the therapy after that time, if they wished, said Dr. Steven P. Treon of the Bing Center for Waldenstrom’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, and his associates.
The primary objective of the study was to determine the overall rate of any treatment response (it was 90.5%) and the rate of major treatment response, defined as a 50% or greater decline in serum IgM levels (it was 73.0%). In addition, at 24 months, the progression-free survival was 69.1% and the overall survival was 95.2%. In comparison, previous studies of other monotherapies have shown overall response rates of only 40%-80% and median progression-free survival of only 8-20 months, the investigators said (N. Engl. J. Med. 2015 April 9 [doi:10.1056/NEJMoa1501548]).
Treatment response was rapid, with a median onset at 4 weeks, and both serum IgM and hemoglobin levels improved even in patients who showed modest or no changes in bone marrow disease burden. “This suggests that a mechanism other than tumor debulking could contribute to the clinical benefit with ibrutinib,” they added.
On CT imaging, 68% of patients showed decreased or resolved adenopathy and 57% showed decreased splenomegaly. Malignant pleural effusions resolved in two of three patients who had them, and peripheral neuropathy stabilized or improved in all nine who were affected. The latter result is “particularly encouraging given the challenging nature of treating IgM-related peripheral neuropathy in Waldenstrom’s macroglobulinemia,” Dr. Treon and his associates noted.
The toxic effects of treatment were moderate in these heavily pretreated patients and included neutropenia (22% of patients), thrombocytopenia (14%), bleeding events (3%), and reversible atrial fibrillation (5%) in patients with a history of arrhythmia. There were few infections, and no unexpected toxicities occurred, the investigators reported.
This study was supported by Pharmacyclics and Janssen Pharmaceuticals; with additional funding by Peter S. Bing, M.D.; the International Waldenstrom’s Macroglobulinemia Foundation; the Leukemia and Lymphoma Society; the Linda and Edward Nelson Fund for Waldenstrom’s Macroglobulinemia Research; the D’Amato Family Fund for Genomic Discovery; the Coyote Fund; and the Bauman Family Foundation. Dr. Treon reported ties to Pharmacyclics and Janssen; his associates reported ties to several industry sources.
Key clinical point: Ibrutinib produced a 90.5% overall response rate and a 73% major response rate in a proof-of-concept trial of 63 patients with refractory Waldenstrom’s macroglobulinemia, a malignant B-cell lymphoma.
Major finding: At 24 months, progression-free survival was 69.1% and overall survival was 95.2%.
Data source: An industry-sponsored prospective multicenter study.
Disclosures: This study was supported by Pharmacyclics and Janssen Pharmaceuticals; with additional funding by Peter S. Bing, M.D.; the International Waldenstrom’s Macroglobulinemia Foundation; the Leukemia and Lymphoma Society; the Linda and Edward Nelson Fund for Waldenstrom’s Macroglobulinemia Research; the D’Amato Family Fund for Genomic Discovery; the Coyote Fund; and the Bauman Family Foundation. Dr. Treon reported ties to Pharmacyclics and Janssen; his associates reported ties to several industry sources.
Trichoepithelioma and Spiradenoma Collision Tumor
The coexistence of more than one cutaneous adnexal neoplasm in a single biopsy specimen is unusual and is most frequently recognized in the context of a nevus sebaceous or Brooke-Spiegler syndrome, an autosomal-dominant inherited disease characterized by cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.1-3 Brooke-Spiegler syndrome is caused by germline mutations in the cylindromatosis gene, CYLD, located on band 16q12; it functions as a tumor suppressor gene and has regulatory roles in development, immunity, and inflammation.1 Weyers et al3 first recognized the tendency for adnexal collision tumors to present in patients with Brooke-Spiegler syndrome; they reported a patient with Brooke-Spiegler syndrome with spiradenomas found in the immediate vicinity of trichoepitheliomas and in continuity with hair follicles.
Spiradenomas are composed of large, sharply demarcated, rounded nodules of basaloid cells with little cytoplasm (Figure 1).4 The basaloid nodules may demonstrate a trabecular architecture, and on close inspection 2 cell types—paler cells with more cytoplasm and darker cells with less cytoplasm—are distinguishable (Figure 2A). Lymphocytes often are scattered within the tumor nodules and/or stroma. In Brooke-Spiegler syndrome, collision tumors containing a spiradenomatous component in collision with trichoepithelioma are not uncommon.1 Spiradenomas in Brooke-Spiegler syndrome have been reported to contain sebaceous differentiation or foci with an adenoid cystic carcinoma (ACC)–like pattern and are known to occur as hybrid lesions of spiradenoma and cylindroma or trichoepithelioma (as in this case).
In this case, 2 distinct neoplasms (spiradenoma and trichoepithelioma) are apparent, side by side, with an intervening hair follicle (Figure 1). Trichoepitheliomas, also known as cribriform trichoblastomas,5 are characterized by lobules of basaloid cells resembling basal cell carcinoma surrounded by a fibroblast-rich stroma. They often contain fingerlike projections and adopt a cribriform morphology within the tumor lobules (Figure 2B).4 Numerous horn cysts may be present, but their absence does not preclude the diagnosis. Mucin may be present within the cribriform tumor islands (Figure 2B) but not in the stroma. Characteristically, trichoepitheliomas are distinctly negative for CK7 (Figure 3), and unlike spiradenomas, they lack a myoepithelial component.6 This staining pattern in combination with the tumor’s proximity to an adjacent hair follicle makes a diagnosis of trichoepithelioma and spiradenoma collision tumor most likely and supports a clinical suspicion for Brooke-Spiegler syndrome.
![]() ![]() |
Although spiradenomas sometimes contain cystic cavities (microcystic change), they typically are filled with finely granular eosinophilic material, not mucin, that is diastase resistant and periodic acid–Schiff positive (Figure 4).7 Spiradenomas classically stain positive with CK7 (Figure 3), epithelial membrane antigen, and carcinoembryonic antigen, and have a substantial myoepithelial component, as evidenced by the myoepithelial component staining with p63, S-100, and smooth muscle actin (SMA).7-9 The distinct lack of staining with CK7 and SMA in the tumor on the left in Figure 3 confirms that these tumors are of different lineage, rather than representing cystic change within a spiradenoma.
![]() | ![]() |
Adenoid cystic carcinoma is a rare neoplasm that may occur in a primary cutaneous form, as a direct extension from an underlying salivary gland neoplasm, or rarely as a focal pattern within spiradenomas occurring both sporadically or in the context of Brooke-Spiegler syndrome.2,7 The tumor is composed of variably sized cribriform islands of basaloid to pink cells concentrically arranged around glandlike spaces filled with mucin (Figure 5A). In contrast to trichoepithelioma, ACC occurs in the mid to deep dermis, often extending into subcutaneous fat with an infiltrative border, and is not often found in close proximity to hair follicles.7 Characteristically, hyaline basement membrane–like material that is periodic acid–Schiff positive is found between the tumor cells and also surrounding the individual lobules. Immunohistochemically, ACC has a myoepithelial component that stains positive with SMA, S-100, and p63; additionally, the tumor cells express low- and high-molecular-weight keratin and demonstrate variable epithelial membrane antigen positivity.10 In the current case, the superficial location, close association with a hair follicle, and lack of staining with both CK7 (Figure 3) and SMA (not shown) make ACC arising within a spiradenoma a less likely diagnosis.
Cylindromas are composed of basaloid islands interconnected in a jigsaw puzzle configuration (Figure 5B).4 Similar to spiradenomas, they also are composed of 2 cell populations. Characteristically, the tumor islands are outlined by a hyalinized eosinophilic basement membrane. Hyalinized droplets of basement membrane zone material also may be noted in the islands. Unlike spiradenomas, they lack both intratumoral lymphocytes and a trabecular growth pattern. Although spiradenocylindromas (cylindroma and spiradenoma collision tumors) are perhaps the most common collision tumor associated with Brooke-Spiegler syndrome, there is no evidence suggesting the presence of a cylindroma in the current case.
![]() ![]() |
Primary cutaneous mucinous carcinoma is a rare neoplasm with a predilection for the eyelids; lesions occurring outside of this facial distribution, particularly of the breast, warrant a workup for metastatic disease.7 It typically occurs in the deeper dermis with involvement of the subcutaneous fat and is characterized by delicate fibrous septa enveloping large lakes of mucin, which contain islands of tumor cells (Figure 6). It has not been reported in association with spiradenomas. In addition, the tumor cells typically are CK7 positive.
1. Kazakov DV, Soukup R, Mukensnabl P, et al. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol. 2005;27:27-33.
2. Petersson F, Kutzner H, Spagnolo DV, et al. Adenoid cystic carcinoma-like pattern in spiradenoma and spiradenocylindroma: a rare feature in sporadic neoplasms and those associated with Brooke-Spiegler syndrome. Am J Dermatopathol. 2009;31:642-648.
3. Weyers W, Nilles M, Eckert F, et al. Spiradenomas in Brooke-Spiegler syndrome. Am J Dermatopathol. 1993;15:156-161.
4. Elston DM, Ferringer T. Dermatopathology. Edinburgh, Scotland: Elsevier Saunders; 2009.
5. Ackerman AB, de Viragh PA, Chongchitnant N. Neoplasms with Follicular Differentiation. Philadelphia, PA: Lea & Febiger; 1993.
6. Yamamoto O, Asahi M. Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. Br J Dermatol. 1999;140:8-16.
7. Calonje JE, Brenn T, Lazar AJ, et al. McKee’s Pathology of the Skin with Clinical Correlations. 4th ed. St Louis, MO: Elsevier Saunders; 2012.
8. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. 1997;19:154-161.
9. Kurokawa I, Nishimura K, Tarumi C, et al. Eccrinespiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells. J Eur Acad Dermatol Venereol. 2007;21:121-123.
10. Thompson LD, Penner C, Ho NJ, et al. Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases. Head Neck Pathol. 2014;8:88-109.
The coexistence of more than one cutaneous adnexal neoplasm in a single biopsy specimen is unusual and is most frequently recognized in the context of a nevus sebaceous or Brooke-Spiegler syndrome, an autosomal-dominant inherited disease characterized by cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.1-3 Brooke-Spiegler syndrome is caused by germline mutations in the cylindromatosis gene, CYLD, located on band 16q12; it functions as a tumor suppressor gene and has regulatory roles in development, immunity, and inflammation.1 Weyers et al3 first recognized the tendency for adnexal collision tumors to present in patients with Brooke-Spiegler syndrome; they reported a patient with Brooke-Spiegler syndrome with spiradenomas found in the immediate vicinity of trichoepitheliomas and in continuity with hair follicles.
Spiradenomas are composed of large, sharply demarcated, rounded nodules of basaloid cells with little cytoplasm (Figure 1).4 The basaloid nodules may demonstrate a trabecular architecture, and on close inspection 2 cell types—paler cells with more cytoplasm and darker cells with less cytoplasm—are distinguishable (Figure 2A). Lymphocytes often are scattered within the tumor nodules and/or stroma. In Brooke-Spiegler syndrome, collision tumors containing a spiradenomatous component in collision with trichoepithelioma are not uncommon.1 Spiradenomas in Brooke-Spiegler syndrome have been reported to contain sebaceous differentiation or foci with an adenoid cystic carcinoma (ACC)–like pattern and are known to occur as hybrid lesions of spiradenoma and cylindroma or trichoepithelioma (as in this case).
In this case, 2 distinct neoplasms (spiradenoma and trichoepithelioma) are apparent, side by side, with an intervening hair follicle (Figure 1). Trichoepitheliomas, also known as cribriform trichoblastomas,5 are characterized by lobules of basaloid cells resembling basal cell carcinoma surrounded by a fibroblast-rich stroma. They often contain fingerlike projections and adopt a cribriform morphology within the tumor lobules (Figure 2B).4 Numerous horn cysts may be present, but their absence does not preclude the diagnosis. Mucin may be present within the cribriform tumor islands (Figure 2B) but not in the stroma. Characteristically, trichoepitheliomas are distinctly negative for CK7 (Figure 3), and unlike spiradenomas, they lack a myoepithelial component.6 This staining pattern in combination with the tumor’s proximity to an adjacent hair follicle makes a diagnosis of trichoepithelioma and spiradenoma collision tumor most likely and supports a clinical suspicion for Brooke-Spiegler syndrome.
![]() ![]() |
Although spiradenomas sometimes contain cystic cavities (microcystic change), they typically are filled with finely granular eosinophilic material, not mucin, that is diastase resistant and periodic acid–Schiff positive (Figure 4).7 Spiradenomas classically stain positive with CK7 (Figure 3), epithelial membrane antigen, and carcinoembryonic antigen, and have a substantial myoepithelial component, as evidenced by the myoepithelial component staining with p63, S-100, and smooth muscle actin (SMA).7-9 The distinct lack of staining with CK7 and SMA in the tumor on the left in Figure 3 confirms that these tumors are of different lineage, rather than representing cystic change within a spiradenoma.
![]() | ![]() |
Adenoid cystic carcinoma is a rare neoplasm that may occur in a primary cutaneous form, as a direct extension from an underlying salivary gland neoplasm, or rarely as a focal pattern within spiradenomas occurring both sporadically or in the context of Brooke-Spiegler syndrome.2,7 The tumor is composed of variably sized cribriform islands of basaloid to pink cells concentrically arranged around glandlike spaces filled with mucin (Figure 5A). In contrast to trichoepithelioma, ACC occurs in the mid to deep dermis, often extending into subcutaneous fat with an infiltrative border, and is not often found in close proximity to hair follicles.7 Characteristically, hyaline basement membrane–like material that is periodic acid–Schiff positive is found between the tumor cells and also surrounding the individual lobules. Immunohistochemically, ACC has a myoepithelial component that stains positive with SMA, S-100, and p63; additionally, the tumor cells express low- and high-molecular-weight keratin and demonstrate variable epithelial membrane antigen positivity.10 In the current case, the superficial location, close association with a hair follicle, and lack of staining with both CK7 (Figure 3) and SMA (not shown) make ACC arising within a spiradenoma a less likely diagnosis.
Cylindromas are composed of basaloid islands interconnected in a jigsaw puzzle configuration (Figure 5B).4 Similar to spiradenomas, they also are composed of 2 cell populations. Characteristically, the tumor islands are outlined by a hyalinized eosinophilic basement membrane. Hyalinized droplets of basement membrane zone material also may be noted in the islands. Unlike spiradenomas, they lack both intratumoral lymphocytes and a trabecular growth pattern. Although spiradenocylindromas (cylindroma and spiradenoma collision tumors) are perhaps the most common collision tumor associated with Brooke-Spiegler syndrome, there is no evidence suggesting the presence of a cylindroma in the current case.
![]() ![]() |
Primary cutaneous mucinous carcinoma is a rare neoplasm with a predilection for the eyelids; lesions occurring outside of this facial distribution, particularly of the breast, warrant a workup for metastatic disease.7 It typically occurs in the deeper dermis with involvement of the subcutaneous fat and is characterized by delicate fibrous septa enveloping large lakes of mucin, which contain islands of tumor cells (Figure 6). It has not been reported in association with spiradenomas. In addition, the tumor cells typically are CK7 positive.
The coexistence of more than one cutaneous adnexal neoplasm in a single biopsy specimen is unusual and is most frequently recognized in the context of a nevus sebaceous or Brooke-Spiegler syndrome, an autosomal-dominant inherited disease characterized by cutaneous adnexal neoplasms, most commonly cylindromas and trichoepitheliomas.1-3 Brooke-Spiegler syndrome is caused by germline mutations in the cylindromatosis gene, CYLD, located on band 16q12; it functions as a tumor suppressor gene and has regulatory roles in development, immunity, and inflammation.1 Weyers et al3 first recognized the tendency for adnexal collision tumors to present in patients with Brooke-Spiegler syndrome; they reported a patient with Brooke-Spiegler syndrome with spiradenomas found in the immediate vicinity of trichoepitheliomas and in continuity with hair follicles.
Spiradenomas are composed of large, sharply demarcated, rounded nodules of basaloid cells with little cytoplasm (Figure 1).4 The basaloid nodules may demonstrate a trabecular architecture, and on close inspection 2 cell types—paler cells with more cytoplasm and darker cells with less cytoplasm—are distinguishable (Figure 2A). Lymphocytes often are scattered within the tumor nodules and/or stroma. In Brooke-Spiegler syndrome, collision tumors containing a spiradenomatous component in collision with trichoepithelioma are not uncommon.1 Spiradenomas in Brooke-Spiegler syndrome have been reported to contain sebaceous differentiation or foci with an adenoid cystic carcinoma (ACC)–like pattern and are known to occur as hybrid lesions of spiradenoma and cylindroma or trichoepithelioma (as in this case).
In this case, 2 distinct neoplasms (spiradenoma and trichoepithelioma) are apparent, side by side, with an intervening hair follicle (Figure 1). Trichoepitheliomas, also known as cribriform trichoblastomas,5 are characterized by lobules of basaloid cells resembling basal cell carcinoma surrounded by a fibroblast-rich stroma. They often contain fingerlike projections and adopt a cribriform morphology within the tumor lobules (Figure 2B).4 Numerous horn cysts may be present, but their absence does not preclude the diagnosis. Mucin may be present within the cribriform tumor islands (Figure 2B) but not in the stroma. Characteristically, trichoepitheliomas are distinctly negative for CK7 (Figure 3), and unlike spiradenomas, they lack a myoepithelial component.6 This staining pattern in combination with the tumor’s proximity to an adjacent hair follicle makes a diagnosis of trichoepithelioma and spiradenoma collision tumor most likely and supports a clinical suspicion for Brooke-Spiegler syndrome.
![]() ![]() |
Although spiradenomas sometimes contain cystic cavities (microcystic change), they typically are filled with finely granular eosinophilic material, not mucin, that is diastase resistant and periodic acid–Schiff positive (Figure 4).7 Spiradenomas classically stain positive with CK7 (Figure 3), epithelial membrane antigen, and carcinoembryonic antigen, and have a substantial myoepithelial component, as evidenced by the myoepithelial component staining with p63, S-100, and smooth muscle actin (SMA).7-9 The distinct lack of staining with CK7 and SMA in the tumor on the left in Figure 3 confirms that these tumors are of different lineage, rather than representing cystic change within a spiradenoma.
![]() | ![]() |
Adenoid cystic carcinoma is a rare neoplasm that may occur in a primary cutaneous form, as a direct extension from an underlying salivary gland neoplasm, or rarely as a focal pattern within spiradenomas occurring both sporadically or in the context of Brooke-Spiegler syndrome.2,7 The tumor is composed of variably sized cribriform islands of basaloid to pink cells concentrically arranged around glandlike spaces filled with mucin (Figure 5A). In contrast to trichoepithelioma, ACC occurs in the mid to deep dermis, often extending into subcutaneous fat with an infiltrative border, and is not often found in close proximity to hair follicles.7 Characteristically, hyaline basement membrane–like material that is periodic acid–Schiff positive is found between the tumor cells and also surrounding the individual lobules. Immunohistochemically, ACC has a myoepithelial component that stains positive with SMA, S-100, and p63; additionally, the tumor cells express low- and high-molecular-weight keratin and demonstrate variable epithelial membrane antigen positivity.10 In the current case, the superficial location, close association with a hair follicle, and lack of staining with both CK7 (Figure 3) and SMA (not shown) make ACC arising within a spiradenoma a less likely diagnosis.
Cylindromas are composed of basaloid islands interconnected in a jigsaw puzzle configuration (Figure 5B).4 Similar to spiradenomas, they also are composed of 2 cell populations. Characteristically, the tumor islands are outlined by a hyalinized eosinophilic basement membrane. Hyalinized droplets of basement membrane zone material also may be noted in the islands. Unlike spiradenomas, they lack both intratumoral lymphocytes and a trabecular growth pattern. Although spiradenocylindromas (cylindroma and spiradenoma collision tumors) are perhaps the most common collision tumor associated with Brooke-Spiegler syndrome, there is no evidence suggesting the presence of a cylindroma in the current case.
![]() ![]() |
Primary cutaneous mucinous carcinoma is a rare neoplasm with a predilection for the eyelids; lesions occurring outside of this facial distribution, particularly of the breast, warrant a workup for metastatic disease.7 It typically occurs in the deeper dermis with involvement of the subcutaneous fat and is characterized by delicate fibrous septa enveloping large lakes of mucin, which contain islands of tumor cells (Figure 6). It has not been reported in association with spiradenomas. In addition, the tumor cells typically are CK7 positive.
1. Kazakov DV, Soukup R, Mukensnabl P, et al. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol. 2005;27:27-33.
2. Petersson F, Kutzner H, Spagnolo DV, et al. Adenoid cystic carcinoma-like pattern in spiradenoma and spiradenocylindroma: a rare feature in sporadic neoplasms and those associated with Brooke-Spiegler syndrome. Am J Dermatopathol. 2009;31:642-648.
3. Weyers W, Nilles M, Eckert F, et al. Spiradenomas in Brooke-Spiegler syndrome. Am J Dermatopathol. 1993;15:156-161.
4. Elston DM, Ferringer T. Dermatopathology. Edinburgh, Scotland: Elsevier Saunders; 2009.
5. Ackerman AB, de Viragh PA, Chongchitnant N. Neoplasms with Follicular Differentiation. Philadelphia, PA: Lea & Febiger; 1993.
6. Yamamoto O, Asahi M. Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. Br J Dermatol. 1999;140:8-16.
7. Calonje JE, Brenn T, Lazar AJ, et al. McKee’s Pathology of the Skin with Clinical Correlations. 4th ed. St Louis, MO: Elsevier Saunders; 2012.
8. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. 1997;19:154-161.
9. Kurokawa I, Nishimura K, Tarumi C, et al. Eccrinespiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells. J Eur Acad Dermatol Venereol. 2007;21:121-123.
10. Thompson LD, Penner C, Ho NJ, et al. Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases. Head Neck Pathol. 2014;8:88-109.
1. Kazakov DV, Soukup R, Mukensnabl P, et al. Brooke-Spiegler syndrome: report of a case with combined lesions containing cylindromatous, spiradenomatous, trichoblastomatous, and sebaceous differentiation. Am J Dermatopathol. 2005;27:27-33.
2. Petersson F, Kutzner H, Spagnolo DV, et al. Adenoid cystic carcinoma-like pattern in spiradenoma and spiradenocylindroma: a rare feature in sporadic neoplasms and those associated with Brooke-Spiegler syndrome. Am J Dermatopathol. 2009;31:642-648.
3. Weyers W, Nilles M, Eckert F, et al. Spiradenomas in Brooke-Spiegler syndrome. Am J Dermatopathol. 1993;15:156-161.
4. Elston DM, Ferringer T. Dermatopathology. Edinburgh, Scotland: Elsevier Saunders; 2009.
5. Ackerman AB, de Viragh PA, Chongchitnant N. Neoplasms with Follicular Differentiation. Philadelphia, PA: Lea & Febiger; 1993.
6. Yamamoto O, Asahi M. Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. Br J Dermatol. 1999;140:8-16.
7. Calonje JE, Brenn T, Lazar AJ, et al. McKee’s Pathology of the Skin with Clinical Correlations. 4th ed. St Louis, MO: Elsevier Saunders; 2012.
8. Meybehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. 1997;19:154-161.
9. Kurokawa I, Nishimura K, Tarumi C, et al. Eccrinespiradenoma: co-expression of cytokeratin and smooth muscle actin suggesting differentiation toward myoepithelial cells. J Eur Acad Dermatol Venereol. 2007;21:121-123.
10. Thompson LD, Penner C, Ho NJ, et al. Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases. Head Neck Pathol. 2014;8:88-109.